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Integrated Experimental and Computational Approaches for the 
Prediction of Drug-Drug Interactions by Hannah Mae Kinvig. 
People living with HIV (PLWH) are highly susceptible to drug-drug 
interactions (DDIs) due to the increased risk of coinfections and comorbidities. 
Antiretroviral (ARV) drugs used for the treatment of HIV can be both victims and 
perpetrators of DDIs with potential effects on drug exposure leading to reduced 
efficacy and toxicity. Transporters have been identified as key mediators of drug 
pharmacokinetics however their role in DDIs remains unclear due to our current 
paucity of knowledge. The complexities surrounding the clinical management of DDIs 
in PLWH is further hindered by a lack of evidence-based guidance for many drug 
combinations. The aim of this thesis was to utilise in vitro and in silico techniques to 
explore the role of transporters in DDIs as well as investigate the magnitude of 
potential DDIs in PLWH that currently have no clinical data to support their 
management.  
 Uptake and efflux transporters facilitate the clearance of drugs in the liver 
however, due to the complex interplay with enzymes along with non-specific probe 
substrates and inhibitors, their role in clinically relevant DDIs have not been fully 
elucidated. In vitro and in silico techniques can be applied synergistically to investigate 
hepatic transporter-mediated DDIs. Chapter 2 describes the development and 
verification of a cryopreserved suspension primary human hepatocyte (SPHH) in vitro 
assay used to calculate the hepatic intrinsic clearance and inhibition constant (Ki) of 
the well-known organic anion transporting polypeptides (OATP) 1B1 and 1B3 
substrate and inhibitor, pitavastatin (PIT) and rifampicin (RIF). This in vitro data was 
then utilised in Chapter 3 in a physiologically based pharmacokinetic (PBPK) model 
to simulate the DDI between PIT and RIF and was successfully verified against 
observed data. Chapter 4 applied the verified in vitro-in silico framework to assess the 
role of transporters in the complex DDI between the hepatitis C (HCV) NS3/4A 
protease inhibitor (PI) grazoprevir (GZR) and HIV PIs atazanavir (ATV), darunavir 
(DRV) and ritonavir (RTV), testing the suitability of the framework in a clinically 
relevant DDI scenario. Additionally, chapter 5 utilised SPHHs from elderly donors in 
vitro alongside an enzyme-linked immunosorbent assay (ELISA) to investigate the 
effect of age on transporter expression and activity. Furthermore, in chapter 6 an 
enzyme induction PBPK model was developed and verified to predict the magnitude 
of DDI between high dose once monthly (QMT) RIF and dolutegravir (DTG) 50mg 
twice-daily for the treatment of leprosy in PLWH as there is currently no evidence-
based guidance to support their clinical management. 
 There is a demand for paralleled clinical management and research of DDIs in 
PLWH. These findings represent a potential in vitro-in silico framework utilising a 
non-drug specific IVIVE correction factor for the investigation of hepatic uptake 
transporters in DDIs. Additionally, these findings could help fill the knowledge gap 
on the role of older age in transporter expression and activity, providing key research 
in this underrepresented population. The reported findings could also help support the 
clinical management of DDIs in high dose QMT RIF regimens, presenting in silico 
assessment strategies for concomitant antiretroviral therapy. 
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1.1 Human Immunodeficiency Virus 
Human immunodeficiency virus (HIV) is a retrovirus that was first discovered 
in 1983, two years after the first diagnosis of acquired immune deficiency syndrome 
(AIDS). Between 1983 and 1984 multiple teams of scientists provided evidence for 
the causal link between HIV and AIDS (1). Since their discovery, 75.7 million people 
have been infected with HIV and 32.7 million have died from AIDS-related illnesses, 
globally. The amount of PLWH has increased approximately 80% since 1990 as shown 
in Figure 1.1, with 38 million PLWH in 2019, of which 1.8 million were children aged 
0 – 14 years. Since the peak of HIV in 1998, the amount of people newly infected with 
HIV has decreased by 40% to 1.7 million people in 2019 (2, 3). As shown in Figure 
1.2, Africa has the largest burden of HIV with over 67% of the total PLWH. However, 
relative to 2010 Africa has the greatest decrease in new diagnosis and AIDS-related 
deaths in comparison to other regions. Europe and the Eastern Mediterranean regions 
have the biggest increase in new diagnosis and AIDS-related deaths and make up 6.8% 
and 1.1% of total PLWH, respectively (4). 
 
 
Figure 1.1 Global PLWH from 1990 to 2019, based on Joint United Nations 
Programme On HIV/AIDS (UNAIDS) and World Health Organisation (WHO) 
estimates (3). The red line represents the estimated mean with the shaded red area 





Figure 1.2 Regional breakdown of PLWH based on UNAIDS and WHO estimates (4). 




HIV is transmitted through the exchange of specific bodily fluids such as 
blood, semen, vaginal secretions and breast milk. Additionally, HIV can be transmitted 
from mother to child during pregnancy. Risk factors for the acquisition of HIV include 
unprotected anal and vaginal sex, sexually transmitted infections, sharing injecting 
equipment such as needles and unsafe medical procedures. Key populations who are 
at high risk of acquiring HIV are men who have sex with men, people who inject drugs 
(PWID), people in prison, sex workers and transgender people (5).  
The survival rate of PLWH has steadily increased over the past few decades 
with the introduction of potent antiretroviral therapy (ART). This has led to a life 
expectancy similar to that of the general population (6). As shown in Figure 1.3, 
UNAIDS and the WHO estimated that globally the amount of PLWH aged ≥50 years 
had more than doubled from 2010 to 2019. Older adults living with HIV (OALWH) 
have previously been defined as HIV-positive adults aged ≥50 years, whereas in the 
general population older adults are often defined as those aged ≥65 years. OALWH 
have a lower age cut-off due to their poorer immunological recovery and increased 
mortality caused by HIV-unrelated factors when compared to PLWH aged ≤50 years 
(7). Furthermore, in comparison to non-HIV infected adults, it has been reported that 
PLWH had an increased biological age (8), further justifying the lower chronological 







Figure 1.3 Global OALWH aged ≥50 years from 1990 to 2019, based on UNAIDS and 
WHO estimates (3). The red line represents the estimated mean with the shaded red 
area representing the upper and lower limits. 
1.1.1 HIV Replication Cycle 
HIV requires a host cell to replicate itself and specifically targets activated CD4 
T lymphocytes as well as resting CD4 T cells, monocytes, macrophages and dendritic 
cells, all of which belong to the immune system (9, 10). CD4 T lymphocytes play a 
key role in the body’s immune response and their depletion through HIV infection 
leaves the body incapacitated against opportunistic infections. The HIV-1 virion is 
spherical in shape with a lipid membrane encompassing cellular proteins and viral 
envelope protein complexes. The viral envelope comprises of external glycoprotein 
120 (gp120) and transmembrane glycoprotein 41 (gp41) which are required for viral 
attachment and fusion, respectively. Within the envelope is a conical capsid containing 
two single strands of viral ribonucleic acid (RNA) and various enzymes and proteins 
necessary for the viral replication cycle. A schematic representation of the viral 
replication cycle is shown in Figure 1.4 which highlights each stage of HIV replication 
and the corresponding antiretroviral (ARV) drug classes targeting them.  
First in the replication cycle is the attachment of the external gp120 on the HIV 
virion to CD4 receptors on the host cell. This binding leads to conformational changes 
that enable gp120 to interact with either the C-X-C chemokine receptor type 4 
(CXCR4) or C-C chemokine receptor type 5 (CCR5) receptors on the host cell. These 
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interactions cause further conformational changes that enable the integration of the 
hydrophobic fusion peptide of the gp41 transmembrane protein into the host cell’s 
membrane. As a result, virion fusion between the host cell and viral membranes occurs, 
followed by uncoating and the distribution of viral content into the cell. The newly 
released single-stranded viral RNA then undergoes reverse transcription producing 
double-stranded deoxyribonucleic acid (DNA). The double-stranded DNA is then 
actively transported across the nuclear pore and integration into the host genome is 
facilitated by the enzyme, integrase. Transcription of the proviral DNA subsequently 
takes place creating viral messenger RNA (mRNA) which is transferred into the cell 
cytoplasm from the nucleus. The viral mRNA is then translated into the encoded viral 
proteins followed by proteolytic cleavage via the protease enzyme. The newly 
produced viral contents are then assembled into a membrane-coated spherical particle 
at the host cell’s plasma membrane for viral release to occur. The new HIV virion 
matures into its infectious form once released, completing the HIV replication cycle 
(9, 11). 
There are three major stages in the progression of untreated HIV: acute HIV, 
asymptomatic HIV and AIDS. Figure 1.5 shows a schematic representation of the 
associated changes in CD4 lymphocyte count and HIV RNA copies throughout these 
stages. The acute stage takes place over a period of weeks after the primary infection 
and is characterised by symptoms such as fever and persistent generalised 
lymphadenopathy as well as a rapid decline in CD4 T lymphocytes and incline in HIV 
RNA copies until a peak is reached. The asymptomatic stage occurs for several years 
after the acute stage and as the name suggests PLWH in this stage may have no HIV-
related symptoms. HIV replication continues at low levels whilst CD4 T lymphocytes 
continue to decline. The final stage, AIDS, is characterised by a CD4 T lymphocyte 
count of less than 200 cells per mm3 as well as the onset of opportunistic infections 
and a dramatic increase in HIV RNA copies. Due to the irreparable damage to the 
immune system caused by chronic HIV infection, those with AIDS will die within a 




Figure 1.4 HIV replication cycle in a CD4 host cell. ARV drug classes and their 





Figure 1.5 Changes in CD4 lymphocyte count and HIV RNA copies throughout the 
three stages of untreated HIV: acute HIV, asymptomatic HIV and AIDS. The red line 
represents HIV RNA copies per ml of plasma and the blue line represents CD4 
lymphocyte count in cells per mm3. Three notable events are highlighted in yellow on 
the graph. Numbers 1, 2 and 3 represent the primary infection, opportunistic infections 
and death, respectively (9, 16).  
1.1.2 Antiretroviral Therapy 
The WHO and UNAIDS estimated that globally in 2019 81% of PLWH knew 
their status, 67% were receiving ART and among those 59% were virally supressed. 
The WHO currently recommends that countries adopt a standard HIV testing strategy 
for diagnosis consisting of three HIV tests (17). HIV tests can be split into two 
categories: serological testing and virological testing. Serological testing involves the 
detection of antibodies produced as part of the immune response to HIV. These tests 
include ELISA, rapid tests and western blot tests. Virological testing involves the 
detection of viral nucleic acids or viral products via polymerase chain reaction (PCR) 
assays (18). It is critical to begin ART as soon as possible after a positive HIV 
diagnosis has been made to achieve efficient viral suppression (19). Additionally, 
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ARV drugs can be used in the preventative methods known as pre-exposure 
prophylaxis (PrEP) and post-exposure prophylaxis (PEP). Both PrEP and PEP are used 
by HIV-negative people who are either at high risk of HIV exposure or have had a 
single high risk HIV exposure, respectively (20).  
There are currently nine classes of ARV drugs: attachment inhibitors, post-
attachment inhibitors, chemokine receptor antagonists, fusion inhibitors, nucleoside 
reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase 
inhibitors (NNRTIs), integrase inhibitors, PIs and pharmacokinetic enhancers (15). 
ARV drugs that are currently licenced for the treatment of HIV can be found in Table 
1.1. Each class of ARV drug, excluding pharmacokinetic enhancers, target a specific 
process during the HIV life cycle to prevent viral replication, as shown in Figure 1.4. 
There are four ARV drug classes that target the processes prior to HIV infiltration of 
the host cell: attachment inhibitors, post-attachment inhibitors, chemokine receptor 
antagonists and fusion inhibitors. Attachment inhibitors prevent HIV from entering 
host cells by binding to the gp120 protein located on the outer surface of the HIV 
envelope, thus preventing interaction with host cell surface receptors. The prodrug 
fostemsavir (FTR) is currently the only U.S. Food and Drug Administration (FDA) 
approved attachment inhibitor and is suitable for heavily treatment experienced PLWH 
with multidrug resistant HIV-1 (21). Post-attachment inhibitors bind to extracellular 
domains on the host cell preventing the conformational changes required for the 
interaction between gp120 and CXCR4 and CCR5 receptors, stopping HIV entry. 
Ibalizumab-uiyk is the first FDA approved monoclonal antibody and post-attachment 
inhibitor for the treatment of HIV-1 in heavily treatment experienced patients (22). 
Chemokine receptor antagonists prevent the binding of gp120 to chemokine receptors 
on the host cell. Maraviroc is currently the only FDA approved chemokine receptor 
antagonist and prevents the binding of gp120 to CCR5 (23). Lastly, the synthetic 
peptide enfuvirtide is currently the only FDA approved fusion inhibitor which blocks 
the conformational changes required for cell fusion by binding to viral gp41, thereby 
preventing viral entry (24). 
There are four classes of ARV drugs that target the life cycle process after HIV 
infiltration of the host cell: NRTIs, NNRTIs, integrase inhibitors and PIs. These ARV 
classes are well established in comparison to attachment inhibitors, post-attachment 
inhibitors and fusion inhibitors, and form the cornerstone of first-line and second-line 
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ART regimens. Both NRTIs and NNRTIs prevent the production of double-stranded 
DNA from viral RNA by inhibiting the reverse transcription of viral RNA. Whereas 
NRTIs undergo intracellular phosphorylation to form their active diphosphate and 
triphosphate metabolites to competitively inhibit reverse transcription, NNRTIs 
produce their inhibitory action non-competitively. Integrase inhibitors stop the 
integration of viral DNA into the host chromosome via inhibition of the integrase 
enzyme used to catalyse covalent bond formation between viral and host DNA. 
Finally, PIs impede mature virion formation in the latter stages of the HIV life cycle 
through HIV protease binding, stopping the required cleavage and assembly of 
polypeptides (9, 25). In addition to the abovementioned ARV classes, there are two 
currently approved pharmacokinetic enhancers: cobicistat (COBI) and the PI, RTV. 
Both ARVs inhibit the cytochrome P450 (CYP3A4) enzyme thereby reducing the 
metabolism of the coadministered ARVs to attain the effective therapeutic plasma 
concentrations. COBI and RTV are given in combination with almost all PIs as well 















Table 1.1 ARV drugs currently approved for the treatment of HIV (15). 
Drug Name Brand Name FDA Approval Date 
Nucleoside Reverse Transcriptase Inhibitors (NRTIs) 
Abacavir* Ziagen 17th December 1998 
Emtricitabine (FTC)* Emtriva 2nd July 2003 
Lamivudine (3TC)* Epivir 17th November 1995 
Tenofovir Disoproxil 
Fumarate (TDF)* 
Viread 26th October 2001 
Tenofovir Alafenamide 
Fumarate (TAF)** 
Genvoya 5th November 2015 
Odefsey 1st March 2016 
Descovy 4th April 2016 
Biktarvy 7th February 2018 
Symtuza 17th July 2018 
Zidovudine (AZT, ZDV) Retrovir 19th March 1987 
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) 
Doravirine (DOR)* Pifeltro 30th August 2018 
Efavirenz (EFV)* Sustiva 17th September 1998 
Etravirine (ETR) Intelence 18th January 2008 
Nevirapine (NVP) Viramune 21st June 1996 
Rilpivirine (RPV)* Edurant 20th May 2011 
Protease Inhibitors (PIs) 
Atazanavir (ATV)* Reyataz 20th June 2003 
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Darunavir (DRV)* Prezista 23rd June 2006 
Fosamprenavir (FPV) Lexiva 20th October 2003 
Ritonavir (RTV)*** Norvir 1st March 1996 
Saquinavir (SQV) Invirase 6th December 1995 
Tipranavir (TPV) Aptivus 22nd June 2005 
Fusion Inhibitors 
Enfuvirtide (T-20) Fuzeon 13th March 2003 
Chemokine Receptor Antagonists 
Maraviroc (MVC) Selzentry 6th August 2007 
Integrase Inhibitors 
Cabotegravir (CAB)* Vocabria 22nd January 2021 
Dolutegravir (DTG)* Tivicay 13th August 2013 
Raltegravir (RAL) Isentress 12th October 2007 
Attachment Inhibitors 
Fostemsavir (FTR) Rukobia 2nd July 2020 
Post-Attachment Inhibitors 
Ibalizumab-uiyk (IBA) Trogarzo 6th March 2018 
Pharmacokinetic Enhancers 
Cobicistat (COBI)* Tybost 24th September 2014 
Adapted from HIVinfo.NIH.gov. * - also available as part of combination HIV medicines under 
different brand names with different FDA approval dates, ** - only available as part of combination 
HIV medicines (as listed), *** - RTV is a PI however it is generally used as a pharmacokinetic 
enhancer in combination HIV medicines. 
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Since the introduction of HIV treatment in 1987 with the NRTI zidovudine, 
ART has evolved from a single monotherapy to a multitude of combination therapies, 
allowing for treatment personalisation. Unlike the original monotherapies, 
combination therapies offer rapid HIV RNA reduction and improved immune 
functionality by targeting multiple processes in the HIV life cycle, resulting in reduced 
rates of HIV morbidity and mortality as well as reducing the risk of transmission (25). 
For adults, the WHO currently recommends the integrase inhibitor DTG alongside two 
NRTIs, known as an NRTI backbone, as a first-line ART regimen. Alternatively, the 
NNRTI efavirenz is recommended in combination with an NRTI backbone. The WHO 
also recommends second-line ART regimens involving DTG alongside an optimised 
NRTI backbone or, for PLWH failing on DTG-based regimens, PIs boosted with a 
pharmacokinetic enhancer in combination with an optimised NRTI backbone (27). All 
currently recommended first-line and second-line ART regimens are shown in Table 
1.2. Current ART requires lifelong treatment for the maintenance of viral suppression. 
Since 2006, several single tablet once daily (QD) combination ART regimens have 
been produced, helping to lower pill burden and combat drug adherence issues. Drug 
adherence is vital to prevent viral rebound and the introduction of transmittable ARV-
resistant HIV mutations (25). Alongside the development of QD single tablet regimens 
consisting of highly potent ARVs with minimal toxicity, long-acting ARVs have been 
of increasing interest with the potential to eradicate adherence issues and improve 
treatment accessibility. The first extended-release long acting injectable for the 
treatment of HIV was approved by the FDA in January 2021. Cabenuva, which 
consists of an injectable cabotegravir (CAB) and rilpivirine (RPV) formulation, is 
suitable for QMT administration with recent studies demonstrating effective viral load 
reduction when administered every two months (28, 29). 
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Table 1.2 WHO guidelines on first-Line and second-line ART regimens (27). 
First-Line Regimens 
for Adults and 
Adolescents 
Preferred Regimen: Alternative Regimen: Special Circumstances: 
TDF + 3TC (or FTC) + DTG TDF + 3TC + EFV 400 mg TDF + 3TC (or FTC) + EFV 600 mg 
AZT + 3TC + EFV 600 mg 
TDF + 3TC (or FTC) + PI/r 
TDF + 3TC (or FTC) + RAL 
TAF + 3TC (or FTC) + DTG 
Abacavir + 3TC + DTG 
Second-Line 
Regimens for Adults 
and Adolescents 
Failing First-Line Regimen: Preferred Regimen: Alternative Regimen: 
TDF + 3TC (or FTC) + DTG 
TDF + 3TC (or FTC) + EFV 
(or NVP) 
AZT + 3TC + EFV (or NVP) 
AZT + 3TC + ATV/r (or LPV/r) 
AZT + 3TC + DTG 
TDF + 3TC (or FTC) + DTG 
AZT + 3TC + DRV/r 
AZT + 3TC + ATV/r (or LPV/r or 
DRV/r) 
TDF + 3TC (or FTC) + ATV/r 
(or LPV/r or DRV/r) 
Adapted from the WHO guidelines. 3TC – lamivudine, ATV/r - atazanavir/ritonavir, AZT- zidovudine, DRV/r - darunavir/ritonavir, DTG – dolutegravir, EFV – efavirenz, 
FTC – emtricitabine, LPV/r - lopinavir/ritonavir, NVP – nevirapine, PI/r - protease inhibitor boosted with ritonavir, RAL – raltegravir, TAF - tenofovir alafenamide, TDF - 




PLWH have an increased risk of acquiring additional infections, known as 
coinfections, due to their weakened immune system as well as through shared routes 
of transmission (30). Coinfections can lead to increased morbidity and mortality in 
PLWH due to debilitated immune responses accelerating disease progression. Rates of 
coinfections are country and sub-population dependent with a large proportion of 
coinfections affecting PLWH in Africa (30). For example, in 2018 tuberculosis (TB) 
produced one in three AIDS-related deaths of which 84% occurred in Africa (31). 
Furthermore, the treatments used for coinfections can incur potential drug-drug 
interactions (DDIs) with ART regimens, with DDIs for both hepatitis C (HCV) and 
leprosy being assessed in Chapters 4 and 6. 
1.2.1 Hepatitis C 
HCV is a bloodborne virus that was first discovered in 1989 and was initially 
referred to as non-A and non-B viral hepatitis (32). Hepatitis A (HAV) and hepatitis B 
(HBV) were discovered in the 1960s and 1970s with a vaccine for HBV being 
approved for human use in 1986. Clinical descriptions of hepatitis date back to 3000 
BC and was thought to spread throughout the middle ages with epidemics taking place 
during the 18th century (33). There were an estimated 2.3 million PLWH with past or 
present serological evidence of HCV coinfection in 2017, accounting for 
approximately 6.2% of total PLWH. The highest burden of coinfection was amongst 
PWID with 84% of total co 
infection cases, of which Central Asia and Eastern Europe had the greatest 
prevalence (34). These demographics are indicative of the similar routes of 
transmission between HIV and HCV, such as through the sharing of injecting 
equipment and unsafe medical procedures as well as unscreened blood transfusions 
(35). Furthermore, there are seven HCV genotypes which vary in their geographical 
prevalence. Genotypes 1, 2 and 3 are prevalent in America, Europe and Japan with 
genotype 1 accounting for more than 50% of cases in these regions. South and 
Southeast Asia has the highest burden of genotypes 3 and 6, with genotypes 4 and 5 
being predominant in Africa. To date genotype 7 has a minimal clinical impact (36).  
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HCV can be categorised into acute and chronic HCV. In most cases acute HCV 
is asymptomatic and can clear without treatment in up to 45% of all cases. If left 
untreated, acute HCV develops into chronic HCV with fibrosis, cirrhosis and liver 
failure ensuing, including hepatocellular carcinoma in some cirrhosis patients. The 
stages of chronic HCV are accelerated in PLWH with multiple studies demonstrating 
advanced progression of hepatic fibrosis and cirrhosis in PLWH co-infected with HCV 
when compared to HIV-negative patients (37). In comparison, the effect of HCV on 
HIV progression is uncertain with contradictions amongst current studies. The SWISS 
cohort study identified an association between HCV infection and AIDS-related 
deaths. On the other hand, the EuroSIDA cohort study found no difference in HIV 
viral load reduction or CD4 count elevation following ART initiation in PLWH co-
infected with HCV vs. PLWH (38, 39). Moreover, a recent cross-sectional study of 97 
patients found that PLWH co-infected with HCV had a larger HIV-1 reservoir when 
compared to PLWH (40). 
Our understanding of the HCV replication cycle remains incomplete however 
considerable advancements in HCV treatment over the past 20 years have enabled up 
to 95% of HCV infections to be cured (35). Current treatment strategies target multiple 
stages in the replication cycle including the HCV lipoviroparticle, viral entry, receptor 
interaction, translation, viral RNA replication and viral assembly (36). The latest 
guidelines from 2016 for the treatment of HCV in adults moved away from the 
previously recommended interferon-based regimens towards the more effective direct 
acting antivirals (DAAs). Current regimens are based on a 12 to 24-week course of 
pangenotypic DAAs, such as daclatasvir/sofosbuvir and ledipasvir/sofosbuvir, 
depending on whether the patient has liver cirrhosis. A multitude of regimens are 
available, with further drugs for the treatment of HCV receiving approval after the 
publication of the 2016 guidelines. Although recommendations for treatment in PLWH 
co-infected with HCV are the same as those infected with HCV alone, special 
consideration must be taken in their clinical management, specifically regarding 
potential DDIs between ART and DAAs (37, 38, 41, 42). 
1.2.2 Leprosy 
Mycobacterium leprae (M. leprae) is the bacterium responsible for the infectious 
disease leprosy, also known as Hansen’s disease, and was first discovered in 1873 by 
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Dr. Gerhard Armauer Hansen. Historically, written clinical descriptions as early as 
1400 BC from India are widely regarded as leprosy, with the spread of the disease 
throughout Europe thought to take place between 1000 – 1400 AD. Since the 
introduction of multi-drug therapy (MDT) by the WHO in 1981, the prevalence of 
leprosy has decreased from an estimated 10 – 12 million cases to a reported 184,212 
registered cases worldwide in 2018. India, Brazil and Indonesia have the highest 
prevalence of leprosy with 50%, 15% and 10% of worldwide cases, respectively (43-
45). There are currently no epidemiological data on PLWH co-infected with leprosy, 
however there is a geographical overlap in high prevalence countries of both leprosy 
and HIV. Studies specifically investigating PLWH co-infected with leprosy are 
limited, however clinical cohort studies in Brazil and India have identified a higher 
prevalence of leprosy in PLWH. Additionally, a study comparing two cohorts of 
leprosy patients with and without HIV in the Amazon region of Brazil concluded that 
HIV and leprosy have independent infectious courses (46). Despite this, there remains 
a lack of understanding of the interplay between leprosy and HIV (47, 48).  
Leprosy transmission is thought to occur through droplets from the nose and 
mouth between close, repeated contact with an untreated patient (49). A study in 
northwest Bangladesh found that the risk of developing leprosy through household 
contact with an untreated patient is 10-fold greater in comparison to the general 
population (50, 51). Leprosy has a prolonged incubation period due to the slow 
multiplication of M. leprae and can take up to 20 years to produce symptoms. The 
skin, nerves and nasal mucosa are primarily affected by leprosy with symptoms 
including skin growths and discolouration, muscle weakness and nosebleeds. 
Untreated leprosy can cause muscle paralysis, blindness and chronic foot ulcers (45, 
49). Current WHO guidelines recommend a three-drug therapy, referred to as MDT, 
consisting of rifampicin (RIF), dapsone and clofazimine for 6 and 12 months for 
paucibacillary (PB) and multibacillary leprosy, respectively. Additionally, single dose 
RIF (SDR) is recommended as chemoprophylaxis in adults and children with close 
contact to a diagnosed leprosy patient (52). The COLEP clinical study found that SDR 
in close contacts reduced the risk of leprosy incidence by 57% in the first two years 
post contact (53). The clinical management of MDT in PLWH must be carefully 
evaluated due to the risk of DDIs between ARVs and RIF, dapsone and clofazimine. 
Whilst the majority of clinically significant DDIs revolve around the coadministration 
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of RIF, dapsone and clofazimine present potential clinically significant and potential 
weak interactions with several ARVs, particularly surrounding adverse effects (54, 
55). 
Although the implementation of MDT has substantially decreased the number 
of cases of leprosy since the 1980’s, the prevalence of leprosy has plateaued over the 
past 10 years (43). The lack of progress towards the elimination of leprosy has 
challenged existing procedures used for prevention and treatment, with research efforts 
currently targeting early detection, contact screening, point-of-care diagnosis tests and 
SDR chemoprophylaxis (56, 57). Current research has explored the use of Bacillus 
Calmette-Guérin (BCG) vaccination alongside SDR for prevention. The MALTALEP 
trial identified a 42% reduction in PB leprosy amongst patients who received SDR 
after BCG vaccination vs. patients who received BCG vaccination alone (51). An 
additional clinical trial has planned to evaluate the effectiveness of SDR administered 
prior to BCG vaccination (58). A further aspect yet to be considered for SDR 
chemoprophylaxis as well as MDT is the implementation of a higher dose of RIF. 
Current guidelines recommend a 600mg RIF dose however a previous study 
demonstrated the ability of 1200mg and 1500mg SDR to reduce the rate at which M. 
leprae were rendered non-infective more effectively than 600mg and 900mg SDR. 
Cost associations and toxicity studies at the time of study led to the preference of 
600mg SDR however recent studies exploring high dose RIF for the treatment of TB 
have found dosing up to 35mg/kg (2450mg for the average 70kg adult) to be safe and 
well tolerated (59-61).  
1.3 Pharmacokinetics 
The dose-exposure-response relationship of a drug is based upon two 
fundamental principles: pharmacokinetics and pharmacodynamics.  Pharmacokinetics 
can be defined as the concentration-time profile of a drug in plasma, tissue or other 
bodily fluid that is regulated by absorption, distribution, metabolism and excretion 
(ADME) mechanisms in the body. Pharmacodynamics can be defined as the 
physiological effect of a drug on the body in relation to its plasma, tissue or other 
bodily fluid concentration (62). The ADME of a drug is influenced by its molecular 
properties as well as the route of administration. The most common route of drug 
administration is oral dosing with many ARVs being administered this way. 
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Alternative routes of administration include intravenous injection (IV), intramuscular 
injection (IM), subcutaneous injection (SC), transdermal and topical, all of which are 
used depending on the desired pharmacokinetic and pharmacodynamic outcome (63). 
For example, as previously mentioned the recently approved Cabenuva is an IM 
injectable containing extended-release CAB and RPV formulations to provide 
effective plasma concentrations for viral suppression over a 1 month period, lowering 
pill burden and increasing drug adherence for PLWH (28).  
Absorption takes place following oral administration when the drug is 
subsequently solubilised and transported across the enterocytes of the gastrointestinal 
(GI) tract into the bloodstream. Several factors influence the absorption of a drug, 
some of which are drug and formulation dependent such as lipophilicity, particle size 
and polarity, and others which are physiologically dependent such as the presence of 
food, intestinal motility, enzyme abundance and transporter abundance. Drug absorbed 
from the GI tract travels via the portal vein to the liver where it is actively and passively 
transported across hepatocyte membranes, undergoing metabolism and biliary 
excretion prior to reaching the systemic circulation. This process is known as first-pass 
metabolism. In contrast, IV administration introduces the drug directly into the 
systemic circulation, bypassing the absorption and first-pass metabolism processes. 
Furthermore, absorption of drug from IM and SC administration is dependent on the 
location of administration with absorption being influenced by both drug, formulation 
and physiological factors such as lipophilicity and tissue vascularity (62, 63).  
Drug is distributed throughout tissues and organs via the systemic circulation 
and again, is dependent on both drug and physiological characteristics. The flow of 
blood to the various tissues and organs is a major contributor to drug distribution, along 
with binding of drug to plasma proteins and the blood-to-plasma ratio (R). Of 
particular importance is the reversible binding of drug to plasma proteins as only the 
fraction of unbound drug in plasma (fu) can exert its pharmacological effect as well as 
undergo metabolism and excretion processes (62). The fu is dependent on a drugs 
physicochemical properties along with the concentration of proteins such as albumin 
and α-acidic glycoprotein in plasma. As previously mentioned, the liver plays a pivotal 
role in the metabolism and excretion of a drug, with metabolism also occurring in the 
GI tract. Drug metabolism can be divided into phase I and phase II metabolism 
whereby a drug is transformed into a more hydrophilic entity to facilitate biliary and 
21 
 
renal excretion. The metabolic pathway of a drug can involve a single enzyme or 
multiple phase I and phase II enzymes. Phase I metabolism consists of oxidative 
reactions carried out predominantly by the cytochrome P-450 (CYP) family of 
enzymes (62, 63). Phase II metabolism consists of conjugation reactions with the UDP-
glucuronosyltransferases (UGT) family of enzymes being key to these processes (64). 
As well as facilitating drug excretion, drug metabolism can also generate the 
pharmacologically active metabolite from the parent drug. For example, the ARV drug 
tenofovir (TFV) is an NRTI that is phosphorylated intracellularly to form the active 
metabolite, TFV diphosphate (TFV-DP). Furthermore, due to TFV’s poor membrane 
permeability and bioavailability, it is administered orally in the prodrug formulations 
TFV alafenamide (TAF) and TFV disoproxil fumarate (TDF) (65, 66). The GI tract, 
liver and kidneys are the predominant pathways in drug excretion where drug is 
removed from the body in the faeces, bile (and ultimately faeces) and urine. The 
kidneys are instrumental in the excretion of a drug and its metabolites and can occur 
through glomerular filtration from the bloodstream into the proximal tubule as well as 
via the interplay between tubular reabsorption and secretion from the bloodstream 
(63). Together, the metabolism and excretion of a drug is referred to as drug 
elimination (67).  
There are several quantifiable parameters used to describe drug 
pharmacokinetics. An example of a plasma concentration-time profile after the oral 
administration of a drug is shown in Figure 1.6, with the processes of absorption and 
elimination highlighted alongside commonly used pharmacokinetic parameters. These 
include the area under the curve (AUC), maximum concentration (Cmax), minimum 
concentration (Cmin) and time of maximum concentration (Tmax). In addition, the 
bioavailability, clearance and volume of distribution (Vss) of a drug are commonly 
referred to pharmacokinetic parameters. The percentage of administered drug reaching 
the systemic circulation is known as the bioavailability of a drug and can be sub-
categorised into the fraction of drug absorbed across the GI tract (Fa), fraction of drug 
escaping metabolism in the GI tract (Fg) and the fraction of drug escaping first-pass 
metabolism in the liver (Fh). Clearance defines the volume of blood cleared of drug 
over time with total clearance comprising most commonly as the sum of hepatic, 
biliary and renal clearance (63). Clearance of a drug is often referred to as apparent 
oral clearance (CL/F) or systemic clearance (CLsys) where CL/F describes the 
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clearance of an orally administered drug and therefore considers the drugs 
bioavailability, whereas CLsys does not and is associated with drugs administered 
through alternative routes such as IV (68). The Vss is a measurement of the distribution 
of drug in tissue and is calculated considering fu of drug in plasma and tissue as well 
as the volume of plasma and tissue, rather than being a physically quantifiable volume 
(63). 
 
Figure 1.6 Example of a concentration-time profile after oral administration of a drug. 
Time is plotted on the x-axis and plasma concentration is plotted on the y-axis. Key 
pharmacokinetic parameters area under the curve (AUC), maximum concentration 
(Cmax), minimum concentration (Cmin) and time of maximum concentration (Tmax) are 
highlighted with red dashed lines. The absorption and elimination phases are 
highlighted in yellow (62). 
 
1.3.1 Transporters 
Transporters are fundamental to ADME processes with our understanding of 
their structure, function and clinical significance vastly improving over the past 20 
years thanks to a multitude of research initiatives (69). Alongside passive diffusion, 
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transporters facilitate the uptake and efflux of drugs across cell membranes. Although 
transporters are located throughout the body with varying expression profiles, those 
located in the liver are of significant clinical importance and will be the primary focus 
in this thesis. Figure 1.7 details the transporters located on the basolateral and apical 
membranes of human hepatocytes in the liver. Liver transporters are responsible for 
the directional transport of drug from the portal vein to hepatocytes and either into the 
bile canaliculi or back into the portal vein. Hepatic uptake transporters therefore 
determine the extent of liver metabolism and biliary excretion of drugs primarily 
transported through active uptake mechanisms, highlighting the extent of their 
pharmacokinetic and clinical importance. Transporters can be categorised into two 
major groups: the solute carrier (SLC) transporter family and the adenosine 
triphosphate (ATP)-binding cassette (ABC) transporter family (70). SLC transporters 
are primarily involved in the uptake into cells whereas ABC transporters are primarily 
involved in the efflux out of cells. ABC transporters utilise the hydrolysis of ATP as a 
source of energy for the primary active transport of drugs against their concentration 
gradient. In contrast, SLC transporters generally behave as either a coupled symporter 
or antiporter which leverage the energy produced from the electrochemical gradient of 
ions for the secondary active transport of drugs either in the same direction or opposite 
direction of the electrochemical gradient, respectively. Additionally, SLC transporters 
can function as a uniporter, transporting drugs down the electrochemical gradient 
through passive facilitated diffusion (71, 72). Whilst we still lack a comprehensive 
understanding of the transport processes employed by SLC transporters, three 
alternating access mechanisms have been suggested: rocker switch, gated-pore and 
elevator. Through these mechanisms the transporters are thought to undergo 
conformational changes from outward facing to inward facing, with the substrate 
binding site therefore being exposed from either the outside or inside of the cell, 
respectively (71, 73, 74).  
Of the transporters located in the liver, the SLC organic anion transporting 
polypeptides 1B1 (OATP1B1; SLCO1B1) and 1B3 (OATP1B3; SLCO1B3) have been 
identified in the disposition of numerous drugs, with statins being a popular example 
(72, 74, 75). Consequently, these transporters are victim to a multitude of clinically 
significant DDIs, especially with ARVs, and will be discussed in more detail in section 
1.4 (72). Drug-transporter relationships are complex, with drugs tending to lack 
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transporter specificity and their affinity towards different transporters varying along 
with the expression profiles of the transporters themselves. For example, PIT is a 
substrate of both OATP1B1 and OATP1B3 with an in vitro study demonstrating that 
OATP1B1 accounts for 90% of the total hepatic clearance of PIT and OATP1B3 for 
the remaining 10% (76). A meta-analysis investigating the expression levels of OATP 
transporters found the expression of OATP1B1 was three times greater than OATP1B3 
in human liver tissue (77). This suggests that although PIT is a substrate of both 
transporters, it seems to have a higher affinity for OATP1B1 over OATP1B3. 
Interestingly, the localisation of OATP1B1 and OATP1B3 expression throughout the 
liver is dissimilar, with OATP1B1 being expressed equally throughout the liver and 
OATP1B3 being expressed largely in hepatocytes surrounding the central vein (78, 
79). Additionally, the variation found in transporter expression is large with the above-
mentioned meta-analysis finding for OATP1B1 from human liver tissue a range of 0.8 
– 44.3 fmol/µg protein across 86 samples from 5 studies (77). Transporter expression 
can also vary under certain disease states such as liver fibrosis and cirrhosis, potentially 
resulting in altered pharmacokinetic drug profiles (79, 80). Furthermore, transporters 
are subject to single nucleotide polymorphisms (SNPs) which can alter their 
functionality. Two SNPs have been found to affect the function of OATP1B1, 
c.388A>G and c.521T>C, which occur in the SLCO1B1*1B, SLCO1B1*5 and 
SLCO1B1*15 haplotypes. Studies in vitro have demonstrated a reduction in the 
activity of OATP1B1 for all three haplotypes, with SLCO1B1*1B also showing an 
increase in activity (81, 82). The frequency of these SNPs differ among populations 
with a genetic study revealing that the haplotypes SLCO1B1*5 and SLCO1B1*15 
were more frequent in European people and Asian people while SLCO1B1*1B was 




Figure 1.7 Human hepatocyte transporters located on the basolateral and apical 
membranes. Uptake transporters on the basolateral membrane include organic cation 
transporter 1 (OCT1; SLC22A1), organic anion transporter 2 (OAT2; SLC22A7), 
organic anion transporter 7 (OAT7; SLC22A9), OATP1B1 (SLCO1B1), OATP1B3 
(SLCO1B3), organic anion transporter 2B1 (OATP2B1; SLCO2B1) and 
sodium/taurocholate co-transporting peptide (NTCP; SLC10A1). Efflux transporters 
located on the basolateral membrane include multidrug resistance-associated protein 3 
(MRP3; ABCC3), multidrug resistance-associated protein 4 (MRP4; ABCC4) and 
multidrug resistance-associated protein 6 (MRP6; ABCC6). Additionally, located on 
the basolateral membrane is the dual uptake and efflux transporter organic solute 
transporter alpha-beta (OSTα-OSTβ; SLC51). Efflux transporters located on the apical 
membrane include the breast cancer resistance protein (BCRP; ABCG2), bile-salt 
export pump (BSEP; ABCB11), P-glycoprotein (P-gp; ABCB1), multidrug and toxin 
extrusion protein 1 (MATE1; SLC47A1) and multidrug resistance-associated protein 




1.4 Drug-Drug Interactions 
A DDI can be defined as the pharmacokinetic and pharmacodynamic outcome 
resulting from the coadministration of two or more drugs. That is, the outcome of each 
drug administered individually differs from when they are coadministered (85). DDIs 
are of significant clinical importance as they can result in ineffective pharmacologic 
drug concentrations as well as drug toxicity. In the example of HIV, a DDI could 
reduce the plasma concentration of an ARV below its minimum effective 
concentration (MEC) enabling viral replication to take place and potentially facilitate 
drug resistant mutations. Conversely, a DDI could increase the plasma concentration 
of an ARV above the minimum toxic concentration (MTC) or, in the case of 
pharmacokinetic enhancers such as RTV, the DDI could increase the plasma 
concentration of an ARV to achieve the pharmacologic effect threshold. DDIs are a 
continuously evolving clinical challenge due to the introduction of new drug regimens, 
high rates of comorbidities and polypharmacy, particularly in PLWH (26, 86, 87).  
DDI mechanisms can be categorised into inhibition and induction and can 
involve both transporters and enzymes. The drugs involved in a DDI are referred to as 
the victim drug or perpetrator drug depending on whether they are affected by or cause 
the DDI, respectively. Inhibition can occur directly in an irreversible time-dependent 
or reversible manner, with reversible inhibition being further defined as competitive, 
non-competitive, uncompetitive or mixed (72, 88). The exact mechanisms of 
transporter inhibition remain unclear however the general principles of inhibition 
appear similar to enzymes, although the kinetic principles can differ. As transporters 
span across membranes and undergo conformational changes to become inward and 
outward facing, exposing the binding site on either side of the cell, they are subject to 
perpetrator binding from either side. So, depending on the location of the perpetrator, 
whether it be inside or outside of the cell, non-competitive inhibition could also exhibit 
uncompetitive kinetics. Furthermore, whereas in competitive enzyme inhibition 
increasing the substrate concentration can overcome the inhibitory effect by increasing 
the probability of substrate binding, this is not always true for competitive transporter 
inhibition as the perpetrator could competitively inhibit from the opposite side, 
producing non-competitive kinetics (89-91).  
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Irreversible inhibition occurs when the perpetrator drug has a high affinity for 
the binding site and will not likely dissociate once bound, whereas dissociation is 
highly likely in reversible inhibition. Competitive inhibition occurs when both the 
victim and perpetrator drug bind directly to the same site. When the inhibitor binds to 
a different site than the substrate this is known as non-competitive inhibition. Similarly 
to non-competitive inhibition, uncompetitive inhibition occurs when the inhibitor 
binds to a different site than the substrate however in contrast this site is only revealed 
after the substrate has bound. Mixed inhibition is comparable to non-competitive 
inhibition however the binding of either the victim or perpetrator to their respective 
sites reduces the binding affinity of the other. For all of the above scenarios, once the 
perpetrator drug has bound to the enzyme or transporter they become inactivated, 
preventing metabolism processes or transport across the cell membrane, respectively 
(92-94). A schematic representation of the four types of reversible enzyme inhibition 
can be found in Figure 1.8. Inhibition in enzyme-mediated DDIs can cause an increase 
in drug plasma concentrations as shown in Figure 1.10, while in transporter-mediated 
DDIs inhibition can cause either an increase or decrease in drug plasma concentrations 
depending on their localisation within a cell and whether they are an uptake or efflux 
transporter (95). Furthermore, as drugs can be substrates and/or inhibitors of both 
enzymes and transporters, the interplay between transporter-mediated and enzyme-
mediated DDIs can produce varying effects on drug plasma concentrations. For 
example, the ARV PIs ATV/r, DRV/r and LPV/r have demonstrated clinically 
significant inhibition of OATP1B1, OATP1B3 and CYP3A4 and their 
coadministration is contraindicated in many scenarios. For example, GZR the HCV 
NS3/4A PI used in combination with elbasvir for the treatment of chronic HCV in 
adults is reported to be a substrate of CYP3A4, OATP1B1, OATP1B3 and P-gp. 
Clinical DDI studies found geometric mean ratios of GZR coadministered with ATV/r, 
DRV/r or LPV/r vs. GZR administered alone for AUC, Cmax and Cmin ranging from 





Figure 1.8 Schematic representation of the four types of reversible enzyme inhibition: competitive (A), uncompetitive (B), non-competitive (C) 
and mixed (D). The key details the enzyme, substrate, products and inhibitors in blue, green, red and purple, respectively. In competitive inhibition 
both the substrate and inhibitor bind to the same site on the enzyme. In uncompetitive inhibition the inhibitor binds to an alternate site on the 
enzyme that is only revealed once the substrate has bound. In non-competitive inhibition the substrate and inhibitor bind to two separate sites. In 
mixed inhibition the substrate and inhibitor bind to two separate sites with the binding of one reducing the binding affinity of the other (92-94, 97).
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In contrast to inhibition, induction occurs indirectly. After entering the 
cytoplasm of a cell, the perpetrator drug binds to the ligand-binding domain on a 
nuclear receptor producing a ligand‐receptor complex where it then translocates to the 
nucleus. After entering the nucleus, the complex forms homodimers or heterodimers 
with the retinoid X receptor via the recruitment of coactivators. These complexes are 
then able to modify the transcription of an enzyme or transporter by binding to specific 
regions of the corresponding target genes that are associated with their regulation. 
Thus, resulting in an increase in enzyme or transporter abundance. A schematic 
representation of this process can be found in Figure 1.9. Similarly to inhibition, the 
induction kinetics for enzymes and transporters differ with enzyme induction causing 
a decrease in drug plasma concentration, as shown in Figure 1.10, and transporter 
induction causing either an increase or decrease in drug plasma concentrations 
depending on their localisation within a cell and whether they are an uptake or efflux 
transporter. Several nuclear receptor transcription factors have been identified and 
their involvement in the induction of different enzymes and transporters varies. Several 
of these nuclear receptors such as pregnane X receptor (PXR), constitutive androstane 
receptor (CAR) and hepatocyte nuclear factor 4a (HNF4α) regulate CYP3A4 
expression with PXR demonstrating a pivotal role. RIF is a potent inducer of several 
enzymes and transporters including CYP3A4, UGT1A1 and P-gp resulting in multiple 
clinically relevant DDIs (98, 99). For example, the integrase inhibitor dolutegravir 
(DTG) is reported to be majorly metabolised by UGT1A1 and CYP3A4 with minor 
metabolism by UGT1A3 and UGT1A9. RIF is coadministered with DTG for the 
treatment of TB in co-infected PLWH however due to their magnitude of DDI current 
guidelines recommend increasing the administration of DTG to 50mg twice daily 
(BID) from 50mg once daily (QD). The increased dose has proven effective in 
overcoming the RIF-mediated induction of UGT1A1 and CYP3A4, producing plasma 
concentrations similar to DTG 50mg QD that are within the effective concentration 




Figure 1.9 Schematic representation of the mechanism of transporter induction by the 
PXR nuclear receptor. The cell is represented by a grey dotted line with the nucleus 
represented by a grey shaded rectangle. The inducer drug, PXR and RXR are 
represented in purple, green and blue respectively, with the target gene, mRNA and 






Figure 1.10 Example of the effect of enzyme-mediated DDIs on the concentration-
time profile a victim drug. Time is plotted on the x-axis and the average plasma 
concentration is plotted on the y-axis. MTC refers to the minimum toxic concentration 
and MEC to the minimum effective concentration. The yellow line represents the 
victim drug administered alone. The blue and green lines represent the victim drug 
coadministered with an inhibitor perpetrator drug and an inducer perpetrator drug, 
respectively. 
1.4.1 Older Adults Living with HIV 
Despite a significant increase in OALWH over the past decade, this population 
remains vastly underrepresented in clinical trials leading to inadequate clinical practice 
guidelines and a disparity in pharmacokinetic knowledge compared to PLWH aged 
≤50 years (102, 103). Clinical management of OALWH is inherently complex with 
comorbidities, geriatric syndromes and polypharmacy requiring simultaneous 
consideration. Comorbidity is defined as the co-existence of multiple chronic health 
conditions (104). Compared to HIV-negative matched controls, several studies have 
shown that OALWH have a higher burden of comorbidities and are thought to occur 
more frequently in this population due to a combination of factors including ART 
toxicity, chronic inflammation and immune dysregulation (105). Commonly occurring 
comorbidities include bone disease, cardiovascular disease, diabetes, kidney disease, 
and non-AIDS malignancies (103, 105, 106). Geriatric syndrome is the umbrella term 
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for clinical conditions resulting from the accumulation of multi-system impairments 
common in older adults. The early onset of geriatric syndromes in OALWH is thought 
to manifest from a combination of factors including chronic inflammation, 
multimorbidity and polypharmacy. A recent cross-sectional study of PLWH aged ≥50 
years described frailty, difficulty with instrumental activities of daily living, cognitive 
impairment, depression and urinary incontinence as the most commonly occurring 
geriatric syndromes (107). Defined as the use of 5 or more medications (108), several 
studies have also demonstrated the increased rate of polypharmacy in PLWH 
compared to non-HIV infected adults with the prevalence of polypharmacy increasing 
yet again when comparing PLWH aged ≤50 years to OALWH (103, 109-114). 
Over the past 10 years multiple clinical cohorts containing or designed 
specifically for OALWH have taken place across Europe and the US. These include 
but are not limited to: HOPS study (109), EuroSIDA study (111), AGEhIV study 
(115), POPPY study (116), COBRA study (117), GEPPO study (118), French 
Dat’AIDS study (110), SWISS HIV study (119) and the FUNCFRAIL study (103). 
Analysis of these studies have recently been published identifying the key issues 
hindering the clinical management of OALWH to encourage their inclusion in clinical 
trials and increase research efforts. Interestingly, one publication analysing several 
European cohorts found that there are currently no studies identifying optimal ARV 
regimens in OALWH. Furthermore, they found that the GEPPO study was the only 
study to assess ARV regimens in OALWH and that one third of participants were 
prescribed non-conventional ARV therapy. They discovered 68 varying ARV 
regimens among the 384 study participants and deduced the rate of multimorbidity and 
polypharmacy to be the cause of such clinical management decisions (103). 
Considering the amalgamation of comorbidities, geriatric syndromes and 
polypharmacy in OALWH an increased risk of DDIs has been hypothesised. The 
POPPY study recently demonstrated an increased risk of potential DDIs in OALWH 
in comparison to younger PLWH in England and Ireland. They found that of the 698 
PLWH aged ≥50 years, 57.3% had ≥1 potential DDI involving ARV and non-ARV 
drugs. Additionally, they found that for DDIs involving non-ARV drugs 36.1% of 
PLWH aged ≥50 years had ≥1 potential DDI (120). Similarly, a smaller study 
consisting of 89 PLWH aged ≥60 years in San Francisco, USA found that 70% of 
participants had ≥1 DDI that required therapy modification (113). In contrast, the 
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Swiss HIV cohort study found no statistically significant difference between potential 
DDIs in PLWH aged ≥65 years in comparison to PLWH aged ≤65 years. They found 
that among the total 996 participants 46% had ≥1 potential DDI, with PLWH aged ≥65 
years having a higher rate of potential DDIs between ARV and cardiovascular drugs 
(119). Recently, a repository describing an aging population was produced and 
implemented into a physiologically-based pharmacokinetic (PBPK) model to gain 
further insight into the effect of ageing on ARV pharmacokinetics and DDIs. They 
found that elderly adults had a reduced rate of drug clearance resulting from decreased 
hepatic and renal blood flow and that ageing did not impact DDIs regardless of 
mechanism. However, it must be taken into consideration that this PBPK analysis was 
limited by the drugs included in the study and by our current understanding of DDI 
mechanisms (121-125). Furthermore, it is important to account for pharmacodynamic 
changes in OALWH when evaluating DDIs. For example, ageing has been reported to 
alter the pharmacodynamics of benzodiazepines and beta blockers, producing an 
increased and decreased effect in older adults compared to younger adults, 
respectively. These pharmacodynamic differences in older adults are thought to be 
caused by a change in homeostatic processes or by a change in the quantity and/or 
affinity of receptors (126).  
To help support the clinical management of OALWH, the HIV Drug 
Interactions website recently published a resource for clinicians and patients 
containing prescribing decision trees as well as information on drug classes and 
common prescribing cascades to avoid (127). The HIV drug interactions website is a 
freely available, evidence-based drug interaction resource that uses a traffic light 
system to categorise drug interactions based on whether there is no clinical interaction 
expected (green), a potential weak interaction expected (yellow), a potential 
interaction expected (orange) or an interaction expected that advises against 
coadministering the drugs in question (red). Based on the variety of ARV regimens 
found to be prescribed in OALWH and the rate of polypharmacy in this population, an 
analysis of the HIV drug interactions website was carried out herein to understand 
potential DDIs in OALWH. The analysis included drug classes prescribed for 
commonly occurring comorbidities and geriatric syndromes found in OALWH (103, 
105-108, 128) and their interactions with the four main groups of antiretrovirals: 
protease inhibitors (PIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), 
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nucleoside reverse transcriptase inhibitors (NRTIs) and entry/integrase inhibitors 
(129). A summary of the analysis can be found in Figure 1.11.  
PIs had 58% of their drug interactions advising against coadministration or 
with a potential weak or potential interaction expected. Most PI drug interactions 
advising against coadministration involved overactive bladder agents and lipid 
lowering agents, of which darifenacin, lovastatin and simvastatin were the largest 
contributors. Of interest, several drug interactions advising against coadministration 
also involved saquinavir together with antidepressants and beta blockers. Drug 
interactions with a potential weak or potential interaction expected typically involved 
overactive bladder agents, antidepressants and beta blockers. Lopinavir and atazanavir 
were involved in several of the potential interactions expected and produced many of 
these interactions with beta blockers. PI drug interactions expecting no clinical 
interaction largely involved hypertension, lipid lowering agents and anti-diabetics. In 
contrast, 98% of NRTI drug interactions had no clinical interactions expected. 
NNRTIs and entry and integrase inhibitors were similar with 80% of their drug 
interactions having no clinical interactions expected and 20% advising against 
coadministration or with a potential weak or potential interaction expected. Of the 
NNRTIs, most of the drug interactions with a potential interaction expected comprised 
of efavirenz, etravirine and nevirapine. Regarding the entry and integrase inhibitors, 
elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide and 
elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate were involved in 
the majority of interactions advising against coadministration or with a potential weak 










Figure 1.11 DDIs between ARV drug classes and commonly prescribed drug classes 
in older adults (103, 105-108, 128, 129). Graph A, B, C and D represent DDIs 
involving protease inhibitors (PIs), non-nucleoside reverse transcriptase inhibitors 
(NNRTIs), nucleoside reverse transcriptase inhibitors (NRTIs) and entry and Integrase 
Inhibitors, respectively. Prescribing guidance do not coadminister, potential 
interaction, potential weak interaction and no clinical interaction are represented in 
red, orange, yellow and green, respectively.  
 
It is evident that clinical trials representative of OALWH are essential for the 
adaptation of current HIV clinical practice guidelines to include appropriate 
comorbidity, polypharmacy and geriatric assessment models, with collaboration 
across multiple medical and research specialities being a vital element in this process  
(103, 107, 130). Specifically, clinical, in vitro and in silico studies are needed to clarify 
the risk and magnitude of DDIs in OALWH compared to younger PLWH. These 
studies would improve our understanding of pharmacokinetics in OALWH and aid in 
the production of ARV and non-ARV drugs with lower DDI potential, helping to 
create more sustainable clinical management practices for OALWH in the future (106).   
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1.5 In Vitro and In Silico Assessment of DDIs 
In vitro and in silico assays can be used for the investigation of transporter 
pharmacokinetics with the ability to elucidate transporter-based clearance as well as 
magnitudes of transporter-mediated DDIs. Moreover, in vitro-in silico frameworks can 
be utilised for the extrapolation of in vitro assays to produce clinically meaningful 
data. These assays can be applied in the development of new molecular entities as well 
as in the exploration of transporter mechanisms to increase our knowledge base. With 
the clinical importance of transporters being uncovered over the past 20 years, 
regulatory agencies have provided guidance on clinical, in vitro and more recently in 
silico protocols for their investigation with a plethora of information now being 
available (131-133).   
1.5.1 In Vitro Assessment of Transporter-Mediated Clearance and DDIs 
There are a multitude of in vitro assay systems utilised for the assessment of 
transporters. These systems can be categorised into expression systems such as 
vesicular based systems or overexpressing transfected cell line systems, and whole cell 
systems such as hepatocytes. Different in vitro assay systems answer different 
transporter questions, with some being more appropriate than others. For example, 
whilst a SPHH assay can estimate hepatic clearance, it is unable to estimate biliary 
clearance, of which a sandwich-cultured human hepatocyte (SCHH) assay would be 
best suited. On the other hand, a SPHH and a plated primary human hepatocyte 
(PPHH) assay can both estimate hepatic clearance although each possess certain 
advantages and limitations. Namely, whilst both SPHH and PPHH assays benefit from 
cell types capable of simultaneous transporter pharmacokinetic assessment, PPHHs 
are impeded by decreased transporter function over the prolonged assay time-course. 
Overall, primary human hepatocytes enable a more physiologically accurate 
representation of transporter expression and function in comparison to expression 
systems, although they can be limited by interindividual differences across donors, as 
previously described in section 1.3.1. Pooled primary human hepatocyte (PHH) donor 
lots however, largely counteract the effect of interindividual differences in expression 
and activity and allow for a more realistic depiction of a population (131). Donor 
information such as gender, race, age, medications, history and cause of death or 
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surgery, depending on whether the hepatocytes were obtained from deceased or living 
patients, should be detailed where possible so that sources of potential variation in 
transporter expression and activity can be examined alongside resulting in vitro data. 
That being said, PHH suppliers often provide personalisation services so that donors 
with certain characteristics can be included or excluded, generating targeted in vitro 
assay systems that overcome some of the abovementioned limitations (134).  
It is therefore essential to determine what data is required and what is its 
intended application. In general, vesicle based and transfected cell line systems are 
capable of estimating the kinetics of a specific transporter whilst hepatocyte or other 
whole cell systems are able to estimate transporter kinetics of whole processes or the 
combination of multiple processes simultaneously. An extensive table detailing the 
types of in vitro assays, their applications, strengths and limitations was previously 
published, providing a key resource for assay decision making (131). In the 
development of new drugs, the FDA currently recommend over-expressing cell line 
systems to determine whether the drug is a substrate and/or inhibitor of a transporter, 
with specified criteria determining the need for further in vivo analysis. For example, 
if a drug is found to be an inhibitor of OATP1B1 in vitro, in vivo studies investigating 
the DDI between likely coadministered drugs in the target population that are known 
substrates of OATP1B1 are recommended (132).  
The assay systems described above can be used to assess both the uptake and 
efflux velocity of a substrate by a transporter as well as transporter-mediated DDIs by 
quantifying cell-associated drug concentrations under varying experimental 
conditions. To note, the term “cell-associated” rather than “intracellular” is used as it 
provides a more accurate description regarding drug concentrations quantified in vitro 
as drug could also be present on the outside of the cell. As this thesis focused on uptake 
transporters and related DDIs, the general concept of their experimental protocols are 
described below. Broadly speaking, transporter uptake studies consist of ≥6 
concentrations of substrate drug in the presence of the cell system being used for the 
assay. The concentration of cell-associated drug present after a specified period of time 
is quantified either through liquid chromatography or radio-labelled based techniques. 
This data is then plotted as shown in Figure 1.12 with the ≥6 substrate concentrations 
plotted on the x-axis and cell-associated substrate concentration plotted on the y-axis. 
This assay type follows Michaelis-Menten kinetics and so the maximum velocity 
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(Vmax) and Michaelis constant (Km) can be calculated. This in turn allows for the 
scaling of in vitro data to calculate the in vivo intrinsic clearance, known as in vitro-in 
vivo extrapolation (IVIVE). As highlighted in the graph, the initial incline follows first-
order kinetics as the rate is affected by substrate concentration whereas the plateau 
follows zero-order kinetics as the substrate concentration no longer effects the rate due 
to transporter saturation.  
 
 
Figure 1.12 Example of a Michaelis-Menten graph of the uptake velocity of a 
transporter substrate. Substrate concentration is plotted on the x-axis and velocity is 
plotted on the y-axis. Key Michaelis-Menten parameters maximum velocity (Vmax), 
50% maximum velocity and the Michaelis-Menten constant (Km) are highlighted with 
red dashed lines. First-order and zero-order kinetics are highlighted in yellow. 
 
Similarly to uptake studies, transporter-mediated DDIs studies generally 
consist of ≥6 concentrations of perpetrator drug along with a constant concentration of 
the victim drug in the presence of the cell system being used for the assay. The 
concentration of cell-associated victim drug present after a specified period of time is 
quantified through the techniques previously described with the resulting data being 
plotted as shown in Figure 1.13. The ≥6 concentrations of perpetrator drug are plotted 
on the x-axis and the concentration of cell-associated victim drug is plotted on the y-
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axis. The half maximal inhibitory concentration (IC50) can then be calculated as a 
measure of inhibitory potency of the perpetrator for the specific victim and transporter 
or transporters (131-133, 135). As the IC50 is relative to the victim and perpetrator 
concentrations applied in the in vitro assay, the inhibition constant (Ki) is often 
preferred and is required for in silico systems. As the calculation of the Ki requires 
numerous, resource intensive studies it is common practice to use the IC50 value to 
calculate the Ki (136). Different equations are used for competitive, uncompetitive, 








( Km 𝑆⁄ +1)
 (2) 
Ki = IC50 (3) 







Figure 1.13 Example of a transporter-mediated DDI inhibition graph. Perpetrator 
concentration is plotted on the x-axis and victim concentration is plotted on the y-axis. 
Key inhibition parameters maximum 50% inhibition and the half maximal inhibitory 
concentration (IC50) are highlighted with red dashed lines. Minimum and maximum 
inhibition are highlighted in yellow. 
 
Although having numerous options for transporter assessment can be 
advantageous, it does come with certain caveats, specifically the variability in 
estimated pharmacokinetic parameters across laboratories. This can be particularly 
problematic when verifying assay system functionality as well as in the in silico 
assessment of transporters when applying previously published in vitro data. The 
underlying question in these scenarios being: which value to use? Practices across 
laboratories differ, for example some could use the average of all availably published 
values whilst others could use a singular value from a comparable assay type. Further 
laboratory variation is introduced when primary cell types are utilised as transporter 
expression varies between donors with introduction section 1.3.1 highlighting a 40-
fold range being found for the expression of OATP1B1 (77). This is in addition to 




It is apparent that the investigation of transporters in vitro and in vivo is 
challenging. Transporter assay standardisation is not as comprehensive as that of 
enzyme based assays with there remaining a lack of specific transporter substrates and 
inhibitors (131, 133). However, in recent years the international transporter consortium 
(ITC) and FDA have highlighted several transporters which they deem clinically 
relevant and should be assessed during drug development. Alongside these 
transporters the FDA have also provided guidance on the drugs to be used for their 
assessment both in vitro and in vivo. Though as mentioned above, current guidance is 
hindered by a lack of specificity. For example, according to the FDA guidelines 
substrates recommended for the in vitro investigation of OATP1B1 are also a substrate 
of OATP1B3. Furthermore, some drugs are substrates of both uptake and efflux 
transporters found in the same cell type, for instance estrone-3-sulfate is a substrate of 
OATP1B1, OATP1B3 and BCRP all of which are found in hepatocytes. This is again 
true for in vitro transporter inhibitors with cyclosporine inhibiting both OATP1B1, 
OATP1B3 and P-gp. Additionally, some drugs are both a substrate and an inhibitor of 
the same transporter, for example estradiol-17β-glucuronide is both a substrate and an 
inhibitor of OATP1B1 and OATP1B3. Moreover, the drugs recommended by the FDA 
for in vitro investigation differ from those recommended for in vivo investigation (75). 
Differences in the in vitro and in vivo substrate and inhibitor pharmacokinetics of drugs 
can further complicate the analysis of assay data and is one of the challenges faced by 
IVIVE methods and in silico techniques. It is evident that the development of 
transporter specific substrates and inhibitors are essential for improving assessment 
strategies as well as expanding our current knowledge of transporters and related 
DDIs. 
 LC-MS/MS Analysis 
As mentioned above, in vitro assays systems can utilise liquid chromatography 
techniques to quantify assay samples. Liquid chromatography with tandem mass 
spectrometry (LC-MS/MS) is a popular quantification technique used throughout 
academia and industry for the quantification of biological samples. Liquid 
chromatography, or rather reverse phase high-pressure liquid chromatography, is a 
separation technique that utilises a high-pressure liquid mobile phase to transport 
molecules through a solid stationary phase. The liquid mobile phase comprises of 
multiple solutions such as water, solvents as well as acid or base additives and is 
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hydrophilic in nature. The stationary phase consists of a column tightly packed with 
micron sized formulated particles that are hydrophobic in nature. Separation is driven 
by the hydrophilic and hydrophobic properties of the liquid mobile and solid stationary 
phases, respectively. In addition to the two phases, there are several other parameters 
that can be optimised for molecule separation including injection volume, mobile 
phase flow rate, column temperature and sample preparation. After separation, the 
molecule is detected through mass spectrometry. Mass spectrometry is a sensitive and 
highly selective analytical technique that quantifies the mass-to-charge (m/z) ratio of 
ions. A mass spectrometer consists of an ion source, a skimmer cone, one or more 
mass analysers, a collision cell, a detector and a vacuum system, each with specific 
parameters that can be optimised for ion detection. Detection occurs in a multi-step 
process whereby the molecule of interest is firstly ionised using either electrospray 
ionisation (ESI), atmospheric pressure ionisation or atmospheric pressure chemical 
ionisation. By utilising electric fields, a mass analyser is then able to separate the ions 
based on their m/z. Examples of mass analysers include quadrupole, ion trap and time-
of-flight. In tandem mass spectrometry ions can then undergo fragmentation using 
gases such as nitrogen within a collision cell before entering a second mass analyser. 
This techniques allows for greater selectivity and sensitivity as well as the acquisition 
of structural information. Finally, the isolated ions are detected using either a point or 
array detector. Specialised LC-MS/MS software presents the resulting data as a 
chromatogram and mass spectrum (139, 140). 
 Quantification of unknown biological samples occurs through the application 
of calibration standards of known concentrations. The FDA provide recommended 
guidelines for the verification of LC-MS/MS methods used to quantify various 
molecules and sample types. A schematic diagram of the LC-MS/MS method 
development and FDA verification workflow is shown in Figure 1.14. Briefly, the drug 
of interest is solubilised in a suitable solution and directly infused into the mass 
spectrometer where a range of parameters are optimised for ion detection. After the 
selection of an appropriate liquid chromatography column and mobile phase, the 
chromatographic method is developed to provide suitable separation and lower limits 
of quantification. The accuracy and precision of the method is then analysed and if 
necessary, an internal standard applied. An internal standard is a substance of known 
concentration that is added to each sample to correct for variations and improve 
44 
 
quantification performance. An internal standard could either be a stable isotope 
version of the drug of interest or a drug with similar chemical properties. Following 
chromatographic method development, the technique used for sample extraction is 
selected based on optimal recovery of drug from the sample. Some samples may 
require minimal extractions procedures whilst others may require the use of liquid-
liquid or solid-phase extraction to achieve adequate recovery. The FDA guidelines are 
then applied to verify the LC-MS/MS method. If the criteria are not met further 




Figure 1.14 Schematic diagram of the LC-MS/MS method development and FDA verification workflow (141).
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1.5.2 PBPK Modelling 
PBPK modelling is an in silico tool that utilises mathematical equations to 
describe the physiological characteristics and ADME processes of the human body. 
The physicochemical properties of a drug can be applied within the model to predict 
the pharmacokinetics of drug regimens in a simulated cohort of virtual patients. 
Various routes of drug administration can be simulated such as oral, IV, SC, IM and 
transdermal. Furthermore, PBPK models can be constructed to describe specific 
patient characteristics such as age, gender, ethnicity and disease state and are not 
restricted to humans, models can also be developed for other species such as mice and 
rats. Both clinical and in vitro data are utilised in PBPK modelling and can therefore 
be described as a bottom-up approach. An example of a whole-body PBPK model for 
oral administration is shown in Figure 1.15, with both first-pass metabolism and 
systemic circulation being highlighted. Within the model organs and tissues are 
represented by compartments with the distribution of drug throughout the body being 
described by reactions occurring between each compartment. Reactions are defined by 
first-order kinetic equations and consist of parameters that are specified by constant 
values, including drug specific variants, or further equations known as rules. Drug 
variants include characteristics such as molecular weight, fu and R. Rules provide 
detailed descriptions of physiological and ADME characteristics, for instance tissue-
to-plasma ratios, organ weight and volume, hepatic and renal clearance as well as 
patient height, weight and BMI. Compartments, reactions, rules, parameters and 
variants work synergistically to predict pharmacokinetic parameters such as AUC, 
Cmax and Cmin which can be monitored over specified timepoints in a simulated cohort 
of virtual patients. Moreover, any parameter within the model can be monitored 
allowing for the analysis of individual processes that go beyond conventional 





Figure 1.15 Schematic diagram of a whole-body PBPK model used to predict drug 
pharmacokinetics after oral administration. Organs and tissues are represented by 
compartments, with drug distribution represented by arrowed lines and calculated by 
first-order kinetic equations. Veins, arteries, and their associated reactions are 
highlighted in blue and red, respectively, with reactions involved in absorption, 
metabolism and excretion highlighted in yellow. Compartments and reactions 
involved in first pass metabolism are located within the grey box, with those involved 
in systemic circulation enclosed within the dashed line (63, 142, 143). 
 
As described above, PBPK models can be tailored to answer specific clinical 
questions in a variety of populations and scenarios. As a result, PBPK modelling has 
proved increasingly popular in drug development as well as in the investigation of 
clinical scenarios absent of evidential data. In 2019, approximately 50% of all newly 
approved drugs contained PBPK modelling in their submission to the FDA, increasing 
by 30% since 2013. Of the total submissions between 2018 and 2019, 40%, 16% and 
9% were concerning enzyme-mediated DDIs, transporter-mediated DDIs and 
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paediatrics, respectively. The remaining 35% were split across several further 
applications such as renal and hepatic impairment, absorption and disease. This data 
demonstrates the current predictive capabilities and confidence in specific PBPK 
modelling applications, with enzyme-mediated DDIs proving most successful in terms 
of regulatory acceptance. This is attributable to our expansive knowledge of enzyme 
function and mechanisms of DDI, experience with related PBPK models as well as the 
quality and quantity of available in vitro and clinical data used for model development 
and verification (144, 145). A recent analysis examining PBPK modelling over the 
past 20 years discovered a delay between trends in FDA submissions and publications, 
providing a potential insight into future regulatory applications. Specifically, they 
found an increase in PBPK model publications for special populations with disease, 
paediatric and ethnicity showing the largest rise over the past 20 years. In comparison, 
the study found minimal publications for transporter-related DDIs and the elderly 
throughout the analysed time period, identifying the need for increased efforts in both 
PBPK modelling and research of these two underrepresented areas (146). 
Encouragingly, as mentioned in introduction section 1.4.1, a PBPK model for a healthy 
adult population aged up to 99 years was recently developed, indicating a positive 
change in research initiatives in the elderly population (125).  
It is interesting that despite any profound increase in publications over the past 
20 years, transporter-mediated DDIs were the second most popular PBPK modelling 
application in FDA drug approval submissions (144-146). Lack of advancements in 
transporter-mediated DDI modelling has been highlighted by the FDA, with the 
existence of knowledge gaps and the resulting implementation of complex IVIVE 
methods as the current challenges in producing successful regulatory applications 
(144, 145). As discussed in introduction section 1.3.1 and 1.5.1, transporters play a 
fundamental role in the ADME of a drug and can be involved in clinically relevant 
DDIs. A drug can be a substrate and/or inhibitor of multiple transporters which due to 
issues surrounding specificity, can prove challenging to assess in vitro. This has an 
adverse downstream effect on the development of PBPK models and their ability to 
accurately describe mechanisms that we do not fully understand. In addition to these 
challenges, PBPK modelling of transporter-mediated DDIs must also consider the 
interplay with enzyme-mediated DDIs. This is of particular relevance in the liver and 
several publications have employed a permeability limited liver structure within a 
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whole-body PBPK model to predict such DDIs. Briefly, multiple extracellular and 
intracellular compartments are constructed with the extracellular compartments being 
connected by reactions considering blood flow rate. Active uptake and efflux as well 
as passive diffusion are applied in reactions linking the extracellular and intracellular 
compartments. Additionally, enzyme metabolism and transporter-mediate biliary CL 
are considered in reactions exiting the intracellular compartments. DDIs are predicted 
through the simulation of the perpetrator drug in a secondary model. For basolateral 
transporter-mediated DDIs, the concentration of perpetrator drug in the plasma or in 
the extracellular compartment in the liver is applied alongside the predetermined 
transporter Ki value in the reactions between the extracellular and intracellular liver 
compartments of the victim drug model. For apical transporter-mediated DDIs, the 
concentration of the perpetrator drug within the intracellular liver compartment is 
applied alongside the predetermined transporter Ki value in the reactions exiting the 
intracellular liver compartment of the victim drug model. Enzyme-mediated DDIs are 
applied similarly to apical transporter-mediated DDIs but instead consider the 
predetermined enzyme Ki value (147, 148). Although these models have been shown 
to predict drug pharmacokinetics and DDIs relatively accurately, they are limited by 
the application of IVIVE correction factors which differ per drug and per publication. 
Until further advancements in our knowledge of the underpinning mechanisms of 
transporters and related DDIs occur, collective efforts are required to unify IVIVE 
methods and rationale to improve the capabilities of our currently impeded PBPK 
model structures (149).  
 Model Workflow 
PBPK model development and verification is a multi-step process and although 
no regulatory guidance strictly exists, verification criteria of observed vs. predicted 
data ratios within 0.5 – 2-fold are widely accepted (150). Figure 1.16 details the general 
workflow applied in PBPK model development and verification. Firstly, drug 
metabolism and pharmacokinetic data along with relevant clinical data are collected 
for the application drug as well as for any further drugs involved in the mechanistic 
verification of the model. Specific compartments, reactions, rules, parameters and 
variants describing the mechanisms involved in the model application as well as the 
application population are then integrated into a generic PBPK model structure 
alongside the collected drug data. These mechanisms are then verified using available 
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clinical data by simulating the corresponding dosing regimens and comparing the 
observed vs. predicted pharmacokinetic data values. The performance of the model 
can be analysed during this process and if necessary various reactions, rules, 
parameters and variants can be tested along with the application of correction factors. 
Once verified according to the above-mentioned criteria, the model can be used to 
predict the outcomes of the application drug (151). Furthermore, version control can 
be applied to the PBPK model to assist in project management, support multi-user 









Although the data predicted by PBPK models can be used to inform clinical 
decisions, it must be analysed with caution and with a clear understanding of its 
limitations. While these limitations vary per model, they are generally based on our 
fundamental understanding of the ADME processes involved in the application as well 
as the type and quality of clinical data applied in the development and verification 
process. As has been highlighted in the previous sections, the mechanism involved in 
the ADME of a drug are complex and we often lack comprehensive knowledge of such 
processes making translation to mathematical frameworks particularly difficult. 
Additionally, the variability found in vitro can become a liability in IVIVE and 
incorporation into PBPK modelling. The appropriateness of the applied in vitro studies 
could also be called to question, with some systems showing little resemblance to 
physiological environments (153). Furthermore, there are several factors regarding the 
clinical data used for model verification that can be problematic. For example, some 
studies such as those used for the investigation of DDIs are conducted in as little as 5 
patients producing data that is not necessarily representative of a whole population. 
Moreover, the available clinical data may not be generated from the population being 
simulated, with many studies being conducted in healthy patients aged 18 – 60 years 
old. The clinical data could also be from studies conducted many years ago using 
outdated practices in comparison to present day, resulting in potentially inaccurate data 
(154). A quality assessment matrix for PBPK modelling is shown in Figure 1.17 
depicting the outcomes of the above-mentioned limitations. In the absence of 
knowledge on the ADME processes involved in a model’s application, correction 
factors may be integrated and optimised according to the clinical data used for model 
verification. On the other hand, when the quality and availability of clinical data for 
model verification is lacking pre-clinical models can be implemented. Both scenarios, 
and all those in between, reduce confidence in model predictions however such PBPK 
modelling applications still provide valuable insight and may instigate further studies 
to fill the knowledge and data gap, providing vital information and allowing for 




Figure 1.17 Quality assessment matrix for PBPK modelling. The reliability of a 
model’s predictive capabilities is defined by the understanding of the implemented 
ADME processes as well as the quality of the clinical data used for model verification 
(155).  
1.6 Aims 
DDIs remain a key issue in the evolving clinical management of PLWH. Clinical 
guidance is currently impaired by the lack of understanding surrounding the 
mechanisms that dictate DDIs, specifically transporter-mediated DDIs. In vitro and in 
silico techniques can be employed synergistically to explore the role of transporters in 
DDIs, providing valuable information towards a more comprehensive knowledge base. 
Furthermore, the paucity of evidence-based guidance for ARV DDIs produces 
additional challenges in the clinical management of PLWH. The aim of this thesis was 
to identify an effective in vitro assay and in silico PBPK modelling framework to 
elucidate the role of hepatic uptake transporters in DDIs. Additionally, we aimed to 
utilise PBPK modelling to predict the outcome of HIV-related DDIs that have not been 
assessed clinically.      
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Chapter 2 aimed to establish and verify an efficient and reproducible in vitro 
assay system for the assessment of transporter-mediated hepatic intrinsic clearance and 
DDIs. This included the development and verification of an appropriate LC-MS/MS 
method. Following the verification of the in vitro assay system, Chapter 3 aimed to 
construct a PBPK model with a detailed mechanistic description of transporter-
mediated uptake and passive diffusion that incorporated the in vitro data produced in 
Chapter 2. The PBPK model was verified against observed clinical data. The in vitro-
in silico framework designed and verified in Chapter 2 and 3 was then applied in 
Chapter 4 to elucidate the unconfirmed role of transporters in the DDI between the 
HCV drug GZR and the ARV PIs ATV, DRV and RTV. In addition, the in vitro assay 
system verified in Chapter 2 was also utilised in Chapter 5 alongside a sandwich-
ELISA assay to quantify the activity and expression of the hepatic uptake transporter 
OATP1B1 in non-elderly vs. elderly primary human hepatocyte (PHH) donors. 
Furthermore, the aim of Chapter 6 was to design a PBPK model to predict the 
magnitude of the enzyme induction-based DDI between high dose RIF QMT and DTG 
BID for the treatment of leprosy in PLWH. In the absence of clinical data, the aim of 
the PBPK model was to determine if a dose adjustment for DTG would be necessary 
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PLWH are susceptible to DDIs due to the high rate of coinfections, 
comorbidities and complex ART regimens. Moreover, ARV drugs used for the 
treatment of HIV have been identified as both victims and perpetrators of several 
clinically relevant DDIs with the resulting changes in drug exposure leading to toxicity 
and reduced efficacy (156). Recent studies have highlighted the prevalence of potential 
DDIs in PLWH across multiple countries. A prospective cohort study of PLWH in 
Tanzania found that of the 1945 participants 33% had at least one potential DDI (157). 
An assessment of PLWH in the Swiss HIV cohort study found that 29% of the 9298 
study participants had at least one potential DDI (158). Additionally, a study of PLWH 
in China identified that out of the 1804 participants 19.15% had at least potential DDI 
(159). 
The liver plays an integral role in drug clearance and contains several 
transporters that mediate the uptake and efflux of a wide range of drugs (160, 161). 
Consequently, these transporters are involved in numerous DDIs and their 
involvement in ARV DDIs has been previously summarised (72). Specifically, 
OATP1B1 and OATP1B3 located exclusively on the sinusoidal membrane of 
hepatocytes have been identified by the FDA and ITC as clinically important 
transporters that should be assessed during drug development (70, 75, 162). The 
investigation of transporters is challenging as the mechanisms surrounding uptake and 
efflux are not well understood and are further complicated by their interplay with 
enzyme metabolism. However, strategies integrating in vitro and in silico techniques 
can be applied to overcome some of these challenges. The FDA and ITC published 
guidelines for the assessment of transporter-mediated clearance and DDIs and provide 
recommendations on probe substrate and inhibitor drugs for the in vitro assessment of 
clinically relevant transporters across several cell systems. Additionally, a detailed 
overview of in vitro assays for transporter assessment has been previously published, 
highlighting the strengths and weaknesses of each system (131).  
LC-MS/MS is a routine technique that allows for the quantification of a plethora 
of biological molecules and is recommended in transporter assessment. Accurate and 
sensitive LC-MS/MS assays are produced through step-wise method development and 
are verified according to guidelines provided by the FDA (141). Briefly, molecules are 
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separated based on their polarity through liquid chromatography before being ionised 
and analysed by their m/z via a tandem mass spectrometer. A calibration curve of 
known analyte concentrations can be applied to allow the quantification of samples 
with unknown analyte concentrations (139). 
The aim of this study was to develop and verify an in vitro system for the 
assessment of hepatic transporter intrinsic clearance (CLint,T) and DDIs using a dual 
OATP1B1 and OATP1B3 probe substrate and inhibitor. Additionally, this study aimed 
to develop and verify a LC-MS/MS method for the quantification of the probe 
substrate in the in vitro assay (141). The in vitro assay can then be implemented into a 
PBPK model and verified against observed clinical data in Chapter 3 to generate a 








Accucore C18 100 x 2.1mm LC-MS/MS column (catalog no. 17126-102130) 
and Accucore C18 10 x 2.1mm LC-MS/MS pre-column (catalog no. 17126-012105) 
and LC-MS/MS grade water (H2OL; catalog no. 10777404) were purchased from 
Thermo Fisher Scientific (Hemel Hempstead, UK). LC-MS/MS grade acetonitrile 
(ACNL; catalog no. 34967), LC-MS/MS grade formic acid (FAL; catalog no. 56302), 
phosphate buffer saline (PBS) tablets (pH 7.2-7.6; catalog no. P4417-100TAB), 
Krebs-Henseleit buffer (KHB) modified (catalog no. K3753-10L) and dimethyl 
sulphoxide (DMSO; catalog no. D8418-50ML) were purchased from Sigma-Aldrich 
(Poole, UK). Cryopreserved hepatocyte recovery medium (CHRM; catalog no. 
CM7000) and HEPES 1M buffer (catalog no. 15630049) were purchased from Life 
Technologies (Paisley, UK). RIF (98% purity; catalog no. R508000) and pravastatin 
(PRA) sodium (98% purity; catalog no. P702000) were purchased from Toronto 
Research Chemicals (Ontario, Canada). PIT calcium (98% purity; catalog no. 318503) 
was purchased from Medkoo Biosciences (North Carolina, USA). Nucleocassettes 
(catalog no. 16704-000014) were purchased from Sartorius (Surrey, UK). Distilled 
water was produced via an Elga PureLab system (Veolia Water Technologies, High 
Wycombe, UK). All other materials were purchased from Thermo Fisher Scientific 
(Hemel Hempstead, UK) and Sigma-Aldrich (Poole, UK). 
2.2.2 Primary Human Hepatocytes 
Pooled donor cryopreserved SPHHs with lot no. HUE120 (catalog no. 
HMCS10) were purchased from Thermo Fisher Scientific (Hemel Hempstead, UK). 
A summary of donor characteristics can be found in Table 2.1. Lot. HUE120 SPHHs 
were used in the CLint,T, DDI and toxicity studies with any remaining SPHHs from 
each study being utilised as the matrix for calibration and quality control (QC) 




Table 2.1 Summary of cryopreserved SPHH pooled donor characteristics. 
Characteristics Lot No. HUE120 
n 10 
Age, years 
Median (range) 56 (30-62) 
Gender, n   
Male (%) 7 (70) 
Female (%) 3 (30) 
Race, n   
Caucasian (%) 10 (100) 
Reported History, n  
Alcohol (%) 8 (80) 
Tobacco (%) 5 (50) 
Recreational Drugs (%) 4 (40) 
Medication (%) 8 (80) 
n – number of patients. 
 
2.2.3 In Vitro Assay Development and Validation 
The in vitro CLint,T and DDI assays were developed from similar studies 
described in the literature (135, 163-168) and validated by comparison to available 
clinical and in vitro data (166). A SPHH in vitro assay utilising PIT and RIF as the 
probe substrate and inhibitor for OATP1B1 and OATP1B3 were selected in 
accordance with the recommendations from the FDA and the ITC (70, 75) as well as 
considering the availability of in vitro and clinical data (166). Both assays were carried 
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out in duplicate and each contained four technical replicates per condition. The SPHH 
in vitro assays assume negligible metabolism. 
 Preparation of Pitavastatin and Rifampicin Stock Solutions 
Stock solutions of both PIT and RIF were prepared such that the final 
concentrations in each cell culture plate well were between 0.1 – 300 µM with a 
constant DMSO concentration of 1% (vol/vol). Firstly, stock solutions of PIT (20 – 
60000 µM) and RIF (20 – 60000 µM) were freshly prepared in 100% (vol/vol) DMSO 
through serial dilution the day before the experiment. The day of the experiment, 
incubation stock solutions of PIT (0.6 – 1800 µM) and RIF (0.6 – 1800 µM) were 
prepared in KHB (pH 7.4) with 30 µl of the corresponding DMSO stock solution being 
aliquoted per 1 ml of KHB. This equated to PIT and RIF incubation stock solutions 
containing 3% (vol/vol) DMSO in KHB. For the CLint,T assay where only PIT was 
present in each well, KHB containing 3% (vol/vol) DMSO was prepared as a substitute 
for RIF in order to maintain the final DMSO concentration of 1% (vol/vol).  
 Preparation of Suspension Primary Human Hepatocytes 
Preparation of cryopreserved SPHHs took place in a class II biosafety cabinet 
(Baker, Maine, USA) with aseptic techniques being applied throughout (163, 169). 
Firstly, cryopreserved SPHHs were thawed in a 37°C water bath for 2 minutes and 
wiped with 70% isopropanol alcohol (IPA) before being placed in a biosafety cabinet. 
A wide-bore pipette was used to slowly drip the thawed hepatocytes in a circular 
motion into the pre-warmed CHRM media (37°C) before being centrifuged at room 
temperature at 100 × g for 10 minutes. The supernatant was then carefully removed 
and disposed of using a stripette, making sure not to disturb the pelleted SPHHs. The 
SPHHs were then resuspended in 8ml of pre-warmed KHB (37°C). Cell viability was 
determined using a NucleoCounter NC-100 apparatus (Sartorius Ltd., Epsom, UK) 
that utilises fluorescence based cytometry.  The concentration of non-viable cells was 
calculated by aliquoting 150 µl of the suspension into a microcentrifuge tube and 
loading them into a Nucleocassette. The Nucleocassette contains propidium iodide that 
stains the cell nuclei of the non-viable cells due to their permeable cell membranes. 
The Nucleocassette was then inserted into the NucleoCounter and the number of non-
viable cells was calculated through the quantification of the propidium iodide 
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fluorescence. The concentration of total cells was calculated by aliquoting 50 µl of the 
SPHH solution into a microcentrifuge tube along with 50 µl of reagent A100 and 
reagent B with 20 seconds of vortexing after the addition of each reagent. These 
reagents lyse the cells enabling the cell nuclei to be stained with propidium iodide. 
Again, the Nucleocassette was inserted into the NucleoCounter and the number of total 
cells was calculated through the quantification of the propidium iodide fluorescence 
(170). Equations 1 – 4 were then used to calculate the percent of viable cells, the 
number of viable cells/ml and the quantity of KHB required to produce a concentration 
of 1×106 cells/ml. The calculated amount of additional KHB required was then added 
to the SPHH solution and 100 µl was aliquoted into each well on the 24-well cell 
culture plate to produce a final incubation SPHH solution of 1×105 cells/well. 
Remaining SPHHs were aliquoted into microcentrifuge tubes at a concentration of 
1×105 cells/ml, centrifuged at 2000 × g for 2 minutes at 4°C, supernatant removed and 
stored at -80°C for future use as the matrix for calibration, QC and blank samples 
during LC-MS/MS analysis.  
 
Cell Viability (%) = 100 - (
Dead Cells (cells/ml) 
Total Cells (cells/ml) × 3
 × 100) (1) 
Cell Viability (cells/ml) = Total Cells (cells/ml) – Dead Cells (cells/ml) (2) 
Total Volume for 1×106 cells/ml Solution = 
Cell Viability (cells/ml) × 7.8ml
1×106 cells/ml
 (3) 
Additional KHB Required = Total Volume for 1×106 cells/ml Solution – 7.8ml (4) 
 
 Pitavastatin CLint,T and Rifampicin DDI In Vitro Assays 
To determine the CLint,T of PIT, 300µl of KHB was added to each well on the 
24-well cell culture plate followed by preincubation with 100 µl KHB (0.5% vol/vol 
DMSO) for 5 minutes. The study was initiated with the addition of 100 µl of PIT KHB 
stock solution (0.5% vol/vol DMSO; 0.1 – 300 µM). To determine the magnitude of 
DDI between PIT and RIF, 300 µl of KHB was added to each well followed by 
64 
 
preincubation with RIF KHB stock solution (0.5% vol/vol DMSO; 0.1 – 300 µM) for 
5 minutes. The study was initiated with the addition of 100µl PIT KHB stock solution 
(0.5% vol/vol DMSO; 0.1 µM). All wells had a final total volume of 600µl with all 
incubations taking place at 37°C on a plate shaker at 150 rpm. Both studies were 
terminated after 2 minutes by placing the cell culture plates on ice and aliquoting 600 
µl ice-cold PBS into each well. Solutions were immediately transferred to 1.5ml 
microcentrifuge tubes and centrifuged at 2000 × g for 2 minutes at 4°C. Incubation 
solutions were then removed from each tube, cell pellets washed with 600 µl ice-cold 
PBS and the centrifugation process repeated. PBS wash solutions were then removed 
from each microcentrifuge tube and the cell pellets were stored at -80°C. Cells were 
lysed by a single freeze-thaw cycle (-80°C to room temperature; 18 – 25°C) prior to 
LC-MS/MS analysis. The in vitro assays were considered validated if the SPHHs 
demonstrated uptake of PIT as well as inhibition of PIT uptake when in the presence 
of RIF.  
Although SPHH in vitro studies investigating PIT and RIF have previously 
been described in the literature (135, 163-168), potential toxicity of PIT and RIF with 
the SPHHs was assessed through a cell viability study. During the assays described 
above, PIT (300 µM) and RIF (300 µM) well conditions were produced, and after the 
termination of the 2 minute incubation, cell viability was determined as described in 
method section 2.2.3.2. PIT and RIF drug concentrations were deemed non-toxic if the 
cell viability had not substantially decrease in comparison to the cell viability 
calculated during the preparation of the cryopreserved SPHHs. 
2.2.4 LC-MS/MS Quantification 
Quantification was carried out on a TSQ Endura LC-MS/MS (Thermo 
Scientific, Hemel Hempstead, UK) using the Thermo Xcalibur Roadmap (version 
4.0.27.42), Chromeleon Xpress and TSQ Endura Tune Application (version 
2.0.1292.15) software. PRA was chosen as the internal standard (IS) for PIT due to 
their structural similarities and was added to calibrator, QC and unknown samples at a 
constant concentration to facilitate the quantification of PIT, as per convention. For 
use in LC-MS/MS quantification, 1mg/ml stock solutions of PIT and IS PRA in 50% 
(vol/vol) ACNL in deionised H2O (dH2O) were freshly made every 2 weeks. 
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 Mass Spectrometer Optimisation 
Several mass spectrometer (MS) parameters were optimised for the detection 
of PIT and IS PRA by directly infusing 500 ng/ml solutions in 50% (vol/vol) ACNL in 
dH2O into the MS. Heated ESI was applied in positive mode to ionise the analytes and 
allow detection of their fragments via selective reaction monitoring (SRM) scanning. 
Ion spray voltage, sheath gas, auxiliary gas, ion transfer tube temperature and vaporiser 
temperature were optimised separately for PIT and IS PRA. The final parameter values 
were selected based upon the maximal detection of PIT as well as the ability to 
sufficiently detect the IS PRA.  
 Chromatographic Separation 
An Accucore C18 (100 x 2.1mm) LC-MS/MS column fitted with an Accucore 
C18 pre-column (10 x 2.1mm) was used to achieve chromatographic separation of PIT 
and IS PRA. Two mobile phases, A and B, comprising of 100%  H2OL with 0.1% FAL 
and 100% ACNL with 0.1% FAL were used in the development of the multi-step 
gradient method. Solutions of 500 ng/ml PIT and IS PRA were prepared in 50% 
(vol/vol) ACNL in dH2O and 100 µl aliquoted into Chromacol fixed insert vials for 
analysis. The method was developed in a stepwise manner to obtain the shortest run 
time whilst providing efficient separation and detection of the analytes.  
 Sample Preparation 
Once brought to room temperature, the lysed cells from the PIT CLint,T and RIF 
DDI in vitro assays were resuspended in 100 µl of 50% (vol/vol) ACNL in dH2O. These 
cell samples are referred to as unknown samples. To produce concentrations within 
the LC-MS/MS calibration curve range, all unknown samples were diluted with a ratio 
of 1:2 in 50% (vol/vol) ACNL in dH2O except for the unknown samples from the PIT 
10 – 300 µM well conditions which were diluted with a ratio of 1:10. These dilution 
ratios were determined by quantifying one replicate per condition from one 
experimental replicate prior to the analysis of all remaining samples, with these 
samples being excluded from the final analysis. Calibration, QC and blank samples 
were prepared according to the FDA guidelines as described in method section 2.2.4.4 
and Table 2.2 (141). At a concentration of 300 ng/ml, 300 µl of IS PRA in 100% 
(vol/vol) ACNL was aliquoted into each unknown, calibration, QC and blank sample 
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microcentrifuge tube. Samples were then vortexed for 10 seconds and centrifuged at 
13,300 × g for 10 minutes at 4°C. The resulting supernatant was carefully aliquoted 
into borosilicate glass tubes and dried in a Jouan RC10.22 vacuum centrifuge for 4 
hours at room temperature (18 – 25°C). Once dry, samples were reconstituted in 100 
µl of 50% (vol/vol) ACNL in dH2O, vortexed for 10 seconds and 50 µl transferred to 
Chromacol fixed insert vials for LC-MS/MS analysis.  
 Assay Verification and In-Study Guidelines 
The LC-MS/MS assay was verified according to the FDA’s recommended 
bioanalytical guidelines for industry, as described in Table 2.2. Specifically, the 
calibration curve, QCs, selectivity, carryover, sensitivity, accuracy, precision and 
carryover were assessed. Both intra-assay and inter-assay accuracy and precision were 
calculated using equations 5 and 6. The percent difference between the nominal and 
quantified concentrations were calculated within the Thermo Xcalibur Roadmap 
software (Hemel Hempstead, UK). Additionally, for in-study analysis, LC-MS/MS 
runs were kept to a maximum of 70 samples, including zero calibrators, non-zero 
calibrators and QC samples. Each in-study analysis quantification was therefore split 
up and quantified accordingly, ensuring all samples within each CLint,T and DDI assay 
replicate were within the same LC-MS/MS analysis. 
 
% Variability of Accuracy = 
Error
Stated Value
 × 100 (5) 
% Variability of Precision = 
Standard Deviation
Mean Assay Value
 × 100 (6) 
 
2.2.5 Data Analysis 
Prism v8 software (GraphPad Software Inc., La Jolla, CA, USA) was used to 
plot the CLint,T and DDI in vitro assay data quantified using the LC-MS/MS method 
described. Michaelis Menten non-linear regression analysis was applied to the PIT (0.1 
– 300 µM) CLint,T assay data to derive the Vmax (µmole/10




6cells/minute) of PIT was calculated as shown in equation 7 (135) and the 
percent inhibition of PIT (0.1 µM) by RIF (0.1 – 300 µM) was calculated as shown in 
equation 8 (168). Uptakesubstrate,inhibitor and Uptakesubstrate are the total PIT (0.1 µM) 
uptake concentrations in the presence and absence of RIF (0.1 – 300 µM), respectively. 
A log(inhibitor concentration) vs. response equation and a least-squares fitting method 
was applied to the percent inhibition data to calculate the IC50 of RIF required to inhibit 
PIT (0.1 µM). Results from both assays were expressed as the mean ± standard 
deviation (SD) of two individual experimental replicates, each containing three or four 
technical replicates per condition, as previously described. Normality was tested using 
a D'Agostino & Pearson test. 
 
CLint,T = Vmax / Km (7) 




Table 2.2 FDA recommended guidelines for LC-MS/MS verification and in-study analysis (141). 
Parameters Verification Recommendations In-Study Analysis Recommendations 
Calibration Curve 
Elements: 
• Every verification run should contain a blank (no 
analyte, no IS), a zero calibrator (blank plus IS), and at 
least six non-zero calibrator levels covering the 
quantification range (including the LLOQ). 
• All blanks and non-zero calibrators should be in the 
same matrix as the study samples. 
• The simplest regression model should be applied to 
the concentration-response relationship. 
 
Acceptance Criteria: 
• In each verification run the non-zero calibrators 
should be ±15% of the nominal concentrations, except 
for the LLOQ which should be ±20%. 
• In each validation run 75% of the non-zero calibrator 
levels (six minimum) should meet the above criteria. 
Elements: 
• The elements outlined for the verification runs should 
also be applied for the in-study analysis runs. 
• The regression model applied in the verification 
should also be used for the in-study analysis.  
 
Acceptance Criteria: 
• The same acceptance criteria as the verification runs 






• At least three verification runs should contain at least 
five replicates of three QC levels L (three times the 
LLOQ), M and H as well as the LLOQ. 
 
Acceptance Criteria: 
• In each verification run ≥67% of the QCs should be 
±15% and LLOQ ±20% of their nominal 
concentrations, with ≥50% of QCs and LLOQ per level 
meeting this criteria.* 
Elements: 
• Every in-study analysis should contain at least two 
replicates of the L, M & H QC levels. 
• The total number of QCs should be 5% of the 
unknown samples or ≥6, whichever number is greater. 
 
Acceptance Criteria: 
• The same acceptance criteria as the verification runs 
should also be applied for the in-study analysis runs. 
Selectivity 
Elements: 
• Blank samples consisting of the same matrix as the 
study samples from at least six individual sources 






• The same acceptance criteria as the verification runs 




• In each verification run the blank and zero calibrators 
should be free of interference at the retention times of 
the analyte(s) and the IS. 
• In each verification run the IS response in the zero 
calibrator should be ±5% of the average IS responses of 
the calibrators and QCs. 
Carryover 
Elements: 
•  The impact of carryover should be assessed. 
 
Acceptance Criteria: 
• In each verification run carryover should not exceed 
20% of the LLOQ. 
Acceptance Criteria: 
• The same acceptance criteria as the verification runs 
should also be applied for the in-study analysis runs. 
Sensitivity 
Elements: 
• Sensitivity is defined by the LLOQ (lowest non-zero 




• The same acceptance criteria as the verification runs 




• In each verification run the LLOQ should be ≥ five 
times the zero calibrator. 
Accuracy and Precision 
Elements: 
• Accuracy and precision should be analysed in at least 
three verification runs with L, M and H QC levels as 
well as the LLOQ, each with ≥ five replicates. 
 
Acceptance Criteria: 
• Accuracy within-run and between runs should be 
±15% of the nominal concentrations, except for the 
LLOQ which should be ±20% (calculated as described 
in equation 1). 
• Precision within-run and between runs should be 
±15% of the CV, except for the LLOQ which should be 




• The same acceptance criteria as the verification runs 





• Recovery should be analysed from extracted samples 




• None specified***. 
Acceptance Criteria: 
• None specified. 
Only data points that fail to meet acceptance criteria may be excluded. This table was adapted from the FDA bioanalytical method validation guidelines (141). IS – internal 
standard, LLOQ – lower limit of quantification, QC – quality control, L – low range, M – mid range, H – high range, CV - coefficient of variation. * - within our lab we 
accept the L QC within ±20% of the nominal concentration, ** - within our lab, for in vitro assay quantification, we accept the analysis from one source, *** - within our 




2.3.1 LC-MS/MS Method Development and Verification  
The LC-MS/MS method was successfully developed and verified according to 
the adapted FDA guidelines (141) as described in method section 2.2.4, with the 
exception of the IS selectivity criteria.  
 Mass Spectrometer Optimisation 
The MS was successfully optimised for the maximal detection of PIT and the 
suitable detection of IS PRA. A summary of the optimised MS parameters as well as 
the detected precursor and products ions of PIT and IS PRA can be found in Table 2.3 
and Table 2.4, respectively.  
Table 2.3 Optimised MS parameters. 
Parameter Setting 
Ion Spray Voltage (V) Positive 4000 
Sheath Gas (arb) 50  
Auxiliary Gas (arb) 5 
Ion Transfer Tube Temperature (°C) 350 
Vaporiser Temperature (°C) 350 
Parameters optimised using PIT and PRA 500 ng/ml stock solutions in 50% (vol/vol) ACNL in dH2O. 







Table 2.4 PIT and PRA precursor and product ions. 
Compound Precursor (m/z) Products (m/z) 
PIT 422.183 260.04, 261.04, 262.04, 
274.111, 276.111, 288.054, 
290.111, 300.125, 318.111, 
362.111 
PRA 447.17 143.065, 241.062, 265.097, 
327.111, 345.097, 385.143, 
387.194, 406.25, 411.097, 
429.28 
Precursor and product ions determined using PIT and PRA 500 ng/ml stock solutions in 50% 
(vol/vol) ACNL in dH2O. PIT – pitavastatin, PRA – pravastatin, m/z - mass-to-charge ratio. 
 
 Chromatographic Separation 
The final multi-step mobile phase gradient is summarised in Table 2.5 and 
achieved a run time of 5 minutes with a flow rate of 300µl/ml and average retention 
times of 0.77 minutes and 0.69 minutes for PIT and IS PRA, respectively. 
Chromatographic representations of 10 µl injections of 500 ng/ml PIT, IS PRA and 
blank stock solutions in 50% (vol/vol) ACNL in dH2O using the optimised multi-step 









Table 2.5 Chromatographic separation method. 
Time (minutes) Mobile Phase A (%) Mobile Phase B (%) 
0 95 5 
0.5 95 5 
1.5 5 95 
3.5 5 95 
3.5 95 5 
5 95 5 
Mobile phase A consisted of 100% H2OL with 0.5% FAL and mobile phase B consisted of 100% 













Figure 2.1 Chromatographic separation of PIT, IS PRA and blank stock solutions 
using the optimised MS parameters and mobile phase gradient method. 
Chromatograms A and B show the peaks produced by a 10 µl injection of 500 ng/ml 
PIT and IS PRA solutions in 50% (vol/vol) ACNL in dH2O, respectively. 
Chromatograms C and D show peaks produced by a 10 µl injection of blank solution 
in 50% (vol/vol) ACNL in dH2O for PIT and IS PRA, respectively. The grey shaded 
areas represent peaks detected and processed by the Thermo Xcalibur Roadmap 
software, with retention time (RT) and peak area (automatic integration; AA) being 
displayed for each detected peak. 
 Calibration Curve 
 A concentration range of 1.95 – 500 ng/ml was chosen for the calibration curve, 
with 1.95ng/ml being determined as the LLOQ. The LC-MS/MS method passed the 
calibration curve verification acceptance criteria with 100% of calibrators in two of 
the verification runs and 88.89% in the third verification run falling within ±15% (non-
zero calibrators) and ±20% (LLOQ calibrator) of their nominal concentrations.  
Furthermore, the calibration curves showed good linearity over the three LC-MS/MS 
verification runs, with R2 values between 0.9965 – 0.9992. A quadratic equation with 
a weighting of 1/X was applied in the Thermo Xcalibur Roadmap software to generate 
the calibration curve for PIT with IS PRA. This regression model was found to be the 
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simplest model that best described the signal response to calibrator concentration 
relationship. 
 Quality Controls 
The LLOQ, low (L), medium (M) and high (H) QC levels were selected as 1.95 
ng/ml, 5 ng/ml, 100 ng/ml and 400 ng/ml, respectively, falling within the calibration 
curve range. Across the three LC-MS/MS verification runs, seven of the QC levels 
attained 100%, four of the QC levels attained 80% and one of the QC levels attained 
60% of their respective samples within ±15% (L, M and H) and ±20% (LLOQ) of their 
nominal concentrations.  
 Selectivity 
Blank and zero-calibrators with the lot. HUE120 SPHHs as their matrix were 
used to evaluate selectivity. Both the blank and zero calibrators were free from 
interference at the RTs for PIT and IS PRA. As previously mentioned, the response of 
the zero-calibrator IS in two of the three verification runs was greater than the ±5% 
verification criteria. The zero-calibrator IS responses in the three verification runs were 
18.60%, 3.54% and 7.23% greater than the average IS responses of the associated 
calibrators and QCs, respectively.  
 Carryover 
The impact of carryover was assessed by comparing the LLOQ to the blank 
sample that was run after the highest calibrator concentration. No carryover was found 
in either of the three LC-MS/MS verification runs, with the blank samples being less 
than 2% of the LLOQ.  
 Sensitivity 
Sensitivity was analysed in the three LC-MS/MS verification runs by 
comparing the concentration of PIT in the blank samples with the LLOQ. In all the 
runs, the LLOQ was at least 5 times greater than the blank sample. 
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 Accuracy and Precision 
The three LC-MS/MS verification runs contained 5 replicates of the LLOQ, L 
QC, M QC and H QC to allow for the assessment of accuracy and precision within and 
between runs. Both intra-assay and inter-assay accuracy and precision were within 
±15% of their nominal values, as summarised in Table 2.6 and Table 2.7, respectively. 
 Recovery 
 Recovery was assessed across three concentrations distributed throughout the 
calibration curve range. The recovery of PIT for the three concentrations 1 ng/ml, 50 
ng/ml and 500 ng/ml were 101.12%, 78.87% and 108.34% producing a mean recovery 





















1.95 (LLOQ) 4.34 8.53 6.25 12.70 3.46 7.92 
5 (L QC) 2.47 5.61 3.17 7.28 1.67 2.86 
100 (M QC) 1.77 4.00 2.60 6.26 1.06 2.40 
400 (H QC) 3.90 9.19 3.48 8.00 4.14 9.87 











1.95 (LLOQ) 2.74 9.96 
5 (L QC) 1.54 6.03 
100 (M QC) 1.32 5.29 
400 (H QC) 2.25 9.16 
Data points that failed to meet the acceptance criteria were excluded. LLOQ – lower limit of 
quantification, QC – quality control, L – low range, M – mid range, H – high range. 
 
2.3.2 In Vitro Assessment of CLint,T and DDI 
 LC-MS/MS Quantification 
As described in method section 2.2.4.4, the assay samples were quantified over 
three separate LC-MS/MS analysis runs, with the first replicate for both CLint,T and 
DDI assays being carried out in one analysis run and the second replicate of CLint,T and 
DDI assays being carried out in two separate runs. The LC-MS/MS method was 
effectively applied for the quantification of PIT in the in vitro assays, with three 
exceptions to the in-study analysis verification criteria. Firstly, the IS was excluded 
during the quantification software processing of analysis run one due to the QC in-
study analysis criteria only being met when the IS was excluded. Secondly, for analysis 
run two the LLOQ was 4 times greater than the blank sample rather than the criteria 
of 5 times greater. Thirdly, during analysis run three the Accucore C18 LC-MS/MS 
column began to malfunction throughout different stages of the run, producing split 
peaks in some of the samples, as shown in Figure 2.2. There were no further samples 
to repeat the LC-MS/MS analysis and so the samples with split peaks were excluded 
from the analysis. These included 28% of non-zero calibrators and QCs and 31% of 
unknown samples, with ≥50% of unknown samples per concentration condition still 
being included in the analysis. Nonetheless, with the exclusion of these samples the 
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in-study analysis verification criteria was still met except for the H QC level which 
had less than two replicates and the IS was 6.58% greater than the average IS responses 
rather than ≤5%. 
 
Figure 2.2 Example of the split peaking caused by the malfunctioning column during 
the chromatographic separation of PIT in replicate two of the DDI assay. The grey 
shaded area represents peaks detected and processed by the Thermo Xcalibur 
Roadmap software, with RT and peak area (manual integration; MA) being displayed 
for each detected peak. 
 Toxicity Study 
The PIT and RIF drug concentrations used in the CLint,T and DDI assays were 
deemed non-toxic as the cell viability had decreased 2.19% and increased 0.36% in 
comparison to the cell viability calculated during the preparation of the cryopreserved 
SPHHs, respectively. 
 CLint,T of Pitavastatin and DDI with Rifampicin 
A summary of the in vitro CLint,T and DDI assay with PIT and RIF can be found 
in Table 2.8. Vmax, Km and IC50 were calculated using Prism v8 software (GraphPad 
Software Inc., La Jolla, CA, USA) with the CLint,T and percent inhibition being 
calculated as described in method section 2.2.5. CLint,T of PIT in the lot. HUE120 
SPHHs was 108.1 ± 34.38 µl/min/106 cells (Figure 2.3). Coincubation of RIF with PIT 
reduced PIT uptake by 74% with maximal inhibition at 300 µM and an IC50 of 0.021 
µM (Figure 2.4). A D'Agostino & Pearson test for normality was conducted using 
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Prism v8 software (GraphPad Software Inc., La Jolla, CA, USA) for both the CLint,T 
and DDI assay data. Both the CLint,T and DDI assay data sets passed the normality test 
with p-values of 0.3601 and 0.6920, respectfully.  
 
Figure 2.3 Total uptake kinetic profile of PIT (0.1 µM) measured in the lot. HUE120 
SPHHs. The blue line and error bars represent the mean total PIT uptake ± SD 
(pmole/minute/106 cells) of two experimental replicates with four technical replicates. 
 
Figure 2.4  Concentration-dependent inhibition of total PIT (0.1 µM) uptake by RIF 
(0.1 – 300 µM) measured in the lot. HUE120 SPHHs. The blue line and error bars 
represent the mean inhibited total PIT uptake ± SD (% of control) of two experimental 




Table 2.8 Summary of the in vitro CLint,T and DDI assay with PIT and RIF. 
PIT Parameter Lot. HUE120 
Vmax (µmole/minute/10
6 cells) 5490 ± 259 
Km (µM) 50.81 ± 7.533 
CLint,T (µl/minute/10
6 cells) 108.1 ± 34.38 
RIF IC50 (µM) 0.021 
RIF Maximum Inhibition (%) 74 
Vmax, Km and CLint,T presented as mean ± SD and RIF IC50 and RIF maximum inhibition presented 
as mean of two experimental replicates with four technical replicates. PIT – pitavastatin, RIF – 
rifampicin, Vmax – maximum uptake velocity, Km – half maximum velocity concentration, CLint,T – 







The mechanisms that govern drug clearance and DDIs can be investigated 
through an abundance of in vitro techniques to provide valuable information in drug 
discovery and the design of clinical trials (131). Recently, the importance of drug 
transporters in such processes has been recognised (70). In particular, the hepatic 
uptake drug transporters OATP1B1 and OATP1B3 have been shown to mediate the 
uptake of a wide range of drugs and facilitate clinically relevant DDIs (160). PHHs 
can be utilised in vitro to elucidate transporter-mediated clearance and DDIs, with the 
FDA and ITC providing specific guidelines and recommendations for their application 
(70, 162). In this study, a cryopreserved SPHH in vitro system was verified using the 
OATP1B1 and OATP1B3 probe substrate and inhibitor, PIT and RIF, for the 
assessment of CLint,T and DDI. In addition, a LC-MS/MS method was developed and 
verified according to FDA guidelines (141) for the quantification of PIT.  
2.4.1 LC-MS/MS Quantification 
The FDA guideline recommendations for the verification of bioanalytical 
methods were implemented herein (141). Some adaptations to the verification criteria 
were applied for the quantification of PIT in SPHHs and were found to be fit-for-
purpose in accordance with the best practices of our laboratory. Firstly, stability was 
not assessed during the LC-MS/MS method verification as the stability of PIT and IS 
PRA has previously been described in the literature (171, 172). It was found that PIT 
at 0.5 ng/ml, 20 ng/ml and 320 ng/ml were stable at room temperature (18 – 25°C), 
refrigerated (4°C), and frozen (-20°C) as well as through two freeze-thaw cycles (-
20°C to room temperature; 18-25°C). A further study demonstrated that PRA was 
stable when refrigerated (4°C) for 5 months (172). Secondly, the effect of dilution was 
not assessed as the LC-MS/MS detection of PIT across the calibration concentration 
range was found to be linear suggesting no impact of dilution on the quantification of 
PIT. Thirdly, for two of the three verification LC-MS/MS analysis runs the zero-
calibrator IS response in comparison to the IS responses of the associated calibrators 
and QCs were 2.23% and 13.6% greater than the FDA’s recommended criteria. 
Nonetheless, as the LC-MS/MS method was successfully verified according to all 
other FDA criteria, the impact of this result was believed to be insignificant. 
85 
 
In addition to LC-MS/MS method verification guidelines the FDA also provide 
acceptance criteria for in-study analysis. These criteria are largely similar to the 
verification criteria with the exception of the number of replicates required for QC 
samples. As described in Results section 2.3.2.1, there were three instances where the 
in-study analysis verification criteria were not met, however in view of the 
circumstances the processed data was considered fit-for-purpose for the following 
reasons. Firstly, ISs are applied in LC-MS/MS quantification to aid in the accuracy 
and precision of a method, yet we found that in analysis run one the IS caused the 
failure of the in-study analysis criteria (173). When the IS was excluded from the 
quantification software processing, the in-study analysis criteria were met. Although 
it is unclear why the IS failed during this analysis, the SD for 93.75% of conditions 
across the CLint,T and DDI assays were ≤25% of the mean and so the impact of 
excluding the IS in this single analysis run was thought to be insignificant.  
Secondly, the zero-calibrator response was slightly higher in analysis run two 
resulting in a LLOQ that was 4 times greater rather than the minimum criteria of ≥5. 
However, as this was only a marginal difference and all other in-study verification 
criteria were achieved, it was deemed inconsequential. Lastly, during analysis run 
three split peaking was found in 28% of non-zero calibrators and QCs and 31% of 
unknown samples. When a peak splits it is suggestive of an issue prior to the separation 
of the analyte, particularly if all analytes are affected in the same way. This 
phenomenon is indicative of a column malfunction, specifically a void at the head of 
the column or a blocked frit (174). To confirm this, the column was replaced, and no 
further split peaking was found. Unfortunately, there were no further samples to repeat 
the analysis however once the samples with split peaks were removed from the 
analysis the in-study verification criteria were still achieved, albeit with two 
exceptions. Two of the three H QC level samples demonstrated split peaking and so 
the criteria for each QC level to contain a minimum of two samples was not met. 
Additionally, the IS response in the zero-calibrator was slightly higher than the 
accepted criteria. Overall, taking into consideration the scarcity of samples, 
experimental cost, data uniformity across the three analyses and the fact that all other 
in-study analysis criteria were met, the data produced from the LC-MS/MS 
quantification were satisfactory. 
86 
 
2.4.2 In Vitro Assessment of Transporter-Mediated Clearance and DDI 
There are several in vitro assay systems outlined by the regulatory agencies for 
the identification of transporter-mediated clearance and DDIs, each with differing 
applications, strengths and limitations. These systems include membrane vesicles, 
recombinant cell lines expressing uptake transporters, polarised cell monolayers, 
PPHH, SPHHs and SCHH. This study required the identification of OATP1B1 and 
OATP1B3 CLint,T and DDIs in an in vitro system that closely resembled the human 
physiological environment. This was in part due to the implementation of the in vitro 
data into a PBPK model, as described in Chapter 3 and 4. Considering the above-
mentioned criteria, a  pooled cryopreserved SPHH in vitro assay system was selected. 
Unlike recombinant cell lines that overexpress the transporter of interest, such as 
human embryonic kidney (HEK293) cells, SPHHs provide an expression of hepatic 
transporters close to that found in vivo. Additionally, by utilising pooled donor SPHHs 
we can account for interindividual variability, which is an important consideration for 
the application of this data in PBPK modelling. Furthermore, SPHHs were selected 
over PPHHs as the experimental protocol is much quicker, reducing the loss of 
transporter activity which is considered a limitation of these in vitro systems (131). 
SPHHs have also been suggested to provide the most accurate IVIVE for the prediction 
of the CLint,T of OATP substrate drugs (175).  
SPHH in vitro assays have been widely described in the literature (135, 163-
168) and alongside the FDA’s and ITC’s recommended guidelines for the investigation 
of drugs as clinically relevant transporter substrates and inhibitors, were the basis of 
the assay developed and implemented herein (70, 162). One key differentiation 
between this study and those previously described was the omission of the in vitro 
assessment of passive uptake at 4°C. Historically passive uptake has been determined 
by running a parallel SPHH in vitro assay at 4°C, however there is much debate as to 
whether this method is most suitable, considering the temperature sensitivity of cell 
membranes (131). More recently, the use of high concentrations of OATP inhibitors 
to determine passive uptake have been explored (176, 177). Theoretically, 
coincubation with a strong inhibitor of the major OATP transporters, which are located 
on the sinusoidal membrane of human hepatocytes, would prevent all active uptake of 
an OATP substrate and therefore passive uptake would be the only mechanism of 
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sinusoidal membrane uptake remaining (176). This method however is dependent on 
our current knowledge of transporters, which is still lacking (69). One study compared 
multiple cellular systems at 37°C, 10°C and 4°C as well as with and without rifamycin 
SV, of which RIF is a derivative of, to determine passive uptake across several 
compounds (178). They suggested that the application of low temperatures may 
overestimate passive uptake whereas the use of rifamycin SV could reliably estimate 
passive uptake (176). Similarly, another study compared the assessment of passive 
uptake at 4°C against rifamycin SV inhibition in human hepatocytes and found that 
RIF inhibition was able to reliably estimate passive uptake (177). Considering the 74% 
maximal inhibition of PIT by RIF calculated in this study, passive uptake could be 
deemed as 26% of the total CLint,T with active uptake as the remaining 74%. 
Interestingly, this value is similar to that previously published, where the fraction of 
PIT transported by passive uptake was calculated through a parallel 4°C study and 
ranged from 0.29 – 0.37 (179). The assay described in this study was developed to 
work in conjunction with a PBPK model that predicts transporter-mediated clearance 
and DDIs in vivo, as described in Chapter 3. A strength of PBPK modelling is the 
ability to estimate parameters that are either unavailable in the literature, or 
experimental evaluation of the parameter is uncertain, and verify them against existing 
clinical pharmacokinetic data. Thus, the contribution of passive uptake to the total 
CLint,T calculated within this study will be estimated using PBPK modelling 
considering both the maximal inhibition calculated herein as well as the fractions 
determined in the literature. 
The CLint,T of PIT determined in this assay fell within the range of values found 
in the literature that were documented in µl/min/106 cells. Table 2.9 summarises these 
values as well as detailing the total mean ± SD. CLint,T was also described in ml/min/g 
liver in the literature and so CLint,T of PIT determined in this assay was converted to 
ml/min/g liver based on 1.39 × 108 cells/g liver for comparison, producing a value of 
15.03 ± 4.78 ml/min/g liver (180). This was similar to the value of 18.5 ± 3.8 ml/min/g 
liver previously reported (181). Furthermore, RIF demonstrated a substantial 
inhibition of PIT in the DDI in vitro assay in this study, which is comparable to the 
previously reported clinical pharmacokinetic parameters of PIT administered with and 
without RIF (166). However, the IC50 determined in this study was dissimilar to the 
IC50 previously reported, with our study presenting a much stronger level of inhibition. 
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Additionally, the toxicity study demonstrated minimal impact of either PIT or RIF on 
cell viability. The large variability of in vitro OATP1B1 and OATP1B3 inhibition data 
between studies has been recently investigated. Analysis of 21 OATP1B1 and 
OATP1B3 substrate and inhibitor pairs found that the most significant contributing 
factors to data variation were the cell system used as well as the pre-incubation and 
co-incubation time with the inhibitor (182). Taking this into consideration, both the 
SPHH donors and co-incubation time with RIF were dissimilar in this study and could 
explain the difference between the previously published data. Therefore, as the DDI in 
vitro assay in this study demonstrated the inhibition of PIT by RIF and alongside the 
results of the CLint,T of PIT, the experimental system described herein was deemed 
verified for its integration into the PBPK model described in Chapter 3. 
Table 2.9 Summary of CLint,T of PIT. 
In Vitro System CLint,T (µl/min/10
6 cells) 




69 ± 14 (184) 
66.9 ± 18.1 (175) 
256 ± 40 (175) 
PPHH 40.7 (185) 
SCHH 53 ± 3.4 (184) 
Total Mean ± SD 80.65 ± 66.23 
Reference for literature values presented in brackets. Data presented as mean or mean ± SD when 
available. CLint,T – hepatic transporter intrinsic clearance, SPHH – suspension primary human 
hepatocytes, PPHH – plated primary human hepatocytes, SCHH – sandwich cultured human 
hepatocytes, SD – standard deviation, * - SD was not reported, ** - calculated from reported Vmax 
(pmol/min/106 cells) and Km (µM) values as described in equation 7. 
 
2.4.3 Conclusion 
This study verified the application of the SPHH in vitro assay alongside LC-
MS/MS quantification to determine the CLint,T and IC50 of the OATP1B1 and 
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OATP1B3 substrate and inhibitor, PIT and RIF. Moreover, this in vitro system can be 
incorporated into a PBPK model for the verification of an in vitro-in silico framework 
as described in Chapter 3. Together this framework can be utilised to explore the role 





Chapter 3  
Physiologically-Based 
Pharmacokinetic Modelling to 
Predict Transporter-Mediated Drug-




3.1 Introduction 92 
3.2 Methods 94 
3.2.1 Whole-Body PBPK Model 94 
 Anatomy 98 
 Intestinal Absorption 102 
 Multi-Compartment Liver 104 
 Drug-Drug Interactions 106 
 Volume of Distribution 106 
 Systemic Circulation 108 
3.2.2 Rifampicin PBPK Model 109 
3.2.3 PBPK Model Verification 111 
3.3 Results 112 
3.3.1 Whole-Body PBPK Model Verification 112 
3.3.2 Rifampicin PBPK Model Verification 114 
3.3.3 Pitavastatin and Rifampicin Drug-Drug Interaction 115 
3.4 Discussion 118 
3.4.1 In Silico Assessment of Transporter-Mediated Clearance and DDI 118 
 Active and Passive Diffusion 120 
 IVIVE Correction Factor 121 
3.4.2 Minimal Rifampicin PBPK Model 121 





PBPK modelling has become an essential pharmacological tool that utilises in 
vitro and clinical data within a mathematical description of the human body for the 
prediction of drug pharmacokinetics. PBPK modelling can be applied in a variety of 
scenarios, for example it can be used to predict the pharmacokinetics of various dosing 
regimens during drug development (186). It can also be used to predict drug 
pharmacokinetics in special populations, particularly those whom clinical data may be 
difficult to obtain such as the elderly (187). Furthermore, PBPK modelling can be used 
for the investigation of DDIs mediated by enzymes and transporters, with the FDA 
recently providing guidance on this application (132, 188).  
Transporters have been recognised as fundamental mechanisms for the ADME 
of a drug and regulatory agencies require their investigation during the drug 
development process (132, 189). Over-expressing cell lines are commonly used in 
vitro to determine if a drug is a substrate of predetermined clinically relevant 
transporters to aid in the design of clinical DDI studies, with the priority of 
understanding if dose adjustments are required or if comedication is contraindicated 
(70). However, due to the lack of specific transporter substrates and inhibitors and 
based on our currently limited understanding of transporter biology and pharmacology, 
it is challenging to delineate the complex interactions of the various processes involved 
from these studies alone (135). Understanding these intricate processes is of particular 
importance in PLWH who are at risk of a multitude of DDIs and as a result require 
extensive analysis of their drug regimens during clinical management. 
PBPK modelling can be employed together with in vitro assays to provide 
comprehensive in vitro-in silico frameworks for the investigation of transporter-
mediated clearance and DDIs. These frameworks can improve our understanding of 
transporter mechanisms of action and provide additional evidence-based guidance for 
the clinical management of PLWH. Blood flow limited descriptions of the liver have 
been successfully implemented in whole-body PBPK models for the assessment of 
transporter-mediated DDIs within the literature (147, 148). However, there is a trend 
in the underprediction of transporter-mediated clearance and DDIs using current in 
vitro assay systems (153, 190). This has become a major challenge in the IVIVE of 
transporter data for PBPK modelling applications. Consequently, drug and study 
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specific correction factors have become commonplace within the field of transporter 
pharmacokinetics, although their rationale is often lacking. It is hypothesised that these 
underpredictions are a result of differing transporter expression and activity in vitro 
and in vivo (133, 147, 179, 191-193). These convoluted IVIVE processes have limited 
the success of PBPK modelling in regulatory applications (145, 146).  
The aim of this study was to develop and verify a whole-body PBPK model 
describing transporter-mediated hepatic clearance that can be applied in conjunction 
with the in vitro system developed and verified in Chapter 2 for PIT. Furthermore, this 
study aimed to develop and verify a minimal PBPK model for the prediction of RIF 
pharmacokinetics to be used alongside the whole-body PBPK model and in vitro 
system for the prediction of the transporter-mediated DDI between PIT and RIF. 
Additionally, we aimed to determine a SPHH specific rather than drug specific 
correction factor for the IVIVE of transporter data in this in vitro-in silico framework. 
The verified framework can then be used to elucidate the role of hepatic transporters 





The PBPK model was designed in Simbiology v5.8, a product of Matlab 2018a 
(MathWorks, Natick, MA, USA; 2018). The model was developed assuming well-
stirred compartments with instant distribution of the drug and that the distribution to 
the compartments was blood-flow limited. Furthermore, it was assumed that there was 
no absorption of orally dosed drug from the large intestine.  The in vitro CLint,T  and 
IC50 data produced in Chapter 2 were applied in the PBPK model. All other 
physicochemical, pharmacokinetic, in vitro and in vivo data for PIT and RIF were 
sourced from literature or if unavailable were estimated via curve fitting. Virtual 
cohorts consisting of 100 male and female patients aged 18 – 60 years were simulated. 
The PBPK model was verified against observed clinical data for PIT and RIF and, 
where applicable, pharmacokinetic parameters and concentration time profile data 
were extracted from charts and graphs using the Plot Digitizer Tool 
(plotdigitizer.sourceforge.net). 
3.2.1 Whole-Body PBPK Model 
A whole-body PBPK model was applied to predict the pharmacokinetic 
parameters and concentration time profile of a single 1mg dose of PIT with and without 
a single 600mg dose of RIF (166). The physicochemical and in vitro data for PIT were 
sourced from the literature or experimentally determined, as described in Chapter 2, 
and can be found in Table 3.1. A schematic overview of the PBPK model utilised 
herein is shown in Figure 3.1 and described in the following sections. 
 
Table 3.1 Physicochemical and in vitro data for pitavastatin. 
Parameters PIT 
Molecular Weight (g/mol) 421.6 (194) 
HBD 3 (194) 




-4 cm/s) 4.688 (191) 
pKa 5.31 (191) 
Protein Binding (%) 99.6 (195) 
fuLiver 0.0405 (196) 
PSA (Å2) 90.65 (194) 
R 0.55 (191) 
Vss (L/kg) 0.22 (191) 
Water Solubility (mg/L) 3.94 (194) 
CLBiliary (ml/minute/kg) 5.48 (197) 
CLint,T (µL/minute/10
6 cells) 108.1E 
CLint,T IVIVE Correction Factor 18 (191) 
CLint,CYP (µL/minute/mg protein) 2.5 (198) 
CLint,UGT (µL/minute/mg protein) 15.2 (175) 
Reference for literature values presented in brackets. HBD – hydrogen bond donor, Log PO:W - 
partition coefficient between octanol and water, Papp – apparent permeability, pKa - logarithmic value 
of the dissociation constant, fuLiver – fraction unbound in the liver, PSA – polar surface area, R – 
blood-to-plasma ratio, Vss – volume of distribution at steady state (an average adult body weight of 
70 kg was assumed), CLBiliary – biliary clearance, CLint,T – hepatic transporter intrinsic clearance, 
IVIVE – in vitro in vivo extrapolation, CLint,CYP – cytochrome P450 enzyme intrinsic clearance, 








Figure 3.1 Schematic diagram of the whole-body PBPK model used to predict the DDI between PIT and RIF. Each compartment represents various 
organs and tissues, as labelled, with each arrowed line representing a reaction described by a first-order kinetic equation to calculate the distribution 
of drug throughout the organs and tissues. Veins, arteries, and their associated reactions are highlighted in blue and red, respectively, with reactions 
involved in absorption, metabolism and excretion highlighted in yellow. Compartments and reactions involved in first pass metabolism are located 





Virtual male and female patients age 18-60 years were simulated in the PBPK 
model. Weight and body mass index (BMI) were defined using data from the National 
Center for Health Statistics as shown in Table 3.2 (199). From these predefined 
characteristics, the height and body surface area (BSA) were calculated using 
equations 1 and 2 (200, 201), with upper and lower limits applied according to the 
National Center for Health Statistics. 
Table 3.2 Predefined male and female characteristics (199).  
Parameter Male Female 
Weight (Kg) 88.8 (0.43) 76.4 (0.42) 
BMI (Kg/m2) 28.7 (0.13) 29.2 (0.17) 
Data presented as mean and standard error in brackets. Sourced from National Center for Health 
Statistics (199). 
 
Height = Weight/BMI (1) 
BSA = Weight0.425 × Height0.725 × 0.007184 (2) 
 
Height, weight, BMI and BSA were then used to determined organ weights 
through allometric equations 3-19 (201). Organ density values shown in Table 3.3 
were then used to calculate organ volume from their weight (202). Blood flows were 
defined as fractions of the total cardiac output as shown in Table 3.4 (203). 
 
Adipose = ((((1.20 × BMI) + (0.23 × Age)  - 16.2) × Weight)/100) ± 0.041 (3) 
Blood = 3.33 × BSA - 0.81 ± 0.1 (4) 
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Bones = exp(0.0689 + 2.67 × log(Height)) ± 0.166 (5) 
Brain = 0.405 × exp(-Age/629) × (3.68 - 2.68 × exp(-Age/0.89)) ± 0.084 (6) 
Gonads = (3.3 + 53 × (1 - (exp((-Age/17.5)5.4)))/1000 ± 0.049 (7) 
Heart = exp(-2.502 + 2.13 × log(Height)) ± 0.069 (8) 
Intestines = exp(-1.351 + 2.47 × log(Height)) ± 0.049 (8) 
Kidneys = exp(-2.306 + 1.93 × log(Height)) ± 0.14 (9) 
Liver = exp(-0.6786 + 1.98 × log(Height)) ± 0.028 (10) 
Lungs = exp(-2.092 + 2.1 × log(Height)) ± 0.195 (11) 
Muscle = 0.93 × Weight - Total Weight (12) 
Pancreas = exp(-3.431 + 2.43 × log(Height)) ± 0.245 (13) 
Remaining = exp(-0.072 + 1.95 × log(Height) ± 0.049 (14) 
Skin = exp(1.64 × BSA - 1.93) ± 0.049 (15) 
Spleen = exp(-3.123 + 2.16 × log(Height)) ± 0.156 (16) 
Stomach = exp(-3.266 + 2.45 × log(Height)) ± 0.0965 (17) 
Thymus = 14 × ((7.1 - 6.1 × exp(-Age/11.9)) × ((0.14 + 0.86 ×  
exp(-Age/10.3))))/1000 ± 0.049 
(18) 
Total weight = Lungs + Heart + Bones + Kidneys + Stomach + Intestines + Spleen 





Table 3.3 Organ density in humans (202). 






















Table 3.4 Organ and tissue blood flow in humans as a fraction of cardiac output (203). 





Hepatic Artery 0.12 






Portal Vein 0.2 









 Intestinal Absorption 
A multi-compartment absorption and transit model was used to simulate the 
intestinal absorption of PIT. Differential equations 20-28 (143, 204) were used in the 
model to describe the transit of PIT in an undissolved and dissolved form from the 
stomach through seven small intestine compartments to the colon, with absorption 
occurring in the small intestine alone. Where A is the amount of drug and UND, DIS 
and ABS are the undissolved, dissolved and absorbed drug. ST, SI, COL, and n are the 
stomach, small intestine, colon, and number of compartments, respectively. Ks, Kt and 
Kc are the transit rates for the stomach, small intestine, and colon, respectively, and 
are shown in Table 3.5 (63). KD, Ka and Csol are the dissociation rate constant, 
absorption rate constant and soluble concentration of PIT, respectively. 
Stomach Compartment:  
dAUND(ST)
dt
 = -Ks × AUND(ST) - KD × AUND(ST) (20) 
dADIS(ST)
dt
 = -Ks × ADIS(ST) + KD × AUND(ST) (21) 
Small Intestine Compartment 1:  
dAUND(SI,1)
dt
 = Ks × AUND(ST) - Kt × AUND(SI,1) - KD × AUND(SI,1) (22) 
dADIS(SI,1)
dt
 = Ks × ADIS(ST) - Kt × ADIS(SI,1) + KD × AUND(SI,1) - Ka × Csol(SI,1) × ADIS(SI,1)  (23) 
dAABS(SI,1)
dt
 = Ka × Csol(SI,1) × ADIS(SI,1) (24) 
Small Intestine Compartment 2-7:  
dAUND(SI,n)
dt
 = Kt × AUND(SI,n-1) - Kt × AUND(SI,n) - KD × AUND(SI,n) (25) 
dADIS(SI,n)
dt





 = Ka × Csol(SI,n) × ADIS(SI,n) (27) 
Colon Compartment:  
dACOL
dt
 = Kt × AUND(SI,7) + Kt × ADIS(SI,7) - Kc × ACOL (28) 
 
Table 3.5 Transit rates for fed and fasted states (63). 
Compartment 
Transit Rate Constant (per hour)  
Fed Fasted 
Stomach (Ks) 1.02 3.96 
Small Intestine (Kt) 0.57 2.1 
Colon (Kc) 0.084 0.084 
Values presented as per hour and were converted from per min literature values for incorporation 
into the PBPK model. The small intestine transit rate constant (Kt) applies to all seven compartments 
as described in equations 22-28. 
 
The soluble drug available for absorption in each small intestine compartment 
was calculated using equation 29 and considers the solubility of PIT (Drugsol) as well 
as the concentration of dissolved drug in each compartment. Ka was calculated as 
described in equation 30 (143), with the apparent permeability (Papp) being calculated 
by the polar surface area (PSA) and hydrogen bond donor (HBD) values for PIT, as 
described in equation 31 (142). Equation 31 is transformed from the logarithmic form 
to the inverse logarithmic form for use in the model. The fraction of PIT available for 
the multi-compartment liver model (Fg) was calculated using equation 32, where Qgut, 
fu,g and CLgut are the blood flow to the gut, fraction unbound in the gut and metabolism 
based clearance of drug from the gut. As we assume that no clinically relevant PIT 
metabolism occurs in the gut CLgut, and therefore Fg, for PIT equals 1. 
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Csol(SI,n) = max(0,min(Drugsol,ADIS(SI,n))) (29) 
Ka =
Papp × scaling factor × 2
Small Intestine Radius
  (30) 
logPapp = -2.546-0.011×PSA-0.278×HBD (31) 
Fg =
Qgut
Qgut + fu,g ×CLgut
 (32) 
 
 Multi-Compartment Liver 
A multi-compartment PBPK liver model was utilised to predict the transporter-
mediated clearance of PIT, as described previously (147). The model is comprised of 
five portal vein and liver compartments (i) connected by blood flow with reactions 
describing the active and passive uptake and efflux of PIT into the liver as well as 
enzyme metabolism and biliary clearance of PIT. These reactions are summarised in 
equations 33-35 where WLiver, WPV, CLiver, CPV and CB are the weight of the liver and 
portal vein and concentration of PIT in the liver compartment, portal vein compartment 
and blood, respectively. CLint,T,a, CLint,T,p, CLBiliary and CLint,liver are the active intrinsic 
clearance by transporters, passive diffusion, biliary clearance, and total metabolic 
intrinsic clearance of PIT, respectively. fu,b, fu,t, Ka and CSI are the fraction unbound in 
plasma, fraction unbound in tissue, the absorption rate constant, and the concentration 
of PIT in the small intestine, respectively.  
Liver Compartment 1-5:  
(WLiver/5) × (dCLiver,i/dt) = (CLint,T,a/5) × fu,b × CPV,i + (CLint,T,p/5) × fu,b × CPV,i - 
(CLint,T,p/5) × fu,t × CLiver,i – (CLBiliary/5) × fu,t × CLiver,i – (CLint,liver/5) × fu,t × CLiver,i 
(33) 
Portal Vein Compartment 1:  
(WPV,i/5) × (dCPV/dt) = QPV × (CB – CPV,i) - (CLint,T,a/5) × fu,b × CPV,i - (CLint,T,p/5) × 




Portal Vein Compartment 2-5:  
(WPV,i/5) × (dCPV/dt) = QPV × (CPV,(i-1) - CPV,i) - (CLint,T,a/5) × fu,b × CPV,i - (CLint,T,p/5) 
× fu,b × CPV,i + (CLint,T,p/5) × fu,t × CLiver,i 
(35) 
 
As described in Chapter 2, CLint,T,a and CLint,T,p were optimised considering the 
74% inhibition of PIT by RIF in vitro alongside the available clinical data. This process 
was carried out in a stepwise manner, with CLint,T,a and CLint,T,p firstly equalling 74% 
and 26% of CLint,T, respectively, with the AAFE and ratio values being calculated for 
predicted vs. observed data. Considering these simulations, a range of percentage 
values were then simulated and their AAFE and ratio values calculated. The 
percentage values achieving the most accurate predictions were then selected. 
PIT undergoes minimal metabolism by CYP2C9 as well as UGT1A1, 
UGT1A3 and UGT2B7 (175, 198, 205, 206). Due to the lack of available data, the 
contribution of UGT enzymes to the metabolism of PIT were determined by 
calculating their percentage contribution to the formation of PIT lactone from an in 
vitro recombinant assay (205). The intrinsic clearance by CYP2C9, UGT1A1, 
UGT1A3 and UGT2B7 were then converted from µL/minute/mg protein to 
µl/minute/pmol using equation 36 where CLint,E and AbundanceE are the intrinsic 
clearance and abundance for each enzyme. These values were then implemented into 
equation 37-39 in the PBPK model where CLint,liverE, MPPGL, WLiver and CLint,liver are 
the intrinsic clearance of the enzyme scaled to the whole liver, the microsomal protein 
per gram of liver, the liver weight and the total metabolic intrinsic clearance for the 
whole liver (207-210).  




CLint,liverE = (CLint,E × AbundanceE × MPPGL × WLiver) (37) 
MPPGL = 101.407 + 0.0158 × Age - 0.00038 × Age^2 + Age^3 (38) 
CLint,liver = ΣCLint,liverE (39) 
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 Drug-Drug Interactions 
The inhibition of PIT by RIF was determined in vitro as described in Chapter 
2. The IC50 was implemented into the PBPK model using equations 40 and 41 by firstly 
converting the IC50 value into its respective Ki value. Ki, IC50, S, KM, fu,b and CInh are 
the inhibition constant, half maximal inhibitory concentration, substrate concentration, 
half maximum velocity concentration, fraction unbound in blood and the concentration 
of inhibitor. In equations 33-35 CLint,T,a is divided by the resulting R-value to simulate 
the magnitude of the DDI (211, 212).   
 
Ki = IC50/(1 + S/KM) (40) 
R = 1 + (fu,b × CInh)/Ki (41) 
 
 Volume of Distribution 
The Vss was calculated using equations 42-47 (213), with equations 46 and 47 
being transformed from the logarithmic form to the inverse log form for use in 
equations 43 and 44. Vt, Ve and Vp are the fractional volumes of tissue, erythrocytes 
and plasma, respectively. Pt:p and E:P are the adipose and non-adipose tissue:plasma 
partition coefficient and erythrocyte:plasma ratio. Vnl, Vph and Vw are the neutral lipid, 
phospholipid and water volume fraction of wet tissue weight, where t is tissue and p is 
plasma. Values for the tissue composition parameters used in the Vss equations can be 
found in Table 3.6 (213). Lastly, D*vo:w is the olive oil:buffer partition coefficient of 
nonionised and ionised species at pH 7.4 and Pvo:w is the n-octanol:buffer partition 
coefficient of nonionised species at pH 7.4. 
 




(D*vo:w × (Vnlt + 0.3 × Vpht)) + (1 × (Vwt + 0.7 × Vpht)) 






(Pvo:w × (Vnlt + 0.3 × Vpht)) + (1 × (Vwt + 0.7 × Vpht)) 





E:P = (B:P - (1 - 0.45))/0.45 (45) 
logDvo:w = 1.115 × logPvo:w – 1.35 (46) 
Monoprotic Acid: LogD*vo:w = LogDvo:w – Log(1 + 10pH – pKa) (47) 
 
Table 3.6 Tissue composition parameters (213).  
Tissue 
Composition (Volume Fraction of Wet Tissue Weight) 
Water Neutral Lipids Phospholipids  
Adipose 0.18 0.79 0.002 
Bone 0.439 0.074 0.0011 
Brain 0.77 0.051 0.0565 
Gut 0.718 0.0487 0.0163 
Heart 0.758 0.0115 0.0166 
Kidney 0.783 0.0207 0.0162 
Liver 0.751 0.0348 0.0252 
Lung 0.811 0.003 0.009 
Muscle 0.76 0.0238 0.0072 
Skin 0.718 0.0284 0.0111 
Spleen 0.788 0.0201 0.0198 
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Plasma 0.945 0.0035 0.00225 
Data representative of a human weighing 70 kg.  
 
To obtain a Vss of 0.22 (L/kg) for PIT, equations 43 and 44 were multiplied by 
a correction factor. The correction factor was determined by simulating a cohort of 
patients, as previously described, and calculating the average Vss. Incremental changes 
were made to the correction factor and the simulations repeated until the average Vss 
equalled 0.22 (L/kg). 
 Systemic Circulation 
The CLsys of PIT was calculated through differential equations. The lungs, 
arterial blood, venous blood, stomach, gut, and kidneys are described in equations 48-
53, with all other non-eliminating organs and tissues being described by equation 54 
(143). Liver equations were previously described in Method section 3.2.1.3. C, Q, V, 
Pt:p and R are the concentration, blood flow rate, volume, tissue:plasma ratio and 
blood:plasma ratio, respectively. LU, AR, VE, ST, GU, KI and T are the lungs, arterial 
blood, venous blood, stomach, gut, kidneys and other non-eliminating organs and 
tissues, respectively. AIR, VIR, TIA and Kr are the arterial infusion rate, venous 
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3.2.2 Rifampicin PBPK Model 
A minimal PBPK model was applied to predict the pharmacokinetic 
parameters and concentration time profile of a single 600mg dose of RIF (214-216). 
Equations 55 and 56 describe the absorption and elimination of RIF in the model where 
D, Ka, CL, C and Vss are the dose, absorption rate constant, clearance, plasma 
concentration and the volume of distribution of RIF, respectively. A diagrammatic 
representation of the minimal RIF PBPK model is shown in Figure 3.2. The 
physicochemical and in vitro data for RIF were sourced from the literature or 





Absorption = D × Ka (55) 





Figure 3.2 Schematic representation of the minimal PBPK model used to predict RIF 
pharmacokinetics. Arrowed lines A and E represent the absorption and elimination 
reactions described by equations 55 and 56, respectively.  
 
Table 3.7 Physicochemical and in vitro data for 600mg RIF. 
Parameters Rifampicin 
Molecular Weight 822.9 (217) 
Protein Binding (%) 80 (218) 
Vss (L/kg) 23.3 (219) 
CL/F (L/h) 7.5 (219) 
Ka (h
-1) 1.15 (214) 
Ki (µM) 0.021
E 
Reference for literature values presented in brackets. Vss – volume of distribution, CL/F – apparent 




3.2.3 PBPK Model Verification 
The whole-body PBPK model and minimal RIF PBPK model were considered 
successfully verified if the ratio of predicted vs. observed pharmacokinetic values for 
PIT, RIF and their DDI were between 0.5 – 2 (150). Where possible we aimed for the 
ratio of predicted vs. observed values to be within 0.75 – 1.25 to generate more 
accurate simulations (220). The absolute average-fold error (AAFE) for the predicted 
vs. observed pharmacokinetic parameters and concentration time profiles were also 
calculated, as defined in equation 57 (209). AAFE values between 1 – 2 were 
considered successfully verified however we aimed for values between 1 – 1.25. To 
verify the DDI between PIT and RIF, the ratio of DDI vs. drug alone were calculated 
(DDIR) for both the predicted and observed values, as described in equation 58 where 
drugDDI and drugsub are the substrate drug parameter value in the presence of the 
perpetrator drug and substrate drug parameter value, respectively. The DDIR was 
verified according to abovementioned criteria. 
 













The PBPK models were successfully verified by comparing the predicted AUC, 
Cmax, Cmin, bioavailability and concentration time profiles with the observed clinical 
data for the oral administration of PIT, RIF and the DDI between PIT and RIF. The 
AAFE and ratio verification results for all drug regimens can be found in Table 3.11. 
3.3.1 Whole-Body PBPK Model Verification 
The whole-body PBPK model was effectively applied for the prediction of a 
single oral dose of PIT 1mg, with ratio and AAFE values for AUC, Cmax, Cmin and the 
concentration time profile within 0.75 – 1.25 and 1 – 1.25, respectively. The 
bioavailability of PIT was within the 0.5 – 2 ratio and 1 – 2 AAFE criteria. The 
predicted vs. observed concentration time profile and pharmacokinetic parameters can 
be found in Figure 3.3 and Table 3.8. As described in Method section 3.2.1.5, the Vss 
was optimised according to the previously reported literature with the application of a 
correction factor value of 0.085 (191). Furthermore, equation 31 used to calculate Papp 
was unable to accurately describe the rapid absorption of PIT and was therefore 
replaced with the previously reported value of 4.688 × 10-4 cm/s (191). Moreover, the 
CLint,T  determined in vitro in Chapter 2 was successfully implemented in the multi-
compartment liver model with the incorporation of the previously reported IVIVE 






Figure 3.3 Predicted vs. observed concentration time profiles for single dose PIT 1mg. 
The blue line and shaded area represent the mean plasma concentration ± SD (ng/ml) 
of the predicted data. The red line represents the observed clinical data (ng/ml) (166). 
 
Table 3.8 Predicted vs. observed pharmacokinetic parameters for a single dose of 1mg 
PIT. 
Parameter Predicted Observed (166) 
AUC0-4 (ng/h/ml) 25.86 ± 2.95 21 ± 7.1 
Cmax (ng/ml) 15.09 ± 2.5 16.5 ± 9.32 
Cmin (ng/ml) 1.25 ± 0.32 1.48 
F (%) 32 53 (195) 
Reference for observed values presented in brackets. Cmin observed value presented as the mean 
(ng/ml) and was obtained from the concentration time profile. Cmin predicted values presented as 
mean ± SD (ng/ml). AUC – area under the curve, Cmax – maximum plasma concentration, Cmin – 
minimum plasma concentration, F – bioavailability. AUC0-4 values presented as mean ± SD 




3.3.2 Rifampicin PBPK Model Verification 
A single oral dose of RIF 600mg was simulated and compared to the AUC0-24, 
Cmax and concentration time profile clinical data as shown in Figure 3.4 and Table 3.9 
(221). The RIF PBPK model was successfully verified according to the criteria, with 
ratio and AAFE values falling within 0.75 – 1.25 and 1 – 1.25, respectively. 
 
Figure 3.4 Predicted vs. observed concentration time profiles for single dose RIF 
600mg. The blue line and shaded area represent the mean plasma concentration ± SD 
(µg/ml) of the predicted data. The red line represents the observed clinical data (µg/ml) 
(221). 
Table 3.9 Predicted vs. observed pharmacokinetic parameters for a single dose of 
600mg RIF. 
Parameter Predicted Observed (221) 
AUC0-24 (µg/h/ml) 93.25 ± 35.02 87.53 ± 27.2 
Cmax (µg/ml) 16.34 ± 4.7 13.07 ± 4.05 
Reference for observed values presented in brackets. AUC0-24 values presented as mean ± standard 
deviation (µg/h/ml). Cmax values presented as mean ± SD (µg/ml). AUC – area under the curve, Cmax 




3.3.3 Pitavastatin and Rifampicin Drug-Drug Interaction 
The DDI between a single oral dose of PIT 1mg and a single oral dose of RIF 
600mg was successfully verified with ratio and AAFE values for AUC, Cmin, AUC 
DDIR, and concentration time profile within 0.75 – 1.25 and 1 – 1.25, respectively. 
The Cmax, Cmax DDIR and bioavailability were within the 0.5 – 2 ratio and 1 – 2 AAFE 
criteria. The predicted vs. observed concentration time profile and pharmacokinetic 
parameters can be found in Figure 3.5 and Table 3.10. As described in Method section 
3.3.1.3, the optimised values for CLint,T,a and CLint,T,p that produced the most accurate 
predictions for the DDI between PIT and RIF were 85% and 15%, respectively. 
 
 
Figure 3.5 Predicted vs. observed concentration time profiles for single dose PIT 1mg 
coadministered with single dose RIF 600mg. The blue line and shaded area represent 
the mean plasma concentration ± SD (ng/ml) of the predicted data. The red line 





Table 3.10 Predicted vs. observed pharmacokinetic parameters for the DDI between a 
single dose of 1mg PIT and a single dose of RIF 600mg. 
Parameter Predicted Observed (166) 
AUC0-4 (ng/h/ml) 110.05 ± 19.48 118 ± 53 
Cmax (ng/ml) 40.88 ± 10.08 78.8 ± 45.3 
Cmin (ng/ml) 1.52 ± 0.31 1.26 
AUC0-4 DDIR 4.26 5.21 
Cmax DDIR 2.71 4.36 
Reference for observed values presented in brackets. AUC0-4 values presented as mean ± standard 
deviation (ng/h/ml). Cmax values presented as mean ± SD (ng/ml). Cmin observed value presented as 
the mean (ng/ml) and was obtained from the concentration time profile. Cmin predicted values 
presented as mean ± SD (ng/ml). DDI ratios calculated as described in equation 58. AUC – area 
under the curve, Cmax – maximum plasma concentration, Cmin – minimum plasma concentration, DDI 





Table 3.11 PBPK model verification summary of predicted vs. observed clinical data. 
Dose Parameter Ratio AAFE 
PIT 1mg Single 
Dose 
AUC0-4  1.23 1.23 
Cmax  0.91 1.09 
Cmin  0.84 1.19 
F  0.6 1.656 
Profile - 1.19 
RIF 600mg Single 
Dose 
AUC0-24  1.07 1.07 
Cmax  1.25 1.25 
Profile - 1.13 
PIT 1mg Single 
Dose with RIF 
600mg Single 
Dose 
AUC0-4  0.93 1.07 
Cmax  0.52 1.93 
Cmin  1.15 1.15 
AUC0-4 DDIR 0.82 1.22 
Cmax DDIR 0.62 1.61 
Profile - 1.2 
PIT – pitavastatin, RIF – rifampicin, AUC – area under the curve, Cmax – maximum plasma 
concentration, Cmin – minimum plasma concentration, F – bioavailability, DDI – drug-drug 
interaction, DDIR – DDI ratio, Profile – concentration time profile. Ratio and AAFE values calculated 






The integration of in vitro and in silico methodologies can support the prediction 
and simulation of complex pharmacokinetics, providing important knowledge to 
support the clinical management of transporter-mediated DDIs as well as in drug 
development. PBPK modelling utilises mathematical equations alongside the 
compartmentalisation of organs and tissues to simulate drug pharmacokinetics in a 
cohort of virtual patients, providing an efficient and ethical resource of simulated 
clinical data. The aim of this study was to develop and verify a whole-body PBPK 
model detailing a multi-compartment liver that encapsulates active and passive 
diffusion of PIT across the sinusoidal membrane of hepatocytes, as well as describing 
the interplay between PIT diffusion, metabolism, and biliary excretion. Moreover, the 
study aimed to develop and verify a secondary minimalistic model to simulate RIF 
pharmacokinetics to predict the magnitude of transporter-mediated DDI between PIT 
and RIF. The models incorporated the in vitro experimental data for PIT and RIF 
determined in Chapter 2 for the overall verification of the in vitro-in silico framework 
for the investigation of ARV transporter-mediated DDIs in Chapter 4. 
3.4.1 In Silico Assessment of Transporter-Mediated Clearance and DDI 
A previously published multi-compartment description of the liver was 
integrated into the whole-body PBPK model to allow the incorporation of transporter 
kinetics whilst reflecting the blood-flow limited hepatic disposition of the dispersion 
model (147). The dispersion model has previously been described as the optimal 
strategy for predicting hepatic clearance. The well-stirred approach implemented for 
the other organs in the PBPK model assumes that there is a uniform concentration of 
drug throughout the organ, whereas the concept of the dispersion model applied herein 
considers the non-uniform concentration of drug as it travels throughout the liver. 
However, as the dispersion model considers enzyme metabolism as the rate limiting 
step rather than transporter kinetics, it is unable to be applied directly thus an adapted 
model is required (222, 223).  
CLint,T of PIT and the Ki for the DDI between PIT and RIF were determined in 
vitro in Chapter 2 and applied in the multi-compartment liver model. This in vitro-in 
silico framework produced accurate predictions of single dose 1mg PIT 
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pharmacokinetics with ratio and AAFE values for all parameters, excluding the 
bioavailability, within the stringent 0.75 – 1.25 ratio and 1 – 1.25 AAFE verification 
criteria. The bioavailability was underpredicted however remained within the 0.5 – 2 
ratio and 1 – 2 AAFE verification criteria widely accepted within the literature, 
demonstrating that the 5-compartment structure was suitable for PIT predictions (150). 
Furthermore, as this parameter is thought to be less imperative for the application of 
this model compared to the other pharmacokinetic parameters, which were all within 
the strict criteria, this underprediction was deemed acceptable. The simulated DDI 
magnitude tended to be underpredicted, with only the AUC, AUC DDIR and Cmin of 
single dose 1mg PIT coadministered with single dose 600mg RIF falling within the 
strict verification criteria. Nonetheless, the Cmax and Cmax DDIR achieved the 0.5 – 2 
ratio and 1 – 2 AAFE criteria.  
Underprediction of transporter-mediated DDIs is commonplace within the 
literature (190), with a previous PIT PBPK model also describing the underprediction 
of the DDI between PIT and RIF in their simulations (191). Interestingly, previous 
models found significant underpredictions using the reported Ki value of 0.9 µM and 
proceeded to use an optimised Ki value of 0.09 µM to obtain more accurate predictions 
(191). Comparatively, the Ki value determined in the in vitro assay in Chapter 2 was 
0.017 µM, demonstrating the suitability of the in vitro assay developed and used 
herein. Curiously, the previously published model described accurate Cmax predictions 
with a Cmax DDIR of 1.82 compared to their documented observed Cmax DDIR of 2.11, 
though the outlined reference for the observed ratio recorded a Cmax DDIR of 9.2 (224). 
Nevertheless, this Cmax DDIR was comparable to that predicted here, with our 
predictions more accurately representing the Cmax DDIR described in the literature 
(166). It should also be noted that the previously published model used single dose 
4mg PIT data obtained from healthy Chinese volunteers (224) whereas our data was 
sourced from a single dose 1mg PIT study in healthy Caucasians (166). This could in 
part explain the difference in DDI ratios found between the studies, with reports of 
higher OATP1B1 expression amongst Asian donors compared to Caucasian donors in 
vitro (225).  
Predicting transporter-mediated DDIs is challenging. The underprediction of 
the Cmax DDIR in this study could be due to a multitude of reasons and is likely based 
on our lack of knowledge surrounding transporter pharmacology. Although PIT has 
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been reported as a specific OATP1B1 and OATP1B3 substrate, our underpredicted 
simulations suggest a further mechanistic pathway involved in the ADME of PIT that 
is affected by the RIF DDI. Consequently, this lack of understanding has led to the 
omission of such pathways in the PBPK model implemented herein, thus failing to 
capture the Cmax DDIR reported in the literature. As previously described (191) and as 
tested during the model development process in this study, decreasing the RIF Ki did 
not improve the accuracy of the Cmax predictions, reinforcing the theory that RIF could 
potentially be inhibiting an additional pathway, increasing the absorption of PIT or 
altering the Vss (190). Considering these scenarios, during the parameter optimisation 
process the effect of different Vss correction factors and Papp values on the 
pharmacokinetics of PIT were analysed. Vss correction factor values lower than the 
final optimised value produced more accurate predictions of PIT Cmax however the 
resulting AUC and Cmin values were overpredicted and outside the 0.5 – 2 ratio and 1 
– 2 AAFE verification criteria and were therefore not selected. Increasing the Papp 
value had minimal impact on the Cmax prediction. Interestingly, the equation used to 
calculate Papp was unable to capture the rapid absorption of single dose 1mg PIT and a 
specific value from the literature was implemented instead. It is clear that with multiple 
factors influencing the pharmacokinetics of PIT and with current clinical and in vitro 
data proving insufficient in combination with our current understanding, dissecting the 
mechanisms involved in DDIs lacks confidence. Yet, by applying these in vitro-in 
silico frameworks we can highlight areas that require further research and apply the 
framework step-by-step towards eliminating the knowledge gap on transporter-
mediated DDIs. 
 Active and Passive Diffusion 
The percentage contribution of active and passive diffusion to the CLint,T 
calculated in vitro differed from the optimised values used in the PBPK model. It was 
found that, although the pharmacokinetics of single dose 1mg PIT were accurately 
predicted, the magnitude of DDI between PIT and RIF was underestimated. When 
CLint,T,a and CLint,T,p were estimated as 85% and 15% of the CLint,T the most accurate 
DDI predictions were achieved. These values are comparable to that described 
previously for PIT, with CLint,T,a being calculated in the range of 80-88% to provide 
optimal predictions (179). In addition, a previously published study found that the in 
vitro assessment of CLint,T,a and CLint,T,p using 4°C experimental conditions were 
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inaccurate and concluded that passive diffusion in vivo is smaller than that determined 
using in vitro systems (135). The inappropriateness of the CLint,T,a and CLint,T,p values 
estimated in vitro in Chapter 2 using the maximal percent inhibition of PIT by RIF 
further highlights the limitations surrounding in vitro techniques for this purpose. 
PBPK modelling could therefore be a suitable alternative for the prediction of active 
and passive diffusion and necessitates further exploration comparing a variety of drugs 
and in vitro systems. 
 IVIVE Correction Factor 
The use of correction factors on the IVIVE of CLint,T data has been described 
multiple times within the literature (133, 147, 179, 191-193). The underprediction of 
CLint,T  from in vitro data remains unclear however it is thought that a reduction in 
transporter expression and activity through isolation and cryopreservation of 
hepatocytes used in vitro could be responsible (133). The issue with applying 
correction factors to the IVIVE of CLint,T data is that, thus far, the values applied differ 
between drug, cell system, PBPK model and laboratory. A previous attempt to define 
an average correction factor for multiple drugs using a SCHH in vitro assay was 
unsuccessful, with a geometric mean and range of 58 and 12-161, respectively (192). 
Nonetheless, to provide consistency the IVIVE value used in this study was chosen 
based on a prior PBPK model developed for the prediction of PIT pharmacokinetics 
(191). An additional PBPK model for PIT also assessed the application of correction 
factors and found similar values between 10-15 produced optimal simulations (179). 
It was found that the use of the previously reported correction factor of 18, which was 
also applied to in vitro SPHH data, proved successful in simulating the 
pharmacokinetics of PIT in this study. This suggests the potential for SPHH assay 
specific IVIVE correction factors to be developed and applied universally and justifies 
further investigation with other drugs.  
3.4.2 Minimal Rifampicin PBPK Model 
A minimal representation of the whole-body PBPK model for the prediction of 
RIF pharmacokinetics was successfully verified according to the stringent 0.75 – 1.25 
ratio and 1 – 1.25 AAFE verification criteria. RIF ADME is complex and the lack of 
knowledge and data surrounding this topic proves challenging for the application of 
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whole-body PBPK models. Therefore, the use of 3-compartment PBPK models has 
been adopted throughout the literature and provides an effective simulation strategy 
(214-216), as verified in this study. A limitation of this model, which must be 
considered when analysing the underprediction of PIT Cmax and the Cmax DDIR, is the 
application of RIF plasma concentration rather than liver concentration for the 
prediction of the DDI. As described above, the lack of data surrounding the 
concentration of RIF found in the liver prevents the verification of a more 
physiologically accurate whole-body PBPK model, which is essential for the 
confidence in model prediction accuracy. Taking this into consideration, it was 
concluded that the application of RIF plasma concentrations was suitable for this 
study.  
3.4.3 Conclusion 
This study successfully verified a multi-compartment liver PBPK model and 
minimal inhibitor PBPK model combined with a SPHH in vitro assay using OATP1B1 
and OATP1B3 probe substrate and inhibitor, PIT and RIF, for the prediction of hepatic 
transporter-mediated clearance and DDIs. Furthermore, a novel PBPK methodology 
for determining hepatic passive diffusion was implemented and could provide a 
sustainable alternative to current in vitro strategies. This in vitro-in silico framework 
could be utilised for the investigation of OATP1B1 and OATP1B3 substrates in ARV 
DDIs, allowing us to gain an imperative insight into the mechanisms involved in these 
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HCV is a bloodborne virus that is estimated to effect 6.2% of PLWH 
worldwide. Of the estimated 2.3 million PLWH coinfected with HCV 84% were PWID 
(34, 226). There is an increased risk of developing chronic hepatitis in PLWH which 
could lead to liver-related morbidity and potentially mortality if left untreated (227). 
Fortunately, since the introduction of DAAs, most HCV infections can be cured with 
12 – 24 week oral dose regimens (228). However, treatment of HIV-HCV coinfection 
must be carefully managed due to the high risk of DDIs associated with ART (229). 
GZR is a HCV NS3/4A PI that is co-formulated with elbasvir for the treatment 
of chronic HCV (genotypes 1, 4 and 6) in adults, particularly difficult to treat adult 
patients such as those coinfected with HIV (230). GZR is reported to be metabolised 
by CYP3A4 and transported by OATP1B1, OATP1B3 and P-gp and as a result, its 
coadministration with several ARV drugs is contraindicated (231). Boosted PIs, such 
as ATV and DRV coadministered with RTV (ATV/r and DRV/r) are recommended in 
combination with an optimised NRTI backbone as preferred second-line regimens for 
PLWH (27). Coadministration of GZR with ATV/r and DRV/r are not recommended 
due to clinical DDI studies demonstrating geometric mean ratios (with/without) of 
AUC, Cmax and Cmin between 5.27 and 11.64. It has been deduced that according to 
these DDI studies, alongside further DDI studies with GZR and CYP3A4, OATP1B1, 
OATP1B3 and P-gp inhibitors, OATP1B1 and OATP1B3 play a significant role in the 
magnitude of the DDI between GZR, ATV/r and DRV/r (231). However, due to the 
unspecific nature of the inhibitors used in the DDI studies alongside the lack of in vitro 
data, the precise contribution of OATP1B1 and OATP1B3 to the overall DDI 
magnitude is unknown.  
Strategies incorporating both in vitro and in silico techniques can be utilised 
alongside observed clinical data for the investigation of the mechanisms underpinning 
DDIs. By delineating the involvement of each pathway in the overall magnitude of 
DDI we can improve our understanding of their functionality and interplay with one 
another. This is of particular importance with transporters considering our current 
deficit of knowledge. Moreover, these practices allow us to verify the in vitro and in 
silico techniques we apply for the prediction of unknown DDI scenarios, which is an 
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integral step towards building reliable systems and identifying research objectives for 
their refinement.  
The aim of this study was to utilise the in vitro-in silico framework developed 
and verified in Chapter 2 and 3 to elucidate the role of OATP1B1 and OATP1B3 in 
the DDI between GZR and ATV, DRV and RTV. Furthermore, this study aimed to 
verify the SPHH specific IVIVE correction factor identified in Chapter 2 and 3 to 
generate a rationale for correction factor application in the in vitro assessment of 
transporters. This data will help provide key information on our understanding of 
transporter-mediated clearance and DDIs and evaluate the application of the in vitro-






Materials used for the CLint,T, DDI and toxicity in vitro studies were previously 
described in Chapter 2. Additionally, GZR (96% purity; catalog no. M424985) was 
purchased from 2BScientific (Oxfordshire, UK) and ATV (≥98% purity; catalog no. 
SML1796), DRV (≥98% purity; catalog no. SML0937) and RTV (≥98% purity; 
catalog no. SML0491) were purchased from Sigma-Aldrich (Poole, UK). Pooled 
donor cryopreserved SPHHs with lot no. HUE120 (catalog no. HMCS10; Thermo 
Fisher Scientific, Hemel Hempstead, UK) were used as detailed in Chapter 2, Method 
section 2.2.2. Likewise, a summary of donor characteristics can be found in Chapter 
2, Table 2.1. 
4.2.2 Grazoprevir CLint,T and Protease Inhibitor DDI In Vitro Assay 
The CLint,T and DDI in vitro assay was previously described in detail in Chapter 
2, Method section 2.2.3. To obtain a comprehensive pharmacokinetic profile the GZR 
DDIs with ATV, DRV and RTV were assessed individually as well as ATV and DRV 
in their boosted form with RTV, thereby replicating the clinically relevant DDI 
scenario. GZR, ATV/r and DRV/r assays were carried out in duplicate with a single 
replicate of the ATV, DRV and RTV assays, all of which had 4 technical replicates 
per condition and were designed based on the assumption that two assays could be 
carried out per vial of cryopreserved SPHHs. PIT and the DDI between PIT and RIF 
were utilised as experimental controls owing to their successful verification of the in 
vitro assay in Chapter 2.  
Briefly, DMSO 100% (vol/vol) stock solutions were freshly prepared the day 
before the experiment with KHB (pH 7.4) stock solutions containing 3% (vol/vol) 
DMSO being prepared the day of the experiment. The concentrations for each drug in 
the DMSO stock solution, KHB stock solution and the final cell culture plate well 
conditions are outlined in Table 4.1. Concentration ranges for each drug were 
established based on their solubility in KHB and were tested prior to the in vitro assays. 
To note, a 1:1 ratio for well conditions containing ATV/r and DRV/r was applied. 
Concentrations of the control drugs were selected to clearly demonstrate transporter-
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uptake and inhibition in the SPHHs. Additionally, in the CLint,T assay where only GZR 
was present in each well, KHB containing 3% (vol/vol) DMSO was prepared as an 
inhibitor substitute to maintain the final DMSO concentration of 1% (vol/vol). 
Furthermore, SPHHs were prepared so that the final incubation solution suspension 
equalled 1×105 cells/well. Any remaining SPHHs were used as the matrix for 
verification and calibrator samples during LC-MS/MS analysis. A schematic 
representation and description of the experimental protocol can be found in Figure 4.1.  
Table 4.1 Drug stock solution and final well condition concentrations.  
Drug DMSO Stock (µM) KHB Stock (µM) Well Condition (µM) 
GZR 6.6 – 20000 0.198 – 600 0.033 – 100 
ATV 1.32 – 4000 0.0198 – 60 0.0033 – 10 
DRV 4 – 13200 0.06 – 198 0.01 – 33 
RTV 4 – 13200 0.06 – 198 0.01 – 33 
ATV/r 1.32 – 4000 0.0198 – 60 0.0033 – 10 
DRV/r 4 – 13200 0.06 – 198 0.01 – 33 
PIT* 20 0.6 0.1 
RIF* 2000 60 10 
DMSO and KHB stock solutions were prepared using serial dilutions. Stock solutions were prepared 
so that the final well conditions consisted of a constant DMSO concentration of 1% (vol/vol). A 1:1 
ratio for well conditions containing ATV/r and DRV/r was applied. DMSO – dimethyl sulfoxide, 
KHB – Krebs-Henseleit buffer (pH 7.4), GZR – grazoprevir, ATV – atazanavir, DRV – darunavir, 
RTV – ritonavir, ATV/r – atazanavir and ritonavir, DRV/r – darunavir with ritonavir, PIT – 




Figure 4.1 Schematic diagram detailing the protocol for the SPHH CLint,T and DDI 
transporter assay. Step 1 – thaw cryopreserved SPHHs in a 37°C water bath for 2 
minutes; Step 2 - using a wide-bore pipette tip, slowly transfer thawed SPHHs into 
pre-warmed CHRM media (37°C) and centrifuge at room temperature at 100 × g for 
10 minutes before removing the CHRM media supernatant; Step 3 – resuspend pelleted 
SPHHs in 8ml of pre-warmed KHB (pH 7.4; 37°C) and, using a nucleocounter 
alongside reagent A100 and B, count the total and non-viable cells to determine the 
viable cells and adjust the concentration of SPHHs to 1×106 cells/ml; Step 4 – aliquot 
cells, KHB and pre-prepared inhibitor stock solutions into their corresponding wells; 
Step 5 – incubate for 5 minutes before initiating assays with the addition of pre-
prepared substrate stock solutions and incubating for 2 minutes at 37°C on a plate 
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shaker at 150 rpm; Step 6 – terminate assay incubations with the addition of 600 µl 
ice-cold PBS and transfer well solutions to microcentrifuge tubes before centrifuging 
at 2000 × g for 2 minutes at 4°C followed by the removal of the supernatant and again, 
add 600 µl ice-cold PBS and repeat centrifugation and removal process before storing 
the pelleted SPHHs at -80°C. 
 
4.2.3 LC-MS/MS Quantification 
GZR quantification was carried out on a TSQ Endura LC-MS/MS (Thermo 
Scientific, Hemel Hempstead, UK) using the Thermo Xcalibur Roadmap (version 
4.0.27.42), Chromeleon Xpress and TSQ Endura Tune Application (version 
2.0.1292.15) software. GZR 1 mg/ml stock solutions in 100% (vol/vol) LC-MS/MS 
grade methanol were freshly made every 2 weeks and stored at 4°C for use in LC-
MS/MS analysis. 
 Mass Spectrometer Optimisation 
GZR 500 ng/ml solution in 50% (vol/vol) ACNL in dH2O was directly infused 
into the mass spectrometer using heated electron spray ionisation in positive mode for 
the optimisation of ion spray voltage, sheath gas, auxiliary gas, ion transfer tube 
temperature and vaporiser temperature. Ionised analytes and their fragments were 
detected using SRM scanning.  
 Chromatographic Separation 
Chromatographic separation of GZR was carried out using an Accucore C18 
(100 x 2.1mm) LC-MS/MS column fitted with an Accucore C18 pre-column (10 x 
2.1mm). A multi-step gradient method consisting of two mobile phases was developed 
using GZR 500 ng/ml solution in 50% (vol/vol) ACNL in dH2O aliquoted into 
Chromacol fixed insert vials to obtain an efficient and effective separation of GZR.  
 Sample Preparation 
Samples were prepared as described in Chapter 2, Method section 2.2.4.3, 
excluding the use of the IS. For the CLint,T assay samples, one replicate per condition 
was quantified prior to the analysis of all remaining samples to determine appropriate 
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dilution ratios for the analysis of GZR concentrations within the LC-MS/MS 
calibration curve range. GZR 10 – 100 µM well conditions were diluted with a 1:10 
ratio whilst all unknown samples were diluted with a 1:2 ratio in 50% (vol/vol) ACNL 
in dH2O. All GZR calibrator and blank samples were prepared in accordance with the 
FDA guidelines (141). 
 Assay Verification 
The LC-MS/MS method for the quantification of GZR was verified 
considering the calibration curve, quality controls, selectivity, carryover, sensitivity, 
accuracy, precision and carryover. Guidelines adapted from the FDA for method 
verification and in-study analysis verification were described in detail in Chapter 2, 
Table 2.2, and were applied herein (141). 
4.2.4 In Vitro Assay Data Analysis 
The CLint,T and DDI in vitro assay data quantified using the GZR LC-MS/MS 
method were processed using Prism v8 software (GraphPad Software Inc., La Jolla, 
CA, USA). Michaelis Menten non-linear regression analysis was applied to the GZR 
(0.033-100 µM) CLint,T assay data to derive the Vmax (µmole/10
6cells/minute) and Km 
(µM) whilst a log(inhibitor concentration) vs. response equation and a least-squares 
fitting method was applied to the DDI assay data to calculate the IC50. CLint,T and the 
percentage inhibition of GZR by the inhibitors was calculated as previously described 
in Chapter 2, Method section 2.2.5. Furthermore, a D'Agostino & Pearson test was 
used to assess the normality of all datasets. 
4.2.5 Grazoprevir In Silico Assessment using PBPK Modelling 
The GZR in vitro CLint,T data was integrated into the PBPK model (Simbiology 
v5.8, a product of Matlab 2018a; MathWorks, Natick, MA, USA; 2018) described in 
detail in Chapter 3, Method section 3.2.1, to simulate GZR pharmacokinetics. All 
equations were applied as previously outlined, except for the olive oil:buffer partition 
coefficient of nonionised and ionised species at pH 7.4 (D*vo:w) which was calculated 
using Equation 1 and further transformed from the logarithmic form to the inverse log 
form for model implementation (213). The logarithmic value of the dissociation 
constant for acid and base are pKa1 and pKa2, respectively. 
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Zwitterionic: LogD*vo:w = LogDvo:w – Log(1 + 10-pKa2 + pH + pKa1 - pH) (1) 
 
A virtual cohort of 100 male and female patients aged 18 – 60 years were 
simulated with physicochemical and pharmacokinetic data for GZR being sourced 
from the literature or via curve fitting when data were unavailable or inadequate. A 
summary of the physicochemical and in vitro data utilised in the GZR PBPK model 
can be found in Table 4.2. Clinically observed pharmacokinetic data and concentration 
time profile for GZR 200mg QD (96) were utilised for PBPK model verification, with 
data being extracted from graphs when necessary using the Plot Digitizer Tool 
(plotdigitizer.sourceforge.net). Verification was carried out as described in Chapter 3, 
Method section 3.2.3, with both the stringent 0.75 – 1.25 ratio and 1 – 1.25 AAFE 
criteria (220) as well as the widely recognised 0.5 – 2 ratio and 1 – 2 AAFE (150) 
criteria being employed.  
Table 4.2 Physicochemical and in vitro data for GZR. 
Parameter GZR 
Molecular Weight (g/mol) 766.903 (232) 
HBD 0.012 (232) 
Log PO:W 4.7 (233) 
pKa (Strongest Acidic) 3.77 (232) 
pKa (Strongest Basic) 1.79 (232) 
Protein Binding (%) 98.8 (232) 
PSA (Å2) 205.69 (232) 
R 0.7 (234) 
Vss (L) 1250 (101) 
F (%) 27 (101) 
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Water Solubility (mg/L) 0.0097 (232) 
CLint,T (µL/minute/10
6 cells) E 
CLint,T IVIVE Correction Factor 18 (191) 
CLint,CYP3A4 (%) 20 (231) 
Reference for literature values presented in brackets. GZR – grazoprevir, HBD – Hydrogen bond 
donor, Log PO:W - Partition coefficient between octanol and water, pKa - logarithmic value of the 
dissociation constant, PSA – polar surface area, R – blood-to-plasma drug ratio, Vss – volume of 
distribution, F – bioavailability, CL,int,T – total hepatic transporter intrinsic clearance, IVIVE – in 
vitro in vivo extrapolation, CLint,CYP – Cytochrome P450 enzyme intrinsic clearance, E – 






4.3.1 LC-MS/MS Method Development and Verification  
The GZR LC-MS/MS method was successfully developed and verified as 
described in Method section 4.2.3.4 with each verification parameter detailed below. 
 Mass Spectrometer Optimisation 
The MS parameters were optimised for the maximum detection of GZR. A 
summary of the finalised MS parameters can be found in Table 4.3, including the 
product and precursor ions used for the detection of GZR.  
Table 4.3 Optimised MS parameters. 
Parameter Setting 
Ion Spray Voltage (V) Positive 4000 
Sheath Gas (arb) 50 
Auxiliary Gas (arb) 9 
Ion Transfer Tube Temperature (°C) 350 
Vaporiser Temperature (°C) 350 
Precursor Ion (m/z) 767.34 
Product Ions (m/z) 189.04, 191.111, 285.151, 326.103, 
489.262, 537.347, 646.405, 739.458 
Parameters optimised using grazoprevir 500ng/ml stock solutions in 50% (vol/vol) ACNL in dH2O. 





 Chromatographic Separation 
A multi-step mobile phase gradient was optimised for the separation of GZR 
and is summarised in Table 4.4. GZR was separated using two mobile phases over 6 
minutes with a flow rate of 300 µl/min and an average retention time of 3.61 minutes. 
Mobile phase A consisted of 100% H2OL with 0.5% FAL and mobile phase B consisted 
of 100% ACNL with 0.5% FAL. Example chromatograms of 10 µl injections of 500 
ng/ml GZR and blank stock solutions in 50% (vol/vol) ACNL in dH2O are shown in 
Figure 4.2. 
Table 4.4 Chromatographic separation method. 
Time (minutes) Mobile Phase A (%) Mobile Phase B (%) 
0 95 5 
0.1 95 5 
0.3 10 90 
4.1 5 95 
5 5 95 
5 95 5 
6 95 5 
Mobile phase A consisted of 100% H2OL with 0.5% FAL and mobile phase B consisted of 100% 





Figure 4.2 Chromatographic separation of GZR and blank stock solution using the 
optimised MS parameters and mobile phase gradient method. Chromatogram A shows 
the peak produced by a 10 µl injection of 500 ng/ml GZR solution in 50% (vol/vol) 
ACNL in dH2O. Chromatogram B shows the peak produced by a 10 µl injection of 
blank solution in 50% (vol/vol) ACNL in dH2O for GZR. The grey shaded areas 
represent peaks detected and processed by the Thermo Xcalibur Roadmap software, 
with RT and peak area (automatic integration; AA) being displayed for each detected 
peak. 
 
 Calibration Curve 
A calibration curve with a concentration range of 1.95 – 500 ng/ml was chosen, 
with 1.95 ng/ml being established as the LLOQ. The LC-MS/MS method met the 
calibration curve verification criteria with two verification runs obtaining 100% of 
calibrators and one verification run obtaining 88.89% of calibrators within ±15% (non-
zero calibrators) and ±20% (LLOQ calibrator) of their nominal concentrations. R2 
values of 0.9964 – 0.9998 were achieved by applying a quadratic equation with 1/X 
weighting and demonstrated good linearity of the LC-MS/MS method. In accordance 
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with the verification criteria, this regression model was found to be the simplest model 
that best described the signal response to calibrator concentration relationship.  
 Quality Controls 
The LLOQ, low (L), medium (M) and high (H) QC levels were selected as 1.95 
ng/ml, 5 ng/ml, 100 ng/ml and 400 ng/ml, respectively. In total, verification run one, 
two and three produced 93.33%, 86.67% and 66.67% of QC levels within ±15% (M 
and H QC) and ±20% (LLOQ and L QC) of their nominal concentrations. 
 Carryover 
The blank sample following the 500 ng/ml calibrator was compared to the 
LLOQ calibrator to evaluate the effect of carryover on sample analysis. In all 
verification runs the blank was less than 1% of the LLOQ, satisfying the verification 
criteria.  
 Sensitivity and Selectivity 
To assess sensitivity, the concentration of GZR in a blank sample was 
compared to the concentration of GZR in the LLOQ calibrator, with the LLOQ being 
at least 5 times greater in all three verification runs. Additionally, blank and zero 
calibrators with a SPHH (lot. HUE120) matrix were free from interference at GZR’s 
RT, as shown in Figure 4.2, demonstrating suitable selectivity of the LC-MS/MS 
method. 
 Accuracy and Precision 
Accuracy and precision were assessed within and between verification runs for 
LLOQ, L QC, M QC and H QC calibrators. Inter-assay and intra-assay accuracy and 
precision variance for all calibrators were within ±15% of their nominal values as show 
in Table 4.5 and 4.6, respectively. 
 Recovery 
The recovery of GZR across 1 ng/ml, 50 ng/ml and 500 ng/ml concentrations 
were 104.94%, 101.85% and 110.78% producing a mean recovery and standard 
deviation of 105.86 ± 3.7%, achieving the verification criteria. 
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1.95 (LLOQ) 0.40 0.94 1.61 3.53 2.12 4.74 
5 (L QC) 2.18 5.13 2.37 5.23 3.13 6.44 
100 (M QC) 1.85 4.57 1.47 3.68 3.94 7.15 
400 (H QC) 1.13 2.59 3.20 6.87 1.57 2.78 











1.95 (LLOQ) 1.17 4.57 
5 (L QC) 2.00 7.60 
100 (M QC) 1.44 5.67 
400 (H QC) 1.38 4.95 
Data points that failed to meet the acceptance criteria were excluded. LLOQ – lower limit of 
quantification, QC – quality control, L – low range, M – mid range, H – high range. 
 
4.3.2 CLint,T Primary Human Hepatocyte In Vitro Assay 
 LC/MS-MS Quantification 
The LC-MS/MS method was successfully applied for the quantification of 
GZR with assay samples being analysed across eight LC-MS/MS analysis runs. Seven 
of the LC-MS/MS analysis runs passed the in-study analysis verification criteria. One 
analysis run passed the in-study criteria albeit with one exception; one of the QC 
concentration levels had 33% of calibrators attaining ±15% of their nominal values 
rather than the required 50%, with one calibrator being marginally below the criteria.  
 Toxicity Study 
The GZR, ATV, DRV, RTV, ATV/r and DRV/r drug concentrations used in 
the CLint,T and DDI assays were deemed non-toxic as the cell viability had decreased 
1.25%, 0.73%, 2.94%, 7.68% 15.39% and 10.6% in comparison to the cell viability 
calculated during the preparation of the cryopreserved SPHHs, respectively. 
 CLint,T of Grazoprevir and DDI with Protease Inhibitors 
A summary of the CLint,T in vitro assay data can be found in Table 4.7 with the 
uptake kinetic profile of GZR being shown in Figure 4.3. Vmax and Km were calculated 
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using Prism v8 software (GraphPad Software Inc., La Jolla, CA, USA) and CLint,T was 
calculated by dividing Vmax by Km. The DDI in vitro assay is summarised in Table 4.8 
with Figures 4.4 – 4.8 detailing the concentration-dependent inhibition of GZR by 
ATV, ATV/r, DRV, DRV/r and RTV, respectively. Due to the irregularity of the DDI 
between GZR, ATV and DRV, the IC50 and maximal percent inhibition was not 
calculated. All data sets were tested for normality using the D'Agostino & Pearson test. 
Excluding the dataset for the DDI between GZR and ATV/r which had a p-value of 
0.0422, all datasets passed the normality test with p-values between 0.0583 – 0.9832. 
 
Figure 4.3 Total uptake kinetic profile of GZR (0.033 – 100 µM) measured in the lot. 
HUE120 SPHHs. The green line and error bars represent the mean total GZR uptake 
± SD (pmole/minute/106 cells) of two experimental replicates with four technical 
replicates. 
Table 4.7 Summary of the GZR CLint,T in vitro assay. 
GZR Parameter Lot. HUE120 
Vmax (µmole/minute/10
6 cells) 5999 ± 220.63 
Km (µM) 23.54 ± 2.43 
CLint,T (µl/minute/10
6 cells) 254.84 ± 90.83 
Data presented as the mean ± SD of two experimental replicates with three or four technical replicates 
as described in method section 4.2.3.3. GZR – grazoprevir, Vmax – maximum uptake velocity, Km – 




Figure 4.4 Concentration-dependent inhibition of total GZR (0.1 µM) uptake by ATV 
(0.0033 – 10 µM) measured in the lot. HUE120 SPHHs. The green line and error bars 
represent the mean inhibited total GZR uptake ± SD (% of control) of two experimental 
replicates with four technical replicates. 
 
 
Figure 4.5 Concentration-dependent inhibition of total GZR (0.1 µM) uptake by 
ATV/r (1:1 ATV:RTV; 0.0033 – 10 µM) measured in the lot. HUE120 SPHHs. The 
green line and error bars represent the mean inhibited total GZR uptake ± SD (% of 





Figure 4.6 Concentration-dependent inhibition of total GZR (0.1 µM) uptake by DRV 
(0.01 – 33 µM) measured in the lot. HUE120 SPHHs. The green line and error bars 
represent the mean inhibited total GZR uptake ± SD (% of control) of two experimental 
replicates with four technical replicates. 
 
 
Figure 4.7 Concentration-dependent inhibition of total GZR (0.1 µM) uptake by 
DRV/r (1:1 DRV:RTV; 0.01 – 33 µM) measured in the lot. HUE120 SPHHs. The 
green line and error bars represent the mean inhibited total GZR uptake ± SD (% of 





Figure 4.8 Concentration-dependent inhibition of total GZR (0.1 µM) uptake by RTV 
(0.01 – 33 µM) measured in the lot. HUE120 SPHHs. The green line and error bars 
represent the mean inhibited total GZR uptake ± SD (% of control) of two experimental 
replicates with four technical replicates. 
 
Table 4.8 Summary of the DDI in vitro assay with GZR, ATV, DRV and RTV. 
GZR Parameter IC50 (µM) Maximal Inhibition (%) 
ATV NC NC 
ATV/r 20.76 46.98 
DRV NC NC 
DRV/r 1.66 68.56 
RTV 22.89 52.01 
Data calculated from two experimental replicates with four technical replicates. GZR – grazoprevir, 
ATV – atazanavir, ATV/r – atazanavir with ritonavir, DRV – darunavir, DRV/r – darunavir with 
ritonavir, RTV – ritonavir, IC50 - half maximal inhibitory concentration, SD – standard deviation, 




4.3.3 Grazoprevir PBPK model 
The PBPK model was successfully verified for the simulation of steady state 
GZR 200mg QD. Ratio and AAFE values for Cmin, Tmax, bioavailability and the 
concentration-time profile were within the stringent 0.75 – 1.25 and 1 – 1.25 
verification criteria, respectively. AUC and Cmax achieved the 0.5 – 2 ratio and 1 – 2 
AAFE criteria. A summary of the predicted vs. observed pharmacokinetic data and the 
concentration-time profile are shown in Table 4.9 and Figure 4.9, respectively. The 
GZR CLint,T determined in vitro was successfully implemented into the multi-
compartment liver model with the application of the IVIVE correction factor and 
active and passive percent contribution values verified in Chapter 3. However, due to 
the unsuitable nature of the in vitro GZR DDI data, the PBPK model was not developed 
or verified for the simulation of the DDI between GZR, ATV/r and DRV/r.  
During model development, five parameters were optimised via curve fitting 
to achieve the most accurate simulations of GZR pharmacokinetics. Firstly, a 
correction factor of 0.4 was applied to the Vss. Secondly, due to the lack of data 
surrounding GZR metabolism and biliary excretion, these parameters were optimised 
alongside the pharmacokinetic profile to achieve 20% metabolism mediated by 
CYP3A4, as specified in the literature (231). A value of 0.26 µl/min/pmol was 
estimated for CYP3A4 intrinsic clearance (CLint,CYP3A4) with CLbiliary being estimated 
as 0.004 ml/min/kg. Thirdly, the equation for Peff was unable to capture the absorption 
of GZR and so this parameter was estimated to be 0.001 cm/s. Lastly, alongside Peff 
optimisation, fasted rather than fed intestinal transit rates were applied in the PBPK 
model to achieve an accurate absorption profile, contrary to the GZR clinical study 





Figure 4.9 Predicted vs. observed concentration time profiles for steady state GZR 
200mg QD. The blue line and shaded area represent the mean plasma concentration ± 







Table 4.9 Predicted vs. observed pharmacokinetic parameters, ratio and AAFE values for steady state GZR 200mg QD. 
Parameter Predicted Observed (96) Ratio AAFE 
AUC (µg/h/ml) 3.58 ± 0.62 2.54 1.41 1.41 
Cmax (µg/ml) 0.46 ± 0.08 0.63 0.73 1.37 
Cmin (µg/ml) 0.01 ± 0.008 0.012 0.83 1.20 
Tmax (h) 4 3 1.33 1.33 
F (%) 24.13 27 (101) 0.89 1.12 
Profile - - - 1.08 
Reference for observed values presented in brackets. Observed values for AUC, Cmax and Cmin presented as mean ± SD. Observed values for Tmax and F presented as the mean. 
Observed AUC is AUC0-24. Predicted values presented as the mean (SD not provided). Predicted AUC is AUC0-∞. Predicted values converted from µM/h (AUC) and µM 
(Cmax and Cmin) to µg/h/ml and µg/ml, respectively. Ratio and AAFE values calculated as described in Chapter 3, Method section 3.2.3. AUC – area under the curve, Cmax – 





The clinical management of PLWH requires a comprehensive knowledge of 
multiple disease areas, special populations and polypharmacy, specifically how co-
medicated drugs interact with one another. Unlike enzyme-mediated DDIs our 
knowledge of transporter-mediated DDIs is lacking, generating research initiatives to 
fulfil the demand for further evidence-based guidance. Currently, there is a paucity of 
transporter specific substrates, inhibitors and inducers available for the assessment of 
DDIs in vitro and in vivo (235). As a result, an array of DDI combinations are studied 
in clinical trials to determine any significant interactions, with the mechanisms of 
action being surmised as a secondary objective. In this study the in vitro-in silico 
framework developed and verified in Chapter 2 and 3 was used to explore the role of 
transporters in the DDI between GZR, ATV/r and DRV/r and further our 
understanding of their mechanisms of action. Additionally, we evaluated the 
capabilities of the framework and an SPHH specific IVIVE correction factor in a 
clinically relevant scenario involving ARV drugs.  
4.4.1 LC-MS/MS Quantification 
The verification criteria adapted from the FDA guidelines were applied 
successfully for the verification of the GZR LC-MS/MS method. Both GZR stability 
and the effect of dilution were not assessed in this study as they had previously been 
evaluated and were in accordance with the methodology applied herein (236, 237). 
Additionally, an IS was not applied as the accuracy and precision of the developed 
method proved adequate without the use of an IS. Unlike the method verification, one 
of the eight in-study analysis’s verification presented one exception to the criteria. As 
previously described, one QC level had 33% of calibrators, rather than 50%, achieving 
the criteria. However, this was due to a single QC level replicate being ±20.96% of 
their nominal value rather than ±15%. As all other criteria were attained and the 
availability of sample was limited, the impact was deemed insignificant and the data 
from the assay was used in this study.  
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4.4.2 In Vitro Assessment of CLint,T and DDI 
The CLint,T assay demonstrated the uptake of GZR into the SPHHs, however 
the DDI assay data for ATV and DRV appeared to be irregular based on previous 
assumptions made in the literature (231). According to previous DDI studies the 
magnitude of interaction between GZR, ATV/r and DRV/r is substantial and has been 
assumed to be predominantly caused by the inhibition of OATP1B1 and OATP1B3. It 
was therefore predicted that the in vitro assay would result in a low IC50 value and a 
high maximal percent inhibition of GZR by ATV and DRV. Yet, the data produced 
herein demonstrated little to no inhibition of GZR by ATV and DRV, even at high 
concentrations, and only under ATV/r and DRV/r conditions could an IC50 be 
calculated. The data for the DDI assay involving ATV/r was also found not to be 
normal according to the D'Agostino & Pearson test, whereas all other datasets were 
normal. The test results for normality were however only marginally outside of the 
criteria for normal data. Conversely, the data produced from the DDI assay between 
GZR and RTV was as expected based on the literature (96), with no inhibition of 
OATP1B1 or OATP1B3 expected at physiologically relevant concentrations. RTV 
demonstrated up to 50% maximal inhibition of GZR uptake at higher RTV 
concentrations, showing that the mechanism involved in GZR uptake into hepatocytes 
can be inhibited in this in vitro assay system. Moreover, the PIT and RIF controls 
applied in the in vitro assays showed uptake of PIT and inhibition of PIT uptake by 
RIF demonstrating suitable functionality of the SPHHs. Additionally, the toxicity 
study demonstrated minimal impact of any of the drugs or drug combinations on cell 
viability. 
There are two rational explanations for this phenomenon. Firstly, and 
potentially more likely, the results obtained for the DDI between GZR, ATV(/r) and 
DRV(/r) are false negatives. False negative results can occur in cell-based in vitro 
assays because of the passive permeability or solubility properties of a drug and are 
considered limitations of these systems (238). Based on these two elements, GZR as 
well as ATV and DRV could have produced a false negative result. Recombinant cell 
line in vitro studies showed similar uptake of GZR (1 µM) in both MDCKII cells stably 
transfected with OATP1B1 and control MDCKII cells, suggesting a high passive 
diffusion of GZR into the cells. In contrast, the uptake of GZR in MDCKII cells stably 
transfected with OATP1B3 was much greater than in control MDCKII cells, 
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suggesting a lower passive diffusion (231). As described in the Chapter 2 discussion 
section, passive diffusion is established through PBPK modelling in this in vitro-in 
silico framework rather than through temperature driven in vitro studies, and so the 
contribution of passive diffusion to the CLint,T determined herein cannot be concluded. 
Furthermore, both ATV (239) and DRV (240) are lipophilic drugs and during the DDI 
in vitro assay it was found that maximum concentrations of 10 µM and 33 µM could 
be solubilised in 1% DMSO in KHB solution, respectively. The lipophilic properties 
of ATV and DRV could of resulted in non-specific binding, producing lower than 
expected concentrations during the assay and potentially producing a false negative 
result (241). Although, it must be taken into consideration that RTV is also a lipophilic 
drug and the results for its DDI study were as anticipated (242).  
Secondly, an alternative mechanism besides the inhibition of OATP1B1 and 
OATP1B3 could be the predominant cause of the DDI found between GZR, ATV/r 
and DRV/r. Clinical DDI study data provided in the Clinical Pharmacology and 
Biopharmaceutics Review for Zepatier (GZR and elbasvir brand name) can be found 
in Table 4.10 (231). The inhibitory profiles of ATV, DRV and RTV as well as those 
present in further DDI clinical studies are shown in Table 4.11. GZR has been 
described as a substrate of CYP3A4, OATP1B1, OATP1B3, P-gp and potentially 
BCRP (231) and the data presented in Tables 4.10 and 4.11 indicate that all of the 
above described mechanisms are potentially inhibited in the DDI between GZR, 
ATV/r and DRV/r. The data from the RIF DDI clinical study alone suggests that 
OATP1B1 and OATP1B3 transport of GZR has been inhibited. Additionally, 
considering that cyclosporine is reported to inhibit CYP3A4, OATP1B1, OATP1B3, 
P-gp and BCRP and that the ratio of DDI was greater than with RIF, it would suggest 
that all pathways may be involved. Consequently, a mechanism of action that we are 
yet to comprehend could be the only viable explanation if considering a DDI 





Table 4.10 Clinical GZR DDI study data (231). 
Coadministered Drug GZR Regimen 
Geometric Mean Ratio of GZR PK With/Without Coadministered Drug 
AUC Cmax C24 
ATV/r 300mg/100mg QD GZR 200mg QD 10.58 6.24 11.64 
DRV/r 600mg/100mg QD GZR 200mg QD 7.50 5.27 8.05 
LPV/r 400mg/100mg QD GZR 200mg QD 12.86 7.31 21.70 
Ketoconazole 400mg QD GZR 100mg S 3.02 1.13 - 
Cyclosporine 400mg S GZR/EBR 200mg/50mg QD 15.21 17.00 3.39 
RIF 600mg S GZR 200mg QD 8.35 6.52 1.62 
RIF 600mg S (IV) GZR 200mg S 10.21 10.94 1.77 
Data sourced from the Clinical Pharmacology and Biopharmaceutics Review for Zepatier (231). Data presented as the mean AUC, Cmax and C24 of GZR with coadministered 
drug/without coadministered drug. All doses were orally administered unless stated otherwise. PK – pharmacokinetics, AUC – area under the curve, Cmax – maximum plasma 
concentration, C24 – plasma concentration at 24 hours, GZR – grazoprevir, ATV – atazanavir, ATV/r – atazanavir with ritonavir, DRV – darunavir, DRV/r – darunavir with 
ritonavir, RTV – ritonavir, LPV – lopinavir, RIF – rifampicin, QD – once daily, S – single dose, IV - intravenous.  
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Table 4.11 Inhibitory profiles of clinical DDI study drugs. 
Perpetrator Transporter Enzyme 
ATV (243) BCRP, P-gp, MRPs, OATPs CYP3A4, UGT1A1, CYP2C8 
DRV (244) P-gp, BCRP, MATE1, OATP1B1, OATP1B3 (with 
COBI), OATPs 
CYP3A4, CYP2D6 (observed with RTV or COBI) 
RTV (245) P-gp, MRP1, OATP-C, BCRP CYP3A, CYP2D6 
LPV (246, 247) BCRP, OATP1B1 CYP3A 
Ketoconazole (75) - CYP3A4 
Cyclosporine (75) P-gp, OATP1B1, OATP1B3, BCRP CYP3A4 
RIF SD (75, 248) OATP1B1, OATP1B3 - 
Reference for each drug presented in brackets. ATV – atazanavir, DRV – darunavir, RTV – ritonavir, LPV – lopinavir, RIF – rifampicin, COBI – cobicistat, SD – single 
dose, BCRP – breast cancer resistance protein, P-gp – P-glycoprotein, MRPs – multidrug resistance proteins, OATPs – organic anion transporter protein, MATE1 – multidrug 
and toxin extrusion 1, OATP1B1 - organic anion transporter protein B1, OATP1B3 - organic anion transporter protein B3, MRP1 – multidrug resistance protein 1, OATP-C 
- organic anion transporter protein B1, CYP3A4 – cytochrome P450 3A4, UGT1A1 - UDP-glucuronosyltransferase 1A1, CYP2C8 - cytochrome P450 2C8, CYP2D6 - 
cytochrome P450 2D6. 
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4.4.3 In Silico Assessment of CLint,T and DDI 
The CLint,T of GZR determined in vitro was successfully applied to the PBPK 
model developed and verified in Chapter 3, with all pharmacokinetic parameters 
achieving either the 0.75 – 1.25 or 0.5 – 2 ratio and  1 – 1.25 or 1 – 2 AAFE criteria. 
The IVIVE correction factor applied in the PIT PBPK model in Chapter 3 was also 
found to be suitable for GZR, suggesting that a SPHH specific IVIVE correction factor 
value could be used in this in vitro-in silico framework, although extensive testing with 
further drugs would be required. Additionally, the verification of the IVIVE correction 
factor would benefit from experimentally determined values for GZR CYP3A4 
metabolism and CLbiliary as these were fitted based on percentage literature data and so 
their accuracy cannot be confirmed. Similarly to the PIT PBPK model, the equation 
for Peff was unable to predict the absorption of GZR. The fed intestinal transit rate 
values also contributed to the incorrect prediction of GZR absorption based on the 
concentration time profile for steady state GZR 200mg. Alternative values were 
applied as per convention and considering that the application of this PBPK is based 
around liver transporter-mediated clearance and DDIs, these parameter optimisations 
were deemed appropriate.  
Unfortunately, due to the irregular data obtained from the in vitro DDI assays 
between GZR, ATV/r and DRV/r it was concluded that implementation of these values 
into the PBPK model for their clinical simulation was inappropriate. PBPK modelling 
is a powerful in silico tool however model predictions are limited by the data used to 
build them and the inclusion of potentially false negative in vitro data creates a lack of 
confidence in any resulting simulated data. This being especially true for complex 
DDIs like that between GZR, ATV/r and DRV/r were three drugs are interacting in 
conjunction with one another across multiple enzyme and transporter pathways. As a 
result, the additional verification of PBPK modelling for the determination of active 
and passive CLint,T described in Chapter 3 could also not be completed.  
4.4.4 Conclusion 
Based upon the above arguments it is clear that further in vitro studies are 
required to produce conclusive evidence of the contribution of OATP1B1 and 
OATP1B3 in the DDI between GZR, ATV/r and DRV/r. Such in vitro studies could 
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include the SPHH GZR DDI assay with RIF to identify the potentially more specific 
in vitro inhibition of OATP1B1 and OATP1B3 by RIF. They could also include the 
use of recombinant over expressing cell lines for DDI assessment, as utilised 
previously for the assessment of GZR uptake in OATP1B1-MDCKII and OATP1B3-
MDCKII cells (231). If false negative results are disproven, additional concepts such 
as time-based transporter inhibition should also be explored (133). Furthermore, the 
secondary aim of this study to verify the in vitro-in silico framework in a clinically 
relevant ARV scenario was not achieved, thus requiring future studies to be completed 
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Since the introduction of potent ART over the past few decades, the survival rate 
of PLWH has steadily increased, leading to a life expectancy approaching that of the 
general population (6). UNAIDS estimated the worldwide total of PLWH ≥50 years 
old had increased from 7.9% in 1990 to 20.8% in 2019 (249). Furthermore, a recent 
European modelling study projected that by 2030, 73% of PLWH in Europe will be 
aged ≥50 years old with 40% of those aged ≥65 years old (105). There is an emergent 
need to understand the role of age-associated changes in ARV pharmacokinetics as 
these demographic changes have led to complex clinical scenarios that involve factors 
not only related to HIV infection but also to ageing. Yet, OALWH remain vastly 
underrepresented in clinical trials leading to a paucity of pharmacokinetic knowledge 
and insufficient clinical practice guidelines for this population (102). Moreover, an 
increased risk of DDIs in OALWH has been hypothesised due to their high prevalence 
of polypharmacy and age-related comorbidities (105, 250). 
PBPK modelling has been utilised to overcome some of the clinical limitations 
experienced in OALWH (121, 187, 251). The reported PBPK model identified 
differences in drug exposure between non-elderly and elderly adults and were 
suggested to be caused by age-related physiological changes such as decreased hepatic 
and renal blood flow, resulting in reduced rates of drug clearance (251). Additionally, 
it has been suggested that ageing does not impact the magnitude of DDIs regardless of 
DDI mechanism or drugs involved, however this PBPK analysis was limited by the 
number of drugs included in the study representing each DDI mechanism of action 
(121). Furthermore, our limited understanding of the mechanisms that underpin 
transporter-mediated DDIs introduces challenges in the analysis of such studies. 
Although several advancements have been made to address the knowledge gap relating 
to transporters over the past few years, the impact of age on clinically relevant 
transporters such as OATP1B1 has yet to be comprehensively studied (69). Existing 
literature regarding the expression of OATP1B1 is contradictory, stating both a weak 
correlation (77) and no correlation between age and OATP1B1 expression (252). 
Moreover, where donor information was available, it was found that a limited number 




In vitro techniques can be applied to investigate the effect of age on OATP1B1 
expression and activity by utilising PHHs from donors across multiple age groups. 
Commercially available sandwich-ELISA kits have been produced for the 
quantification of several transporters and provide a more accessible approach in 
comparison to the resource and skill intensive LC-MS/MS technique commonly 
applied for protein quantification (253). The SLCO1B1 ELISA kit utilises antigen 
interactions between SLCO1B1 and antibody-SLCO1B1 alongside a horseradish 
peroxidase (HRP) colorimetric system for the detection of SLCO1B1 antigen targets. 
By implementing a calibration curve with known SLCO1B1 concentrations, the 
concentration of unknown samples of SLCO1B1 can be quantified (254). 
Additionally, SPHHs can be utilised in vitro to assess transporter-mediated clearance 
and DDIs, with FDA guidelines identifying probe substrate and inhibitors for a range 
of clinically relevant transporters (75, 131, 132).   
The aim of this study was to quantify the expression of the hepatic uptake drug 
transporter OATP1B1 using a commercially available sandwich-ELISA kit. We also 
aimed to apply the SPHH in vitro assay developed in Chapter 2 to quantify the CLint,T 
and IC50 for the OATP1B1 probe substrate and inhibitor, PIT and RIF, in non-elderly 
adults (30 – 62 years), elderly adults (70 – 80 years) and mixed age adults (18 – 74 
years). This work aimed to further understand the role of age in the expression and 
activity of OATP1B1 and expand our current knowledge of transporters to help 






Materials used for the CLint,T, DDI and LC-MS/MS in vitro studies were 
previously described in Chapter 2. Additionally, the Human SLCO1B1 ELISA Kit 
(catalog no. MBS9323360) was purchased from MyBioSource (California, USA). 
Pierce BCA Protein Assay Kit (catalog no. 23227), Mem-PERTM Plus Membrane 
Protein Extraction Kit (catalog no. 89842), Trypan blue (catalog no. 15250061) were 
purchased from Thermo Fisher Scientific (Hemel Hempstead, UK). All other materials 
were purchased from Thermo Fisher Scientific (Hemel Hempstead, UK) and Sigma-
Aldrich (Poole, UK).  
5.2.2 Cryopreserved Primary Human Hepatocytes 
Pooled cryopreserved SPHH with lot no. HUE120 (catalog no. HMCS10; non-
elderly) and HUE50-0 (catalog no. HMCS50; mixed-age) were purchased from 
Thermo Fisher Scientific (Hemel Hempstead, UK). Individual cryopreserved SPHH 
with lot no. IGG, JCM, KQF, TJP (catalog no. F00995; elderly) and MNO (catalog no. 
M00995; elderly) were purchased from BioIVT (West Sussex, UK). A summary of 
donor characteristics can be found in Table 5.1. The non-elderly (30 – 62 years), 
mixed-age (18 – 74 years) and elderly (70 – 80 years) SPHHs were all used in the 
quantification of OATP1B1 by sandwich ELISA. However, only the individual elderly 
SPHH donor aged 80 years old (lot no. MNO) was used in the in vitro PIT and RIF 
CLint,T and DDI study as this was the only elderly donor previously qualified for 
transporter uptake studies. Data from the non-elderly SPHH CLint,T and DDI study in 







Table 5.1 Summary of primary human hepatocyte donor characteristics. 
Characteristics Non-Elderly Mixed-Age Elderly 
n 10 50 5 
Age, years 
56 (30-62) 52.5 (18-74) 77 (70-80) Median (range) 
Gender, n    
Male (%) 7 (70) 24 (48) 1 (20) 
Female (%) 3 (30) 26 (52) 4 (80) 
Race, n    
Caucasian (%) 10 (100) 43 (86) 5 (100) 
African American (%) 0 (0) 4 (8) 0 (0) 
Asian (%) 0 (0) 2 (4) 0 (0) 
Hispanic (%) 0 (0) 1 (2) 0 (0) 
Reported History, n     
Alcohol (%) 8 (80) 32 (64) 2 (40) 
Tobacco (%) 5 (50) 31 (62) 3 (60) 
Recreational Drugs (%) 4 (40) 23 (46) 0 (0) 
Medication (%) 8 (80) 31 (62) 3 (60) 
Non-elderly – lot no. HUE120, Mixed-age – lot no. HUE50-0, Elderly – lot no. IGG, JCM, KQF, 




5.2.3 OATP1B1 Quantification by Sandwich ELISA  
OATP1B1 expression in the non-elderly, mixed-age and elderly SPHHs were 
quantified using a SLCO1B1 ELISA kit (MyBioSource, California, USA). The kit has 
a sensitivity of 0.1 ng/ml and detection range of 0.625 – 20 ng/ml (254). Firstly, the 
SPHH samples were thawed and resuspended in KHB (pH 7.4) at a concentration of 
1x106 cells/ml as previously described in Chapter 2. ELISA wash solution was diluted 
1:20 with dH2O and all reagents were brought to room temperature (18 – 25°C). Three 
technical replicates of each SPHH sample were generated by aliquoting 750µl of each 
suspension into microcentrifuge tubes. The remaining SPHHs were stored at -80°C 
and used as described in method section 5.2.3.1. The SPHHs were then centrifuged at 
2000 × g for 2 minutes at 4°C and the resulting supernatant was removed. Cell pellets 
were washed with 1ml of ice-cold PBS before centrifugation was repeated. The 
supernatant was removed and 75 µl of ice-cold PBS was aliquoted into each 
microcentrifuge tube and the cell pellet resuspended. On ice, each sample was passed 
slowly through a 30 gauge needle ten times followed by centrifugation at 14,000 × g 
for 20 minutes to pellet the cell debris. A control sample of SPHHs was prepared as 
described above, stained with trypan blue and visually inspected under a microscope 
to confirm cell lysis (255). 
Following the above sample preparation, 50 µl of supernatant was aliquoted 
into the ELISA plate wells, producing a final relative concentration of 5×105 cells/well. 
Similarly, 50 µl of pre-prepared standard and blank solutions were added in duplicate 
to the ELISA plate wells and 100 µl of HRP-conjugate reagent was aliquoted into each 
well. The ELISA plate was then covered with a closure plate membrane and incubated 
at 37°C for 1 hour. Following incubation, the ELISA plate was manually washed by  
disposing the incubation mixtures into a waste container and filling each well with 
wash solution and leaving to stand for 1 minute. The wash solution was then disposed 
of into a waste container before being inverted and hit onto absorbent paper towels 
until no moisture was present. This process was repeated four times and once 
completed, 50 µl of Chromogen solution A and B were successively aliquoted into 
each well. The ELISA plate was then covered to protect the Chromogen solutions from 
light and incubated at 37°C for 15 minutes. Finally, 50 µl of stop solution was 
aliquoted into each well and the ELISA plate was left to stand for 5 minutes. A GENios 
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microplate reader (Tecan, Männedorf, Switzerland) was then used to read the optical 
density of each well at 450nm.  
 Data Analysis 
Prism v8 software (GraphPad Software Inc., La Jolla, CA, USA) was used to 
plot the sandwich ELISA standard curve absorbance data and interpolate the unknown 
OATP1B1 values in ng/ml for the non-elderly, mixed-age and elderly SPHH samples. 
In order to normalise OATP1B1 expression to fmol/µg total membrane protein, a 
Pierce BCA Protein Assay Kit (Thermo Fisher Scientific, Hemel Hempstead, UK) was 
used to quantify the total membrane protein content in each sample. Membrane and 
membrane-associated proteins were firstly isolated from the hepatocyte samples using 
a Mem-PERTM Plus Membrane Protein Extraction Kit (Thermo Fisher Scientific, 
Hemel Hempstead, UK). The remaining SPHHs from the sandwich ELISA were 
brought to room temperature (18 – 25°C) and 5ml was aliquoted into 15ml centrifuge 
tubes. For elderly hepatocyte donor lot no. TJP and IGG, only 1.5ml and 2.5ml were 
available for analysis, respectively. SPHH samples were centrifuged at 300 × g for 5 
minutes at 4°C and the supernatant was removed before the cell pellets were washed 
with 3 ml of wash solution. This process was repeated, and the cell pellets were 
resuspended in 1.5 ml of wash solution before being transferred to microcentrifuge 
tubes. SPHH samples were centrifuged at 300 × g for 5 minutes at 4°C and supernatant 
removed before 750 µl of permeabilization buffer was added. Cell pellets were 
resuspended via brief vortexing and incubated with constant mixing for 10 minutes at 
4°C. The now permeabilised cells were centrifuged at 16,000 × g for 15 minutes at 
4°C and the supernatant containing cytosolic proteins was carefully transferred to new 
microcentrifuge tubes. Immediately before use, 50 µl of protease/phosphatase inhibitor 
cocktail was added to 5 ml of solubilisation buffer and 500 µl aliquots of buffer were 
added to each sample. The cell pellets were resuspended in the solubilisation buffer 
and incubated with constant mixing for 30 minutes at 4°C. SPHH samples were then 
centrifuged at 16,000 × g for 15 minutes at 4°C and supernatant containing solubilised 
membrane and membrane-associated proteins were transferred to new microcentrifuge 
tubes in preparation for the Pierce BCA protein assay. 
To quantify the total membrane protein content, 25µl of each membrane 
protein sample were aliquoted in triplicate into a 96-well cell culture plate. Albumin 
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standards were diluted with PBS as described in the Pierce BCA protein assay kit 
protocol (256), producing a detection range of 25 – 2000 µg/ml. Similarly, 25 µl of 
albumin standards and blank PBS were aliquoted into the 96-well cell culture plate. A 
working reagent was produced by mixing 10 ml of kit reagent A with 200 µl of kit 
reagent B and 200 µl of the working reagent was added to each well. The plate was 
mixed thoroughly on a plate shaker for 30 seconds before being incubated for 30 
minutes at 37°C. Following incubation, the plate was cooled to room temperature over 
30 minutes. A GENios Tecan microplate reader was used to read the optical density of 
each well at 562nm.  
Prism v8 software (GraphPad Software Inc., La Jolla, CA, USA) was used to 
plot the Pierce BCA protein assay standard curve absorbance data and interpolate the 
unknown total membrane protein values in µg/ml for the non-elderly, mixed-age and 
elderly SPHHs. The OATP1B1 sandwich ELISA data was then normalised to fmol/µg 
total membrane protein using equation 1. Statistical analysis of the OATP1B1 
expression data was also carried out using Prism v8 software (GraphPad Software Inc., 
La Jolla, CA, USA). Due to the lack of data points normality was unable to be tested 
and therefore statistical significance between the non-elderly, mixed-age and elderly 
SPHH’s OATP1B1 expression values were assessed using a Mann-Whitney (non-
parametric) test. 
 
OATP1B1 (fmol/µg total membrane protein) =  
OATP1B1 (fmol/ml)




5.2.4 In Vitro Pitavastatin and Rifampicin CLint,T and DDI Study 
The in vitro PIT and RIF CLint,T and DDI assays were adapted from literature 
(135, 163-168) and previously described in detail in Chapter 2. Both assays were 
carried out in duplicate and each contained four technical replicates per condition. 
Briefly, stock solutions of PIT and RIF were freshly prepared in 100% (vol/vol) 
DMSO the day before the experiment. The day of the experiment, incubation solution 
concentrations of the probe substrate PIT (0.1 – 300 µM) and probe inhibitor RIF (0.1 
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– 300 µM) were prepared in KHB (pH 7.4) through serial dilution, providing a constant 
DMSO final concentration of 1% (vol/vol) per well. Cryopreserved SPHHs were then 
thawed, resuspended in KHB at a concentration of 1×106 cells/ml and aliquoted into 
24-well cell culture plates to produce a final incubation solution suspension of 1×105 
cells/well. To determine the CLint,T of PIT, cells were preincubated with KHB for 5 
minutes and the study was initiated with the addition of PIT (0.1 – 300 µM). To 
determine the magnitude of DDI between PIT and RIF, cells were preincubated with 
RIF (0.1 – 300 µM) for 5 minutes and the study was initiated with the addition of PIT 
(0.1 µM). All incubations took place at 37°C on a plate shaker at 150rpm. Both studies 
were terminated after 2 minutes by placing the 24-well plates on ice and aliquoting 
ice-cold PBS into each well. Solutions were immediately transferred to 
microcentrifuge tubes followed by centrifugation at 2000 × g for 2 minutes at 4°C. 
Incubation solutions were then removed from each tube, cell pellets washed with ice-
cold PBS and the centrifugation process repeated. Cell pellets were stored at -80°C 
followed by a single freeze-thaw cycle (-80°C to room temperature; 18 – 25°C) to lyse 
the cells in preparation for LC-MS/MS analysis. 
 Quantification of Pitavastatin by LC-MS/MS 
PIT concentrations were determined using a TSQ Endura LC-MS/MS (Thermo 
Scientific, Hemel Hempstead, UK) and validated chromatographic method previously 
described in Chapter 2. To summarise, lysed cell pellet samples were resuspended in 
100 µl of 50% (vol/vol) ACN in dH2O and pre-determined dilutions carried out 
accordingly. At a concentration of 300 ng/ml, 300 µl of IS PRA in 100% (vol/vol) 
ACN were aliquoted into each microcentrifuge tube. Samples were vortexed for 10 
seconds and centrifuged at 13,300 × g for 10 minutes at 4°C. The resulting supernatant 
was aliquoted into borosilicate glass tubes and dried in a vacuum centrifuge for 4 hours 
at room temperature (18 – 25°C). Once dry, 100 µl of 50% (vol/vol) ACN in dH2O 
was aliquoted into each glass tube, vortexed for 10 seconds and 50 µl transferred to 
LC-MS/MS vials for analysis. Standard, QC and blank samples were prepared in a 
similar manner in accordance with FDA guidelines (141). Chromatographic separation 
of PIT and IS PRA was achieved using an Accucore C18 (100 x 2.1mm) LC-MS/MS 
column fitted with an Accucore C18 pre-column (10 x 2.1mm). Mobile phases 
comprising of 100% H2OL with 0.1% FAL and 100% ACNL with 0.1% FAL were 
applied in a multi-step gradient method over 5 minutes with a flow rate of 300 µl/ml, 
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as described in Chapter 2. Heated ESI was applied in positive mode to ionise the 
samples and allow detection of the breakdown products via SRM scanning. 
 Data Analysis 
Prism v8 software (GraphPad Software Inc., La Jolla, CA, USA) was used to 
plot the CLint,T and DDI in vitro assay data for both the non-elderly SPHHs and 
individual elderly SPHH donor aged 80 years old. Michaelis Menten non-linear 
regression analysis was applied to the PIT (0.1 – 300 µM) CLint,T assay data to derive 
the Vmax (µmole/10
6cells/minute) and Km (µM). CLint,T (µl/10
6cells/minute) of PIT was 
then calculated as shown in equation 2 (135). The percent inhibition of PIT (0.1 µM) 
by RIF (0.1 – 300 µM) was calculated as shown in equation 3 (168), were 
Uptakesubstrate,inhibitor and Uptakesubstrate are the total PIT (0.1 µM) uptake concentrations 
in the presence and absence of RIF (0.1 – 300 µM), respectively. A log(inhibitor 
concentration) vs. response equation and a least-squares fitting method was applied to 
the percent inhibition data to derive IC50 of RIF required to inhibit PIT (0.1 µM).  
 
CLint,T = Vmax / Km (2) 
% Inhibition = 100 – (Uptakesubstrate,inhibitor / Uptakesubstrate × 100) (3) 
 
 
Results from both assays were expressed as the mean ± SD of two individual 
experimental replicates, each containing three or four technical replicates for each 
condition as described in method section 5.2.4.1. Statistical analysis of the CLint,T and 
DDI in vitro assay were also carried out using Prism v8 software (GraphPad Software 
Inc., La Jolla, CA, USA). Normality was tested using a D'Agostino & Pearson test and 
the statistical significance between the non-elderly and individual elderly SPHH 




5.3.1 OATP1B1 Quantification by Sandwich ELISA 
OATP1B1 expression in the non-elderly (30 – 62 years), mixed-age (18 – 74 
years) and elderly (70 – 80 years) SPHHs were successfully quantified using a 
SLCO1B1 sandwich ELISA kit. Cell lysis was confirmed via visual inspection with a 
trypan blue stain. The Pierce BCA protein assay kit determined a mean ± SD total 
membrane protein yield of 3.57 ± 0.55 mg/100mg liver tissue across all samples. For 
both the SLCO1B1 sandwich ELISA kit and Pierce BCA protein assay kit the average 
of each standard was calculated from one independent experiment that contained two 
technical replicates for each condition, as described in method section 5.2.3. 
Furthermore, the average absorbance reading for the blank samples was deducted from 
each calibration and unknown sample prior to analysis, as per convention. The 
standard curve obtained from the SCLO1B1 sandwich ELISA kit and Pierce BCA 
protein assay kit can be found in Figure 5.1 and Figure 5.2, respectively.  The mean ± 
SD of the non-elderly, mixed-age and elderly SPHHs were calculated from one 
independent experiment that contained three technical replicates for each condition, as 
described in method section 5.2.3. 
Using the yield of total membrane protein, OATP1B1 expression was 
normalised to fmol/µg total protein. OATP1B1 expression in the 70 year old female, 
74 year old female, 77 year old female, 78 year old female and 80 year old male SPHHs 
were 0.811 ± 0.042 fmol/µg total protein, 0.333 ± 0.039 fmol/µg total protein, 0.458 
± 0.036 fmol/µg total protein, 0.438 ± 0.069 fmol/µg total protein and 0.277 ± 0.023 
fmol/µg total protein, respectively (Figure 5.3). OATP1B1 expression in the non-
elderly, mixed-age and mean of the individual elderly SPHHs were 0.845 ± 0.102 
fmol/µg total protein, 0.619 ± 0.062 fmol/µg total protein and 0.463 ± 0.191 fmol/µg 
total protein, respectively (Figure 5.4). When compared to the non-elderly, OATP1B1 
expression in the mixed-age and elderly SPHHs were 27% (p=0.2) and 45% 
(p=0.0172) lower, respectively. Additionally, when compared to the mixed-age 




Figure 5.1 Standard curve produced by the OATP1B1 ELISA kit. Data presented as 
the average OATP1B1 concentration from two technical replicates (ng/ml). 
 
 
Figure 5.2 Standard curve produced by the Pierce BCA Protein Assay kit. Data 





Figure 5.3 OATP1B1 expression determined by sandwich ELISA in elderly PHH. The 
red, blue, green, yellow, purple and grey bars and error bars represent the mean 
OATP1B1 expression (fmol/µg protein) ± SD of three technical replicates from the 
mean elderly, 70-year old female, 74-year old female, 77-year old female, 78-year old 
female and 80-year old male PHH, respectively. 
 
Figure 5.4 OATP1B1 expression determined by sandwich ELISA in non-elderly (30 – 
62 years), mixed-aged (18 – 74 years) and elderly (70 – 80 years) SPHHs. The yellow, 
blue and red bars and error bars represent the mean OATP1B1 expression (fmol/µg 
protein) ± SD of three technical replicates from the non-elderly, mixed-age and elderly 
SPHHs, respectively. Statistical significance between non-elderly, mixed-age and 




5.3.2 In Vitro Assessment of CLint,T and DDI 
A summary of the in vitro CLint,T and DDI assay with PIT and RIF can be found 
in Table 5.2. The mean ± SD of each PIT parameter was calculated from two 
independent experiments that contained three or four technical replicates for each 
condition, as described in method section 5.2.4. Samples were successfully quantified 
using the previously verified LC-MS/MS method for PIT described in Chapter 2. Vmax, 
Km and IC50 were calculated using Prism v8 software (GraphPad Software Inc., La 
Jolla, CA, USA) and CLint,T were calculated as described in method section 5.2.4. 
CLint,T of PIT in the non-elderly and individual 80 year old SPHHs were 108.1 ± 34.38 
µl/min/106 cells and 53.57 ± 20.67 µl/min/106 cells, respectively (Figure 5.5). 
Coincubation of RIF with PIT reduced PIT uptake by 74% (maximal inhibition at 300 
µM; IC50 0.021 µM) and 85% (maximal inhibition at 10 µM; IC50 0.29 µM) in the non-
elderly and individual 80 year old SPHHs, respectively (Figure 5.6). A D'Agostino & 
Pearson test for normality was conducted using Prism v8 software (GraphPad Software 
Inc., La Jolla, CA, USA) for both the CLint,T and DDI assay data. All data sets passed 
the normality test with p-values in the range of 0.0732 – 0.6917. Unpaired t-tests were 
carried out to assess if there were statistical significance between the non-elderly and 
individual 80 year old SPHHs in both the CLint,T and DDI assays. The unpaired t-tests 
determined that, although the CLint,T was 50.44% lower in the individual 80 year old 
SPHHs compared to the non-elderly SPHHs, by convention this difference was not 
statistically significant with a p-value of 0.1945. Conversely, it was found that the 
difference in IC50 between the non-elderly SPHHs and individual 80 year old SPHHs 




Table 5.2 Summary of the in vitro CLint,T and DDI assay with PIT and RIF. 
PIT Parameter Non-Elderly* Male 80 Years 
Vmax (µmole/minute/10
6 cells) 5490 ± 259 4826 ± 348.9 
Km (µM) 50.81 ± 7.533 90.08 ± 16.88 
CLint,T (µl/minute/10
6 cells) 108.1 ± 34.38 53.57 ± 20.67 
RIF IC50 (µM) 0.021 0.29 
RIF Maximum Inhibition (%) 74 85 
Vmax, Km and CLint,T presented as mean ± SD and RIF IC50 and RIF maximum inhibition presented 
as mean of two experimental replicates with four technical replicates. Non-elderly – lot no. HUE120, 
Male 80 Years – lot no. MNO, RIF – rifampicin, Vmax – maximum uptake velocity, Km – half 
maximum velocity concentration, CLint,T – hepatic transporter intrinsic clearance, IC50 – half maximal 
inhibitory concentration, SD – standard deviation. * - Data produced in Chapter 2. 
 
 
Figure 5.5 Total uptake kinetic profile of PIT (0.1 µM) measured in the individual 80 
year old and non-elderly SPHHs. The blue and red lines and error bars represent the 
mean total PIT uptake ± SD (pmole/minute/106 cells) of two experimental replicates 






Figure 5.6 Concentration-dependent inhibition of total PIT (0.1 µM) uptake by RIF 
(0.1 – 300 µM) measured in the individual 80 year old and non-elderly SPHHs. The 
blue and red lines and error bars represent the mean inhibited total PIT uptake ± SD 
(% of control) of two experimental replicates with four technical replicates in the 






The demographic of PLWH is changing (6, 105, 249), introducing new clinical 
scenarios in an ageing population that is underrepresented in clinical trials, practice 
guidelines and research (102). Moreover, a higher burden of DDIs is hypothesised in 
OALWH due to the manifestation of comorbidities, geriatric syndromes and 
polypharmacy found in this population (105). When clinical data is scarce, in vitro 
techniques can be utilised to elucidate the mechanisms and magnitudes that govern 
DDIs. Transporters play a vital role in the ADME of several drugs and as a result are 
involved in numerous DDIs (70). However, to our knowledge there are no in vitro 
studies investigating the effect of age on transporter-related DDIs. In this study, the 
impact of age on the hepatic uptake transporter OATP1B1 was determined through the 
quantification of OATP1B1 expression and activity in non-elderly, mixed-age and 
elderly cryopreserved SPHHs.  
5.4.1 OATP1B1 Expression 
Using the SLCO1B1 ELISA kit, a decrease in the expression of OATP1B1 was 
found with increased age. The non-elderly SPHHs presented the highest OATP1B1 
expression with the expression in the mixed-age SPHHs and elderly SPHHs being 27% 
and 45% lower, respectively. There was a statistically significant difference in 
OATP1B1 expression between the non-elderly and elderly SPHHs whereas the mixed-
age SPHHs did not show a statistically significant difference when compared to either 
of the other age groups. Interestingly, within the elderly SPHH group, the youngest 
SPHH donor aged 70 years had the highest OATP1B1 expression whilst the eldest 
SPHH donor aged 80 years had the lowest. Moreover, the 70-year-old SPHH donor 
had an OATP1B1 expression similar to that of the non-elderly SPHHs. When 
compared to the mean of the four other elderly SPHHs, the OATP1B1 expression in 
the 70 year old SPHH donor was 54% higher. Post-transcriptional and post-
translational mechanisms have been suggested to control the expression of OATP1B1 
with a study demonstrating no significant correlation between the mRNA and protein 
expression level of OATP1B1 from human liver bank and SPHH samples (257). These 
mechanisms have previously been reported to be disrupted with age and could provide 
an explanation for the decrease in OATP1B1 expression found herein. However, post-
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transcriptional and post-translational mechanisms are currently poorly understood and 
further studies are required to improve our knowledge on the genetic and molecular 
basis of ageing (82, 258).  
Existing literature on the expression of OATP1B1 is contradictory with two 
individual meta-analysis studies stating both a significant but weak positive correlation 
(77) and no correlation between age and OATP1B1 expression (252). However, when 
exclusion criteria were not applied to the study where no correlation was found, a 
significant positive correlation was observed between age and OATP1B1 expression. 
Interestingly, in this meta-analysis a significant but weak positive correlation was 
found between age and OATP2B1 (252). Investigating the relationship between age 
and transporter expression data is challenging, and several factors must be considered 
when analysing the existing literature as well as the current study. Firstly, the 
availability of high-quality PHH samples for the elderly is low and only a limited 
number of elderly patients have been included in these studies. For example, from the 
two above-mentioned meta-analysis studies only one provided individual donor 
information and it was found that just 3.75% (n=3) were ≥70 years old (77). 
Furthermore, during the current study it was found that there were no pooled donor 
SPHHs available exclusively from donors ≥70 years old. Moreover, there were few 
individual SPHHs from donors ≥70 years old, limiting the amount of elderly SPHH 
donors utilised in this study to five. Larger sample sizes of donors ≥70 years old are 
required to make definitive conclusions on the correlation between OATP1B1 
expression and age.  
Secondly, the inclusion of non-Caucasian donors must be taken into 
consideration as an increased expression of OATP1B1 has previously been reported 
in Asian and African American donors (225). The mixed-age SPHHs used in this study 
included non-Caucasian donors as a pooled SPHH lot consisting solely of Caucasian 
donors in the required age range was unobtainable. Additionally, the meta-analysis 
study that found a significant but weak positive correlation between OATP1B1 and 
age did not state the exclusion of non-Caucasian hepatocyte donors in their selection 
criteria and no data on the demographics of the samples included in their study were 
provided. In contrast, the meta-analysis study that found no correlation applied 
exclusion criteria omitting non-Caucasian donors. Thirdly, a large variation in 
OATP1B1 expression has been described throughout the literature (77, 135, 252). In 
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comparison to the previously published meta-analysis studies, the mean OATP1B1 
expression level in this study was 86% and 96% lower (77, 252). Yet, the value 
determined herein was within the range of values previously reported for SPHHs (77). 
In contrast, a further study quantifying OATP1B1 expression in PHHs and liver tissue 
reported values 82% and 84% lower than that found in this study, respectively (135). 
To note, the yield of total membrane protein determined in this study (3.57 mg/100mg 
liver tissue) was comparable to that reported in the literature (3.7 mg/100mg liver 
tissue), providing reassurance in the accuracy of unit normalisation considering protein 
levels (259). 
Fourthly, the quantification technique used in this study differed from those in 
the meta-analysis studies, with these studies predominantly consisting of data 
produced via proteomic LC-MS/MS quantification. Historically, western blotting was 
used to determine semiquantitative transporter expression data but they were limited 
by the lack of recombinant standards of membrane proteins and transporter specific 
antibodies available (252). Proteomics techniques utilising LC-MS/MS were therefore 
developed providing robust and quantitative transporter expression data however these 
techniques require expensive specialist equipment and skilled personnel, restricting 
accessibility (253). Recently, ELISA kits for the quantification of transporters have 
been developed as a more accessible alternative to proteomic LC-MS/MS techniques. 
These kits produce accurate and reliable results as demonstrated by the manufacturer 
although, to our knowledge, are yet to be described in practice in the literature (254). 
In addition, the sample preparation techniques varied between this study and the meta-
analysis studies, with this study being limited to mechanical cell lysis techniques due 
to the compatibility of the SLCO1B1 ELISA kit. The above described differences in 
quantification and sample preparation techniques could explain the large variation in 
OATP1B1 expression levels. Contrariwise, the smaller study that reported an 82% and 
84% lower OATP1B1 level in comparison to this study also used proteomic LC-
MS/MS quantification, suggesting that the large variation may not be caused by the 
quantification or sample preparation technique used (135). Further studies are 
warranted to compare the quantification of OATP1B1 expression by ELISA vs. 
proteomic based LC-MS/MS methodologies in order to confirm the suitability of the 
simpler and more accessible ELISA technique.  
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Lastly, all donors in this study had reported alcohol, tobacco, recreational drug 
and medication history although no information on underlying disease were provided. 
Of the two previously published meta-analysis studies, that which found no correlation 
between age and OATP1B1 expression applied exclusion criteria to form a healthy 
Caucasian sub database by removing non-Caucasian donors and those with underlying 
disease from their initial database (252). Whereas the other meta-analysis study did 
not (77). Previous reports have suggested a link between disease state and transporter 
expression with a previous study describing a reduction in OATP1B1 expression in 
donors with fatty liver disease compared to donors with a normal liver appearance 
(252). Furthermore, neither meta-analysis studies provided information on reported 
alcohol, tobacco, recreational drug or medication history of the included donors (77, 
252). Lifestyle factors such as these are associated with increased biological age in 
comparison to chronological age and their contribution towards OATP1B1 expression 
is currently unknown. Future studies analysing the relationship between biological age 
and OATP1B1 expression would be of great interest as they would allow for the 
consideration of the effect of health and lifestyle factors on transporter expression. 
Previous studies have demonstrated that telomere length decreases with age and could 
therefore be used as a biomarker of biological ageing in such future studies (260, 261).  
5.4.2 OATP1B1 Activity 
Utilising the CLint,T and DDI in vitro assay developed in Chapter 2, a marked 
reduction in PIT CLint,T was found in the individual 80 year old SPHH donor in 
comparison to the non-elderly SPHHs. However, this decrease was found not to be 
statistically significant. This suggests that, although OATP1B1 expression in the 80 
year old SPHH donor was 68% lower than that of the non-elderly SPHHs, there was 
no significant alteration in transporter function with increased age. However, a 
statistically significant 93% decrease in IC50 value was found in the non-elderly 
SPHHs when compared to the 80 year old SPHH donor. Though, the maximal percent 
inhibition of PIT by RIF was 11% greater in the 80 year old SPHH donor compared to 
the non-elderly SPHHs. The IC50 values indicate that the magnitude of transporter-
mediated DDIs in elderly adults may be less pronounced in comparison to non-elderly 
adults. This potentially less pronounced DDI in the elderly implies that although the 
function of hepatic uptake was not altered with age, the mechanisms that govern 
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transporter-mediated DDIs may be. Several factors must be taken into consideration 
when analysing this data and due to these limitations, further studies are required 
before we are able to draw definitive conclusions on the impact of age on OATP1B1 
activity.  
Firstly, as described for the OATP1B1 expression study, the biggest limitation 
of the CLint,T and DDI in vitro study was the small number of available elderly SPHH 
donors. Only one of the five elderly SPHH donors sourced for this analysis had 
previously been qualified for transporter uptake studies and although this donor was 
the eldest, it is unclear whether other elderly donors would produce similar results. 
Secondly, a large variation was found for the IC50 value of the non-elderly SPHHs in 
comparison to a previous study which reported an IC50 value for the inhibition of PIT 
by RIF of 2.2 ± 0.3 µM (166). The main differences between these studies were the 
period of time the assay was carried out for and the quantification technique used. 
Incubation times utilised for the in vitro assessment of transporter-mediated DDIs have 
been identified as significant contributing factors towards inter-study variation (182). 
Additionally, it must be noted that the previously published study did not provide 
demographic data for the PHH donors used (166). It is therefore unclear whether the 
difference in IC50 between the non-elderly SPHHs and the 80 year old SPHH donor is 
caused by age or from experimental variation. However, as discussed in Chapter 3 the 
IC50 produced in non-elderly SPHHs in this study proved accurate in simulating the 
DDI between PIT and RIF using PBPK modelling. Furthermore, a previously 
published PBPK model described an underprediction in the DDI between RIF and PIT 
unless a 10-fold decrease in the Ki value was applied (191). The resulting Ki value was 
similar to that produced in this study suggesting that the in vitro assay system used 
herein produces accurate IC50 values. Thirdly, the 80 year old SPHH donor had no 
report of alcohol, tobacco or recreational drug history and one reported medication 
history whilst the non-elderly SPHHs had between 40 – 80% of donors with reported 
alcohol, tobacco, recreational drug and medication history. As described in section 
5.4.1, the contribution of these factors towards OATP1B1 activity is unclear. Lastly, 
the CLint,T and DDI in vitro study was limited by the use of one OATP1B1 probe 
substrate and inhibitor. Although both PIT and RIF are recommended by current FDA 
guidelines, a comparison between multiple probe substrate and inhibitors with varying 
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OATP1B1 sensitives would provide valuable information for the determination of the 
relationship between age and OATP1B1 activity (75). 
Literature comparing non-elderly vs. elderly CLint,T and DDI are scarce and to 
our knowledge there is only one study comparing the clinical DDI between an 
OATP1B1 substrate and an ARV OATP1B1 inhibitor among different age groups 
(123). This study found no difference in the magnitude of DDI between rosuvastatin 
(ROS) and DRV/r in non-elderly adults ≤60 years old compared to OALWH with a 
mean age and SD of 67.7 ± 5.3 years. However, there are two limitations of the study 
that must be considered. Firstly, the data for the two age groups were obtained from 
separate studies. Secondly, in contrast to the study containing OALWH, the non-
elderly data were obtained from HIV-negative patients who were on a different ROS 
and DRV/r dosing regimen. Larger clinical studies are required to comprehensively 
assess the impact of age on OATP1B1 activity.  
5.4.3 Conclusion 
This study determined a statistically significant decrease in OATP1B1 
expression with increased age however, there was no statistically-significant decrease 
in the CLint,T of PIT suggesting no significant alteration of the transporter function with 
aging. Furthermore, a statistically significant decrease in the RIF IC50 value was found 
in non-elderly SPHHs when compared to the individual 80 year old SPHH donor 
which implies that transporter-mediated DDIs in elderly adults could potentially be 
less pronounced in comparison to non-elderly adults. However, due to the limitations 
of this study further in vitro investigations with larger PHH sample sizes including a 
wider range of substrates and inhibitors are warranted to verify these observations. 
This data could generate improved PBPK modelling verification strategies allowing 
for greater confidence in transporter-mediated DDI predictions in the elderly. Overall, 
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RIF represents a pivotal component of several anti-infective therapies however 
there have been no advances in the application of RIF for the treatment of TB as well 
as in other indications such as leprosy over the past 40 years. Of late, there has been a 
growing interest in the use of higher doses of RIF, particularly for shortening TB 
therapy and to overcome resistance (262). Recent studies focusing on the safety and 
efficacy of high dose RIF demonstrated that doses of up to 35 mg/kg were safe and 
well tolerated (59-61). In the case of leprosy, a previous study demonstrated that single 
RIF doses of 1200 mg and 1500 mg were more efficient at reducing the rate at which 
M. leprae were rendered non-infective than 600 mg and 900 mg (60). However, due 
to cost associations and toxicity studies at the time, a lower dose of 600 mg RIF QMT 
was prioritised in the MDT regimen which consists of 100 mg dapsone QD and 300 
mg QMT and 50 mg QD clofazimine (52, 60, 61).  
At the end of 2018 the WHO reported 184,212 registered cases and 208,619 new 
cases of leprosy worldwide, with approximately 75% of these cases being reported in 
India (50%), Brazil (15%) and Indonesia (10%) (43). Previously published studies 
have indicated a higher prevalence of leprosy in PLWH (47), however large cohort 
studies encompassing HIV and leprosy are lacking (48). It is clear that there is a 
geographical overlap of PLWH and people infected with leprosy. Despite the limited 
epidemiological data, it is fair to postulate that DDIs between ART and the MDT 
regimen used for the treatment of leprosy could occur in a clinical setting. Both 
dapsone and clofazimine have the potential to produce weak and clinically significant 
interactions with ARVs. Dapsone is unlikely to cause pharmacokinetic interactions 
with ARVs however it may increase the risk of adverse effects such as peripheral 
neuropathy. Clofazimine could increase the risk of QT prolongation when 
coadministered with ARVs such as ATV however as clofazimine is a moderate 
CYP3A4 inhibitor it could also cause potentially weak and significant interactions 
with CYP3A4 substrates such as maraviroc (54, 55). In comparison, RIF produces 
several clinically significant DDIs due to its potent induction of CYP3A4, UGT1A1 
and P-gp which are involved in the metabolism and transport of several ARV drugs 
(54, 98, 99, 156). RIF also shares overlapping hepatotoxicity profiles with ARVs, 
increasing the risk of adverse effects during coadministration (55). Specifically, the 
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ARV drug DTG which is used in the first-line treatment of HIV is metabolised largely 
by UGT1A1 and CYP3A4 with minor metabolism by UGT1A3 and UGT1A9 (263). 
There are currently no data on how to manage the potential DDI between DTG and 
high dose RIF QMT for the treatment of PLWH coinfected with leprosy.  
In the absence of such data, PBPK modelling can be applied to predict the 
magnitude of DDIs, providing evidence-based guidance for their clinical management. 
PBPK models predict drug pharmacokinetics through the mathematical description of 
ADME processes. Moreover, mechanisms of DDIs can be simulated by applying our 
knowledge of their functionality alongside in vitro and clinical data. In the example of 
enzyme induction, previously published equations have described the change in 
enzyme abundance by considering the basal enzyme abundance level, the maximum 
fold increase by the inducer, the concentration of inducer that achieves half maximal 
induction as well as the concentration of the inducer at the site of DDI. These equations 
however are only applicable for steady state induction interactions (63). Further 
equations have been developed to incorporate the relationship between enzyme 
transcription and translation, considering the activation of nuclear receptors by the 
inducer as well as the synthesis and degradation of mRNA and enzyme. Such equations 
allow for the simulation of induction over time, rather than at steady state alone (264). 
The aim of this chapter was to develop and verify a whole-body PBPK model 
capable of simulating the induction effect of single dose RIF on CYP3A4 and 
UGT1A1. The verified PBPK model aimed to predict the magnitude of DDI between 
RIF 1200mg QMT and DTG 50mg BID and determine if DTG dose adjustments would 
be necessary. These findings may provide support for the clinical management of 
PLWH coinfected with leprosy as well as in other DDI scenarios involving the 
administration of high dose RIF on a non-daily basis. Additionally, these findings 
could aid in the design of DDI clinical studies investigating high dose RIF for the 




All PBPK models described herein were designed in Simbiology v5.8, a product 
of Matlab 2018a (MathWorks, Natick, MA, USA; 2018). Virtual cohorts consisting of 
100 male and female patients aged 18 – 60 years were simulated. The PBPK models 
were developed for DTG, midazolam (MDZ), nifedipine (NIF), raltegravir (RAL) and 
RIF, and verified against observed clinical data, respectively. Physicochemical, 
pharmacokinetic, in vitro and in vivo data were sourced from literature or if unavailable 
were estimated via curve fitting. Where applicable, pharmacokinetic parameters and 
concentration time profile data were extracted from charts and graphs using the Plot 
Digitizer Tool (plotdigitizer.sourceforge.net).   
6.2.1 Rifampicin PBPK Model 
A minimal PBPK model was developed to predict the pharmacokinetic 
parameters and concentration time profile of RIF, as previously described in Chapter 
3 (214). In addition to the prediction of RIF 600mg QD, the model was expanded to 
predict single dose RIF 1200mg. The physicochemical and in vitro data for both doses 
of RIF can be found in Table 6.1. Due to the lack of observed clinical data surrounding 
the Vss and CL/F of higher doses of RIF, these parameters were estimated by curve 
fitting with the observed data (265). As literature suggests a non-linear decrease in 




Table 6.1 Physicochemical and in vitro data for 600mg and 1200mg RIF. 
Parameters RIF 600mg RIF 1200mg 
Molecular Weight 822.9 (217) 822.9 (217) 
Protein Binding (%) 80 (218) 80 (218) 
Vss (L/kg) 23.3 (219) E
 
CL/F (L/h) 7.5 (219) E 
CYP3A4 EC50 (µM) 1.18 (264) 1.18 (264) 
UGT1A1 EC50 (µM) 0.321 (266) 0.321 (266) 
Reference for literature values presented in brackets. Vss – volume of distribution, CL/F – apparent 
oral clearance, CYP3A4 – cytochrome P450 3A4, UGT1A1 - uridine diphosphate 
glucuronosyltransferase 1A1, EC50 – concentration at half maximum induction, E - the value was 
estimated.  
 
6.2.2 Whole-Body PBPK Model 
A whole-body PBPK model was developed to predict the pharmacokinetic 
parameters and concentration time profiles of DTG, MDZ, NIF and RAL. The 
anatomy, intestinal absorption, intestinal metabolism and systemic distribution was 
previously described in Chapter 3. In contrast to Chapter 3 which implemented hepatic 
transporter-related clearance mechanisms using multiple blood flow limited 
compartments, hepatic clearance was estimated using equations 1 – 4 in a single well-
stirred compartment (207-209): 
 
CLint,liverE = (CLint,E × AbundanceE × MPPGL × WLiver) (1) 
MPPGL = 101.407 + 0.0158 × Age - 0.00038 × Age^2 + Age^3 (2) 
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CLint,liver = Σ CLint,liverE (3) 
Total Hepatic Clearance = 
(Qhv × fu/R × CLint,liver)




Where CLint,liverE, CLint,E, AbundanceE, MPPGL and WLiver are the intrinsic 
clearance of the enzyme scaled to the whole liver, the intrinsic clearance of the 
enzyme, enzyme abundance, microsomal protein content per gram of liver and weight 
of the liver in kg. CLint,liver represents the sum of all CLint,liverE values for each enzyme 
involved in the drug’s metabolism. Qhv, fu and R are the hepatic blood flow, the 
unbound fraction of drug and the blood-to-plasma ratio. Due to the complexity of 
DTG’s metabolic pathway, the CLint,liverE of CYP3A4, UGT1A1, UGT1A3 and 
UGT1A9 were determined using reported CL/F fractions, as previously described 
(267, 268). The CLint,E values for DTG were then estimated via retrograde modelling 
as previously described (269). For MDZ, NIF and RAL CLint,E values for CYP3A4 
and UGT1A1 were sourced from the literature. Additionally, for MDZ and NIF the 
monoprotic equation described in Chapter 3 was utilised for the calculation of the olive 
oil:buffer partition coefficient of nonionised and ionised species at pH 7.4 (D*vo:w). In 
contrast, the zwitterionic D*vo:w equation was applied for DTG and RAL, as described 
in Chapter 4. These equations were applied accordingly towards the calculation of the 
Vss. 
6.2.3 CYP3A4 and UGT1A1 Induction Model 
A dynamic PBPK model for the RIF based induction of CYP3A4 and UGT1A1 
via the PXR nuclear receptor was defined using previously described equations (264). 
The equations assume negligible intestinal induction and are therefore only applied in 
the liver. As per convention, induction of mRNA and enzyme was evaluated as the 
fold increase over the observed value on day 0.  
 
RNAI = RNA / RNA0 (5) 
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ENZYMEI = ENZYME / ENZYME0 (6) 
p = ENZYME0 / Ki,NF (7) 
q = 
(krna,pxr × kenzyme,syn)





1 + p 




- kinact,pxr ×PXRact (9) 
dRNAI 
dt
 = krna,deg × (1 + q × PXRact – RNAI) (10) 
dENZYMEI 
dt
 = kenzyme,deg × (RNAI – ENZYMEI) (11) 
 
Where RNAI, RNA, RNA0, ENZYME
I, ENZYME and ENZYME0 are the fold 
change value, induction value and baseline value of mRNA and enzyme, respectively. 
Ki,NF, PXRact, kinact,pxr, RIF and EC50 are the constant for negative feedback inhibition, 
normalised amount of activated PXR, inactivation rate constant for activated PXR, 
RIF plasma concentration and RIF concentration at half maximum induction, 
respectively. krna,pxr, kenzyme,syn, krna,deg and kenzyme,deg are the rate constants for PXR-
mediated mRNA synthesis, enzyme synthesis, mRNA degradation and enzyme 
degradation, respectively. When simulating RIF DDIs, AbundanceE in equation 1 was 
multiplied by the ENZYMEI value to account for the RIF induced fold change in 
enzyme level over time. 
6.2.4 PBPK Model Verification 
The PBPK model was considered successfully verified if the ratio of predicted 
vs. observed values for each drug and DDI pharmacokinetic parameter were between 
0.5 – 2 (150). However, where possible we strived for the ratio of predicted vs. 
observed values to be within 0.75 – 1.25 or 0.5 – 1.5 to allow for more accurate results 
(220). The AAFEs for the predicted vs. observed pharmacokinetic parameters and the 
concentration time profiles were also calculated, as defined in equation 12 (209), and 
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were considered successfully verified if the value was within 1 – 2. Similarly to the 
ratio of predicted vs. observed, we strived for the AAFE value to be within 1 – 1.25 or 
1 – 1.5 to produce greater accuracy. The more stringent evaluation of the concentration 
time profiles using AAFE evaluation compared to the commonly accepted visual 
inspection reinforces more accurate results (150, 270). For the DDIs, the percentage 
of DDI vs. drug alone (DDI%) were also calculated for both the predicted and observed 
values, as defined in equation 13. The DDI% was verified as outlined above.  
 







DDI% = (drugDDI / drugsub) × 100 (13) 
 
Where AAFE, drugDDI and drugsub are the absolute average-fold error, substrate 
drug parameter value in the presence of the perpetrator drug and substrate drug 
parameter value, respectively. 
6.2.5 PBPK Model Development 
 Whole-Body PBPK Model 
Physicochemical and in vitro data for DTG, MDZ, NIF and RAL were sourced 
as previously described and a summary can be found in Table 6.4. These were applied 
in the whole-body PBPK model with hepatic clearance equations constructed 
according to the metabolic pathway of each drug. To obtain the most accurate 
predictions, a correction factor was estimated and applied to the predicted Vss of each 
drug via curve fitting and considering their respective literature Vss values. This 
process was carried out in a stepwise manner. Initially, simulations for each drug were 
carried out with no correction factor applied to the Vss. As described in method section 
6.2.4, AAFE and ratio values were calculated for predicted vs. observed and based 
upon these results a range of Vss correction factor values to obtain the most accurate 
predictions were estimated. Three Vss correction factor values within the estimated 
range were applied and simulations for each drug were performed. Again, AAFE and 
ratio values were calculated for predicted vs. observed data and the Vss correction 
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factor with the most accurate predictions was selected. Furthermore, fed and fasted 
intestinal transit rates were applied according to the clinical data, unless stated 
otherwise. 
 CYP3A4 Induction PBPK Model 
The RIF PBPK model together with the induction model described in method 
sections 6.2.1 and 6.2.3 were firstly simulated with the previously published induction 
parameters to predict the CYP3A4 fold change induction profile following repeated 
oral administration of RIF 600mg QD (264). These models in conjunction with the 
whole-body PBPK model described in method section 6.2.2 were used to predict the 
DDI dosing regimens of MDZ and NIF as well as the extended CYP3A4 fold change 
induction profile following 28 days repeated oral dosing of RIF 600mg QD and 28 
days after the last dose of RIF. The predicted vs. observed DDI% values were 
calculated as described in method section 6.2.4 and the ratio and AAFE values were 
used to analyse whether the previously published induction parameters required further 
optimisation to accurately simulate the extended CYP3A4 fold change induction 
profile. Specifically, timepoints were assigned to each of the observed clinical datasets 
for NIF and MDZ and the CYP3A4 fold change at each timepoint were calculated. 
Timepoints 1 – 5 correspond to hours 8 – 32, 648 – 672, 816 – 840, 984 – 1008 and 
1320 – 1344, respectively. The ratio and AAFE results were used to assess whether no 
change, an increase or a decrease in the CYP3A4 fold change induction profile was 
required at each of the corresponding timepoints. 
To optimise the CYP3A4 fold change induction profile, alternative values for 
each of the induction parameters were sourced from the available literature, as shown 
in Table 6.2. Where data was not available, induction parameters were estimated via 
curve fitting to observed MDZ and NIF data. Firstly, the effect of each of the induction 
parameters, Kinact,pxr, Kenzyme,deg, Krna,deg, q and p, on the CYP3A4 fold change induction 
profile were determined by simulating a range of values. Secondly, utilising the above 
information the CYP3A4 fold change induction profile was optimised in a stepwise 
manner by either estimating induction parameter values or, when available, applying 
alternative values from the literature. Induction parameter values were estimated 
similarly to that described for Vss optimisation in method section 6.2.5.1. Briefly, a 
range of values were initially estimated through test simulations and three values 
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selected based upon visual inspection. Simulations for each value were conducted and 
AAFE and ratio values of the DDI% were calculated for predicted vs. observed data. 
The parameter value with the most accurate predictions was selected. Again, for the 
available literature values the ratio and AAFEs of the DDI% were calculated and the 
values providing the most accurate predictions were selected. Lastly, the MDZ and 
NIF optimised induction parameter values were further verified using the observed 
DTG clinical data. 
Table 6.2 CYP3A4 induction parameter values. 
Parameter Original Values (264) Alternative Values 
kinact,pxr (h
-1) 0.0527 E 
krna,deg (h
-1) 0.0530 0.0756 (271) 
Kenzyme,deg (h
-1) 0.0282 0.0096 (272), 0.005 - 0.07 
(273) 
q 4.34 E 
p 0.313 E 
Reference for literature values presented in brackets.  kinact,pxr - inactivation rate constant for activated 
PXR, krna,deg – rate constant for mRNA degradation, Kenzyme,deg – rate constant for enzyme degradation, 
p – equation 9, q – equation 10, E – estimated value. 
 
 UGT1A1 Induction PBPK Model 
Unlike CYP3A4, there are no previously published induction PBPK models or 
UGT1A1 fold change induction profiles available. Therefore, the UGT1A1 induction 
PBPK model could not be developed or verified in the same manner as the CYP3A4 
induction PBPK model. However, as UGT1A1 has been reported to be induced via the 
same PXR mechanism as CYP3A4 (274), induction equations 5-11 described in 
method section 6.2.3 were utilised. The UGT1A1 fold change induction profile was 
optimised as described for CYP3A4, with two exceptions. Firstly, the value estimated 
for kinact,pxr via the CYP3A4 optimisation process was applied in the UGT1A1 
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induction equations. Secondly, the UGT1A1 p value was calculated by determining 
Ki,NE from the estimated CYP3A4 p value and applying it to the p equation for 
UGT1A1.  
Alternative induction parameter values sourced from the literature are shown 
in Table 6.3. A reported UGT1A1 fold change in vitro value of 2.8 ± 0.81 was targeted 
during induction parameter optimisation (274). Observed RAL clinical data was used 
to verify the predicted UGT1A1 fold change induction profile, as described in method 
section 6.2.4. In addition, the AAFE and ratio value for the predicted vs. observed 
UGT1A1 fold change value was calculated and verified using the previously described 
criteria.  
Table 6.3 UGT1A1 induction parameter values. 
Parameter Original Values (264) UGT1A1 Values 
kinact,pxr (h
-1) 0.0527 ECYP3A4 
krna,deg (h
-1) 0.0530 0.0385 (275), 0.0756 
(271) 
Kenzyme,deg (h
-1) 0.0282 0.0144 (271), 0.0243 
(275), 0.0729 (276) 
q 4.34 E 
p 0.313 C 
Reference for literature values presented in brackets. kinact,pxr - inactivation rate constant for activated 
PXR, krna,deg – rate constant for mRNA degradation, Kenzyme,deg – rate constant for enzyme degradation, 
p – equation 9, q – equation 10, ECYP3A4 – CYP3A4 estimated value, E – estimated value, C – 
calculated value. 
 
6.2.6 Prediction of Once Monthly Rifampicin with Dolutegravir 
Once optimised and verified, the RIF and whole-body induction PBPK models 
were applied to predict the currently approved DTG dosing strategy during the 
coadministration of RIF 600mg QD. The current dosing strategy simulations consisted 
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of 35 days of repeated oral administration of DTG 50mg BID with a single oral 
administration of RIF 1200mg on day 7. The pharmacokinetic parameter’s Cmax, Cavg 
and Cmin mean ± SD were calculated and compared to the minimum target 
concentration of 4 x PA-IC90 of DTG (0.256 µg/ml) (277). The predicted data was 
used to determine if the current dosing guidelines for DTG coadministered with RIF 
would be suitable for RIF 1200mg QMT or if an alteration in the dose of DTG would 
be required (278).  
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Table 6.4 Physicochemical and in vitro data for DTG, MDZ, NIF and RAL. 
Parameters DTG MDZ NIF RAL 
Molecular Weight (g/mol) 419.4 (279) 325.8 (280) 346.3 (281) 444.4 (282) 
HBD 2 (279) 0 (280) 1 (281) 3 (282) 
Log Po:w 2.2 (279) 3.89 (280) 2.49 (281) -0.39 (282) 
Papp (10
-6 cm/s) 40.17 (283) 37.9 (284) 250 (285) 6.6 (286) 
pKa -0.51, 8.2 (279) 6.57 (280) 3.93 (287) -1.5 (282), 6.7 (286) 
Protein Binding (%) 98.9 (279) 97 (280) 98 (281) 83 (282) 
PSA (Å2) 99.18 (279) 30.18 (280) 110.45 (281) 150.02 (282) 
R 0.535 (220) 0.53 (288) 0.67 (289) 0.6 (286) 
Vd (L/kg) 0.25 (279) 1 – 3.1 (280) 0.71 (289) 0.4 – 2 (290) 
Water Solubility (mg/L) 95 (291) 9.87 (280) 5.9 (292) 5.39×104 (293) 
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CL/F (L/h) 0.9 (294) 103 ± 53 (295) 20.5 (289) 39.1 (296) 
CYP3A4 (ml/min/mg protein) – 0.584 ± 0.065 (297) 0.21 ± 0.01 (298) – 
UGT1A1 (ml/min/106 
hepatocytes) 
– – – 12.4 (286) 
Reference for literature values presented in brackets. DTG – dolutegravir, MDZ – midazolam, NIF – nifedipine, RAL – raltegravir, HBD – Hydrogen bond donor, Log Po:w 
– Partition coefficient between octanol and water, Papp – apparent permeability, pKa - logarithmic value of the dissociation constant, PSA – polar surface area, R – blood-to-
plasma drug ratio, Vd – volume of distribution (an average adult body weight of 70 kg was assumed), CL/F – apparent oral clearance, CYP3A4 – cytochrome P450 3A4, 




The PBPK model was successfully verified by comparing the predicted AUC, 
Cmax and Cmin pharmacokinetic parameters and concentration time profiles with the 
observed clinical data for the oral administration of each of the validation drugs and 
DDIs outlined in the method section. A summary of the AAFE and ratio verification 
results can be found in Tables 6.11 and 6.12. 
6.3.1 Rifampicin Verification 
Verification of the RIF PBPK model was carried out using available AUC0-24 
and Cmax observed clinical data for the oral administration of RIF 600mg QD (219) as 
well as digitised Cmax and Cmin observed clinical data from the available concentration 
time profile for the oral administration of single dose RIF 1200mg (265). Due to the 
lack of observed clinical data, both the CL/F and Vss for single dose RIF 1200mg were 
estimated as described in method section 6.2.1. The estimated values for Vss and CL/F 
were 23.3 ± 6.96 L/kg and 3 ± 0.9 L/h, respectively. The predicted vs. observed 
concentration time profiles are shown in Figures 6.1 and 6.2. The predicted vs. 
observed AUC0-24 (µg×h/ml), Cmax (µg/ml) and Cmin (µg/ml) can be found in Table 6.5. 
AAFE and ratio values for the predicted vs observed pharmacokinetic parameters and 
concentration time profiles of RIF 600mg QD and single dose RIF 1200mg were 





Figure 6.1 Predicted vs. observed concentration time profiles for RIF 600mg QD. The 
blue line and blue shaded area represent the mean plasma concentration ± SD (µg/ml) 
of the predicted data. The red line represents the observed clinical data (µg/ml) (219). 
 
Figure 6.2 Predicted vs. observed concentration time profiles for single dose RIF 
1200mg. The blue line and blue shaded area represent the mean plasma concentration 





Table 6.5 Predicted vs. observed RIF pharmacokinetic parameters. 
Drug Regimen Parameter Predicted Observed 
RIF 600mg QD AUC0-24  90.73 ± 40.48 79.7 (219) 
Cmax 17.23 ± 7.67 15.6 (219) 
Single Dose RIF 1200mg Cmax 38.44 ± 11.73 32.38 (265) 
Cmin 4.15 ± 4.7 3.56 (265) 
AUC0-24 values presented as mean ± SD (µg/h/ml). Cmax and Cmin values presented as mean ± SD 
(µg/ml). RIF – rifampicin, AUC – area under the curve, Cmax – maximum plasma concentration, Cmin 
– minimum plasma concentration.  
 
6.3.2 CYP3A4 Induction Model Optimisation and Verification 
 Published CYP3A4 Induction Model 
Utilising the verified RIF PBPK model and previously published induction 
model and parameters described in method section 6.2.1 and 6.2.3 (264), the CYP3A4 
fold change induction profile following repeated oral administration of RIF 600mg QD 
was predicted, as shown in Figure 6.3. An AAFE value of 1.055 was calculated for the 
predicted vs observed CYP3A4 fold change induction profile, which was within the 




Figure 6.3 Predicted vs. observed CYP3A4 fold change following repeated oral 
administration of RIF 600mg QD. The blue line and blue shading represent the mean 
CYP3A4 fold change ± SD predicted using previously published induction parameters. 
The red line represents the published CYP3A4 fold change (264). 
 
The DDI% were calculated using available AUC0-24 and Cmax observed clinical 
data for the oral administration of NIF 10mg and NIF 10mg coadministered with RIF 
1200mg (299) as well as MDZ 2mg QD (300) and MDZ 2mg QD 0, 1, 2 and 4 weeks 
after the last dose of coadministered RIF 600mg QD (301). As described in method 
section 6.2.5.2, the RIF induction model in conjunction with the whole-body PBPK 
model were used to predict the above-mentioned dosing regimens as well as the 
extended CYP3A4 fold change induction profile. The predicted DDI% was calculated 
and the predicted vs. observed ratios and AAFEs were determined. A summary of the 
results can be found in Table 6.6. The ratio and AAFE results for timepoints 1, 3 and 
4 were generally greater than the 0.75 – 1.25 ratio and 1 – 1.25 AAFE verification 
criteria. Timepoint 2 and 5 were within the stringent criteria. From these results it was 
concluded that further optimisation of the extended CYP3A4 fold change induction 





Table 6.6 Analysis of predicted vs observed clinical data as a percentage of DDI vs drug alone using previously published induction parameters. 




AUC Cmax AUC Cmax 
NIF 10 S 1200 S 1 1.12 1.76 1.13 1.76 1.13 
MDZ Week 0 2 QD 600 QD 2 9.03 1.07 1.18 1.07 1.18 
MDZ Week 1 2 QD 600 QD 3 1.96 1.60 1.89 1.60 1.89 
MDZ Week 2 2 QD 600 QD 4 1.01 1.41 1.75 1.41 1.75 
MDZ Week 4 2 QD 600 QD 5 1.00 0.98 0.98 1.02 1.02 
RIF – rifampicin, NIF – nifedipine, MDZ – midazolam, S – single dose, QD – once daily, AAFE – absolute average fold error, AUC – area under the curve, Cmax – maximum 




 CYP3A4 Induction Model Optimisation 
Based on the results in Table 6.6, an increase in CYP3A4 fold change at 
timepoints 1, 3 and 4 and no change at timepoint 2 and 5 were required to optimise the 
CYP3A4 fold change induction profile to obtain more accurate predictions. The effect 
of each of the induction parameters, Kinact,pxr, Kenzyme,deg, Krna,deg, q and p on the 
extended CYP3A4 fold change induction profile were determined, as described in 
method section 6.2.5.2. An increase in Kinact,pxr  resulted in a decrease in CYP3A4 fold 
change across all timepoints in the CYP3A4 fold change induction profile. A decrease 
in Kenzyme,deg caused a decrease in the CYP3A4 fold change at timepoints 1 and 2 whilst 
increasing the CYP3A4 fold change at timepoints 3 and 4. Timepoint 5 remained the 
same. Increasing Krna,deg caused an increase in CYP3A4 fold change at timepoint 1 and 
a decrease at timepoints 2, 3 and 4 with timepoint 5 remaining the same. An increase 
in q resulted in an increase in CYP3A4 fold change across all timepoints in the 
CYP3A4 fold change induction profile. Finally, an increase in p had minimal effect on 
timepoint 1 and 5 and decreased CYP3A4 fold change at timepoints 2, 3 and 4. 
The CYP3A4 fold change induction profile was optimised in a stepwise 
manner utilising the above findings alongside the MDZ and NIF observed clinical data, 
as described in method section 6.2.5.2. The optimised parameter values for Kinact,pxr, 
Kenzyme,deg, Krna,deg, q and p were 0.1 h
-1, 0.0096 h-1 (272), 0.0756 h-1 (271), 14 and 3, 
respectively. The resulting CYP3A4 fold change induction profile following 28 days 
repeated oral administration of rifampicin 600mg QD and 28 days after the last RIF 
dose can be found in Figure 6.4. A comparison of the optimised vs. published CYP3A4 
fold change induction profile can be found in Figure 6.5. The CYP3A4 fold change 
values for timepoints 1 – 5 were 1.35 vs 1.12, 7.69 vs 9.03, 3.54 vs 1.96, 1.51 vs 1.01 




Figure 6.4 Predicted CYP3A4 fold change following 28 days repeated oral 
administration of RIF 600mg QD and 28 days after the last RIF dose, using the 
optimised induction parameters. Data expressed as mean fold change ± SD. 
 
 
Figure 6.5 Predicted vs. observed CYP3A4 fold change following 28 days repeated 
oral administration of RIF 600mg QD and 28 days after the last RIF dose. The blue 
line represents the mean CYP3A4 fold change predicted using induction parameters 
optimised with observed clinical MDZ data (301). The red line represents the mean 
CYP3A4 fold change predicted using previously published induction parameters 
(264). Weeks 0, 1, 2 and 4 after the last dose of RIF are highlighted by blue and red 




 Midazolam Verification 
The MDZ PBPK model was verified using available AUC0-24 and Cmax 
observed clinical data for the oral administration of MDZ 2mg QD (300) and MDZ 
2mg QD 0, 1, 2 and 4 weeks after the last dose of coadministered RIF 600mg QD. To 
note, MDZ 2mg QD values were used for MDZ 2mg QD 4 weeks after the last dose 
of RIF as described in the literature (301). An estimated correction factor of 0.125 was 
applied to the predicted Vss as described in the method section 6.2.5.1. The predicted 
vs. observed Vss was 0.42 L/kg vs. 1 L/kg (280). Additionally, the fed intestinal transit 
rate values were applied to achieve optimal simulation performance. In contrast, the 
MDZ and RIF DDI clinical study stated participants fasted prior to administration and 
the MDZ 2mg QD clinical study did not state fed or fasted prior to administration. The 
predicted vs. observed concentration time profiles are shown in Figure 6.6. The 
predicted vs. observed AUC0-24 (ng×h/ml) and Cmax (ng/ml) can be found in Table 6.7.  
Approximately 68% of the predicted parameters were within the 0.75 – 1.25 and 1 – 
1.25 ratio and AAFE verification criteria, respectively. A further 24% achieved the 0.5 
– 1.5 ratio and 1 – 1.5 AAFE criteria, with most of these involving the DD% for MDZ 
2mg QD 0 and 1 week after the last RIF dose. The concentration time profile for MDZ 
2mg QD 4 weeks after the last RIF dose was within the 1 – 2 AAFE verification 
criteria, whereas for 1 and 2 weeks after the last RIF dose the concentration time profile 
AAFE value did not meet the criteria. However, upon visual inspection the simulations 












Figure 6.6 Predicted vs. observed concentration time profiles for MDZ 2mg QD (A) 
and MDZ 2mg QD 0 (B), 1 (C), 2 (D) and 4 (E) weeks after the last RIF 600mg QD 
dose. Blue lines and blue shaded areas represent the mean plasma concentration ± SD 
(ng/ml) of the predicted data. Red lines represent the observed clinical data (ng/ml) 
from each of their respective studies (300, 301). 
 
Table 6.7 Predicted vs. observed MDZ pharmacokinetic parameters. 
Drug Regimen Parameter Predicted Observed 
MDZ 2mg QD AUC0-24  26.25 ± 13.19 23.48 ± 11.55 (300) 
Cmax 9.43 ± 3.62 10.33 ± 3.1 (300) 
MDZ 2mg QD/RIF 
600mg QD Week 0 
AUC0-24 3.90 ± 1.56 2.64 (301) 
Cmax 1.61 ± 0.65 1.33 (301) 
MDZ 2mg QD/RIF 
600mg QD Week 1 
AUC0-24 9.41 ± 5.46 8.2 (301) 
Cmax 3.845 ± 2.07 3.31 (301) 
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MDZ 2mg QD/RIF 
600mg QD Week 2 
AUC0-24 17.71 ± 7.02 17.44 (301) 
Cmax 6.8 ± 2.27 6 (301) 
MDZ 2mg QD/RIF 
600mg QD Week 4 
AUC0-24 28.99 ± 15.83 23.48 ± 11.55 (300) 
Cmax 9.98 ± 4.01 10.33 ± 3.1 (300) 
Reference for observed values presented in brackets. AUC0-24 values presented as mean ± standard 
deviation (ng×h/ml). Cmax values presented as mean ± standard deviation (ng/ml). MDZ – midazolam, 
RIF – rifampicin, AUC – area under the curve, Cmax – maximum plasma concentration.  
 
 Nifedipine Verification 
The NIF PBPK model was verified using available AUC0-24 and Cmax observed 
clinical data for the oral administration of single dose NIF 10mg and single dose NIF 
10mg coadministered with single dose RIF 1200mg (299). An estimated correction 
factor of 0.15 was applied to the predicted Vss as described in the method section 
6.2.5.1. The predicted vs. observed Vss was 0.28 L/kg vs. 0.71 L/kg (289). 
Additionally, the fed intestinal transit rate values were applied to achieve optimal 
simulation performance, whereas the observed clinical data stated study participants 
fasted prior to administration. The predicted vs observed concentration time profiles 
are shown in Figure 6.7. The predicted vs. observed AUC0-24 (µg×h/ml) and Cmax 
(µg/ml) can be found in Table 6.8.  All single dose NIF 10mg parameters achieved the 
ratio and AAFE criteria of 0.75 – 1.25 and 1 – 1.25, respectively. For single dose NIF 
10mg coadministered with single dose RIF 1200mg the Cmax and the DDI% for Cmax 
fell within the 0.75 – 1.25 and 1 – 1.25 criteria for ratio and AAFE whilst the AUC 






Figure 6.7 Predicted vs. observed concentration time profiles for single dose NIF 
10mg (A) and single dose NIF 10mg coadministered 8 hours after single dose RIF 
1200mg (B). Blue lines and blue shaded areas represent the mean plasma concentration 





Table 6.8 Predicted vs. observed NIF pharmacokinetic parameters. 
Drug Regimen Parameter Predicted Observed (299) 
NIF 10mg AUC0-24  0.54 ± 0.22 0.57 ± 0.014 
Cmax 0.16 ± 0.05 0.17 ± 0.006 
NIF 10mg/RIF 1200mg AUC0-24 0.28 ± 0.16 0.21 ± 0.016 
Cmax 0.11 ± 0.04 0.12 ± 0.008 
Reference for observed values presented in brackets. AUC0-24 values presented as mean ± standard 
deviation (µg/h/ml). Cmax values presented as mean ± standard deviation (µg/ml). All drug regimens 
were single dose. NIF – nifedipine, RIF – rifampicin, AUC – area under the curve, Cmax – maximum 
plasma concentration.  
 
6.3.3 UGT1A1 Induction Model Optimisation and Verification 
 UGT1A1 Induction Model Optimisation 
Due to the lack of literature data surrounding the induction of UGT1A1 by RIF, 
the complete UGT1A1 fold change induction profile could not be verified and was 
instead verified against a singular steady state fold change value. Induction parameters 
were optimised according to the observed clinical data for RAL 400mg QD and RAL 
400mg QD coadministered with RIF 600mg QD, as described in method section 
6.2.5.3. The DDI% was calculated for both predicted and observed data and the ratio 
and AAFE were determined. The optimised UGT1A1 induction parameter values for 
Kinact,pxr, Kenzyme,deg, Krna,deg, q and p were 0.1 h
-1, 0.0144 h-1 (271), 0.0756 h-1 (271), 
0.2 and 0.272, respectively. The resulting UGT1A1 fold change induction profile 
following 28 days repeated oral administration of rifampicin 600mg QD and 28 days 
after the last RIF dose can be found in Figure 6.8. The maximum UGT1A1 fold change 
was 1.75 ± 0.25 vs. 2.28 ± 0.81 (274) for predicted vs. observed, respectively. This 
corresponded to a ratio value of 0.77 and AAFE value of 1.3, achieving the 0.75 – 1.25 




Figure 6.8 Predicted UGT1A1 fold change following 28 days repeated oral 
administration of RIF 600mg QD using the optimised induction parameters. Data 
expressed as mean fold change ± SD. 
 
 Raltegravir Verification 
The RAL PBPK model was verified using available AUC0-24 and Cmax data for 
the oral administration of RAL 400mg QD and RAL 400mg QD coadministered with 
RIF 600mg QD (302). As described in the method section 6.2.5.1, an estimated 
correction factor of 0.6 was applied to the predicted Vss. The predicted vs. observed 
Vss was 0.22 L/kg vs. 0.4 L/kg (290). The predicted vs. observed concentration time 
profiles can be found in Figure 6.9. The predicted vs. observed AUC0-24 (µg×h/ml) and 
Cmax (µg/ml) pharmacokinetic parameters can be found in Table 6.9. The AUC for 
both RAL 400mg QD and RAL 400mg QD coadministered with RIF 600mg QD were 
within the 0.5 – 1.5 and 1 – 1.5 criteria for ratio and AAFE, respectively. The Cmax and 
DDI% for both AUC and Cmax were within the stringent criteria of 0.75 – 1.25 and 1 – 
1.25 for ratio and AAFE, respectively. The concentration time profile for RAL 400mg 
QD was within the 1 – 1.5 criteria for AAFE whilst RAL 400mg QD coadministered 





Figure 6.9 Predicted vs. observed concentration time profiles for RAL 400mg QD (A) 
and RAL 400mg QD coadministered with RIF 600mg QD (B). Blue lines and blue 
shaded areas represent the mean plasma concentration ± SD (µg/ml) of the predicted 





Table 6.9 Predicted vs. observed RAL pharmacokinetic parameters. 
Drug Regimen Parameter Predicted Observed (302) 
RAL 400mg QD AUC0-24  16.5 ± 13.15 12.25 
Cmax 4.14 ± 1.96 3.83 
RAL 400mg QD/RIF 
600mg QD 
AUC0-24 9.46 ± 7.93 7.34 
Cmax 2.64 ± 1.43 2.37 
Reference for observed values presented in brackets. AUC0-24 values presented as mean ± SD 
(µg/h/ml). Cmax values presented as mean ± SD (µg/ml). NIF – nifedipine, RIF – rifampicin, AUC – 
area under the curve, Cmax – maximum plasma concentration.  
 
6.3.4 Dolutegravir Verification 
The DTG PBPK model was verified using the optimised induction parameters 
for both CYP3A4 and UGT1A1. Observed AUC0-24, Cmax and Cmin clinical data for the 
oral administration of DTG 50mg QD, DTG 50mg QD coadministered with 600mg 
RIF (303), DTG 50mg BID and DTG 50mg BID coadministered with 600mg RIF 
(100) were utilised. An estimated correction factor of 0.08 was applied to the predicted 
Vss as described in the method section 6.2.5.1. The predicted vs. observed Vss was 0.16 
L/kg vs. 0.25 L/kg (279). Furthermore, the fasted intestinal transit rate values were 
applied to achieve optimal simulation performance, whereas the observed clinical data 
stated study participants ate a meal prior to administration. The predicted vs. observed 
concentration time profiles are shown in Figures 6.10 and 6.11. The predicted vs. 
observed AUC0-24, Cmax, and Cmin can be found in Table 6.10. Around 50% of the 
predicted pharmacokinetic parameters and concentration time profiles were with the 
0.75 – 1.25 ratio and 1 – 1.25 AAFE criteria. Approximately 38% were within the 0.5 
– 1.5 ratio and 1 – 1.5 AAFE criteria with the remaining 12% being within 0.5 – 2 and 
1 – 2 for ratio and AAFE, respectively. Moreover, the combined CYP3A4 and 






Figure 6.10 Predicted vs. observed concentration time profiles for DTG 50mg QD (A) 
and DTG 50mg QD coadministered with RIF 600mg QD (B). Blue lines and blue 
shaded areas represent the mean plasma concentration ± SD (ng/ml) of the predicted 






Figure 6.11 Predicted vs. observed concentration time profiles for DTG 50mg BID (A) 
and DTG 50mg BID coadministered with RIF 600mg QD (B). Blue lines and blue 
shaded areas represent the mean plasma concentration ± SD (ng/ml) of the predicted 




Table 6.10 Predicted vs. observed DTG pharmacokinetic parameters. 
Drug Regimen Parameter Predicted Observed 
DTG 50mg QD AUC0-24  53.97 ± 21.69 52.1 (303) 
Cmax 3.60 ± 1.25 3.97 (303) 
Cmin 1.56 ± 1.11 1.06 (303) 
DTG 50mg QD/RIF 
600mg QD 
AUC0-24 17.66 ± 6.81 22.75 (303) 
Cmax 1.91 ± 0.50 2.57 (303) 
Cmin 0.12 ± 0.16 0.156 (303) 
DTG 50mg BID AUC0-24 112.76 ± 46.82 92.7 (100) 
Cmax 6.22 ± 2.72 5.55 (100) 
Cmin 4.49 ± 2.63 2.41 (100) 
DTG 50mg BID/RIF 
600mg QD 
AUC0-24 35.66 ± 20.61 42.6 (100) 
Cmax 2.32 ± 0.75 3.13 (100) 
Cmin 0.71 ± 0.55 0.67 (100) 
Reference for observed values presented in brackets. AUC0-24 values presented as mean ± SD 
(µg/h/ml). Cmax and Cmin values presented as mean ± SD (µg/ml). DTG - dolutegravir, RIF – 
rifampicin, AUC – area under the curve, Cmax – maximum plasma concentration, Cmin – minimum 








Table 6.11 PBPK model verification summary of predicted vs. observed clinical data. 
Drugs Dose (mg) 
Ratio AAFE 
AUC Cmax Cmin Cavg AUC Cmax Cmin Cavg Profile 
RIF 600 QD 1.14 1.10 - - 1.14 1.10 - - 1.11 
RIF 1200 SD - 1.19 1.17 - - 1.19 1.17 - 1.02 
RAL 400 QD 1.35 1.08 - - 1.35 1.08 - - 1.62 
RAL/RIF 400 QD/600 QD 1.29 1.11 - - 1.29 1.11 - - 1.43 
NIF 10 S 0.94 0.96 - - 1.06 1.04 - - 1.21 
NIF/RIF 10 S/1200 S 1.33 0.94 - - 1.33 1.06 - - 1.42 
MDZ 2 QD 1.12 1.91 - - 1.12 1.10 - - 1.11 
MDZ/RIF Week 0 2 QD/600 QD 1.50 1.23 - - 1.50 1.23 - - 1.13 
MDZ/RIF Week 1 2 QD/600 QD 1.15 1.15 - - 1.15 1.15 - - 3.72 
MDZ/RIF Week 2 2 QD/600 QD 1.02 1.13 - - 1.02 1.13 - - 3.30 
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MDZ/RIF Week 4 2 QD/600 QD 1.23 0.97 - - 1.23 1.06 - - 1.98 
DTG 50 QD 1.04 0.91 1.47 - 1.04 1.10 1.47 - 1.31 
DTG/RIF 50 QD/600 QD 0.78 0.76 0.77 - 1.28 1.31 1.30 - 1.01 
DTG 50 BID 1.22 1.12 1.86 - 1.22 1.12 1.86 - 1.23 
DTG/RIF 50 BID/600 QD 0.84 0.74 1.06 - 1.19 1.35 1.06 - 1.24 
Ratio data presented as predicted vs observed. AAFE data calculated as previously described in method section 6.2.4, equation 12. RAL – raltegravir, RIF – rifampicin, NIF 
– nifedipine, MDZ – midazolam, DTG – dolutegravir, S – single dose, QD – once daily, BID – twice daily, AAFE – absolute average fold error, AUC – area under the curve, 








Table 6.12 PBPK model verification of predicted vs observed clinical data as a percentage of DDI vs drug alone. 
Drug Dose (mg) RIF Dose (mg) 
Ratio AAFE 
AUC Cmax Cmin AUC Cmax Cmin 
RAL 400 QD 600 QD 0.96 1.03 - 1.05 1.03 - 
NIF 10 S 1200 S 1.45 0.98 - 1.45 1.02 - 
MDZ Week 0 2 QD 600 QD 1.34 1.35 - 1.34 1.35 - 
MDZ Week 1 2 QD 600 QD 1.02 1.26 - 1.02 1.26 - 
MDZ Week 2 2 QD 600 QD 0.91 1.24 - 1.10 1.24 - 
MDZ Week 4 2 QD 600 QD 1.10 1.06 - 1.10 1.06 - 
DTG 50 QD 600 QD 0.68 0.84 0.53 1.48 1.19 1.90 
DTG 50 BID 600 QD 0.69 0.61 0.57 1.45 1.63 1.76 
Ratio data presented as predicted vs observed. AAFE data calculated as previously described in method section 7.2.4, equation 12. RAL – raltegravir, RIF – rifampicin, NIF – 
nifedipine, MDZ – midazolam, DTG – dolutegravir, S – single dose, QD – once daily, BID – twice daily, AAFE – absolute average fold error, AUC – area under the curve, 
Cmax – maximum plasma concentration, Cmin – minimum plasma concentration.  
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6.3.5 Once Monthly Rifampicin Coadministered with Dolutegravir  
The verified DTG PBPK model together with the CYP3A4 and UGT1A1 
induction PBPK model were used to predict 35 days repeated oral administration of 
DTG 50mg BID with single dose RIF 1200mg administration on day 7. The predicted 
CYP3A4 and UGT1A1 fold change induction profiles following the administration of 
single dose RIF 1200mg can be found in Figures 6.12 and 6.13, respectively. Predicted 
Cmax, Cavg and Cmin as well as the minimum target concentration of 4 x PA-IC90 of 
DTG (0.256 µg/ml) (277) are shown in Figure 6.14. The predicted Cmax, Cavg and Cmin 
mean values for DTG 50mg BID coadministered with single dose RIF 1200mg were 
above 4 x PA-IC90 of DTG throughout the simulation time period. However, these 
pharmacokinetic parameter values were substantially reduced after the administration 
of RIF 1200mg and took up to 28 days to return to their steady state values. The 
maximum CYP3A4 and UGT1A1 fold changes were 10.5-fold and 1.4-fold and were 
reached 56 hours and 57 hours after RIF 1200mg administration, respectively. When 
considering the predicted SD, the Cmin ± SD for DTG 50mg BID coadministered with 
RIF 1200mg QMT fell below 4 x PA-IC90 of DTG on days 1, 2, 3 and 4 after RIF 
administration. A summary of the results are shown in Table 6.13. 
 
Figure 6.12 Predicted CYP3A4 fold change following the administration of single 





Figure 6.13 Predicted UGT1A1 fold change following the administration of single 
dose RIF 1200mg. Data expressed as mean fold change ± SD. 
 
 
Figure 6.14 Predicted concentration time profile for DTG following 35 days repeated 
oral administration of DTG 50mg BID with single dose RIF 1200mg administration 
on day 7. The blue, green and yellow lines represent the mean Cmax, Cavg, and Cmin 
(µg/ml) of DTG, respectively. The blue, green and yellow circles represent the 
administration of RIF on day 7. The red dashed line represents the minimum target 




Table 6.13 Predicted DTG Cmin following 35 days oral administration of DTG 50mg 
BID with single dose RIF 1200mg administration on day 7. 
Days After RIF Dose DTG Cmin (µg/ml) 
0 2.63 ± 1.97 
1 0.75 ± 0.75 
2 0.59 ± 0.54 
3 0.64 ± 0.55 
4 0.80 ± 0.61 
5 1.01 ± 0.71 
6 1.26 ± 0.82 
7 1.53 ± 0.94 
DTG Cmin values are presented as mean ± SD. Cells highlighted in purple represent Cmin 
concentrations ± SD that fell below 4 x PA-IC90 of DTG (0.256 µg/ml). RIF – rifampicin, DTG – 





The implementation of higher doses of RIF across several clinical scenarios has 
been of growing interest recently. RIF is a potent inducer of several enzymes and the 
magnitude of DDIs resulting from higher doses is unknown (99). PBPK modelling is 
a powerful tool that can be used to elucidate unknown clinical scenarios, aid in the 
design of clinical studies and provide direct insight to clinicians during such 
investigative periods. In this study, a dynamic PBPK model describing the combined 
induction of CYP3A4 and UGT1A1 by RIF was developed and verified to predict the 
magnitude of DDI between RIF 1200mg QMT and DTG 50mg BID for the treatment 
of leprosy in PLWH. 
6.4.1 Minimal Rifampicin PBPK Model 
Owing to the lack of knowledge and data surrounding RIF ADME, it is 
common practice to adopt less mechanistically correct designs when predicting RIF 
pharmacokinetics via PBPK modelling (214-216). Although the minimal RIF PBPK 
model employed in this study does not describe the complexities of RIF ADME, it was 
able to predict RIF pharmacokinetic and concentration time profile data within the 
strict 0.75 – 1.25 ratio and 1 – 1.25 AAFE verification criteria. The model utilised 
published data on protein binding, CL/F and Vss and when data were unavailable, 
estimated these parameters according to observed clinical data. 
6.4.2 CYP3A4 Induction Model 
A dynamic PBPK model that accounts for the variations in the level of enzyme 
activity over time was selected for this study as the prediction of QMT RIF induction 
rather than steady state RIF induction was required. Most dynamic models consider 
the induction of enzyme synthesis to occur in a concentration dependent manner, 
however previous studies have described a delay in the time taken for mRNA to reach 
its maximum level after the administration of RIF (264, 304, 305). Therefore, a more 
complex model with mathematical descriptions of enzyme transcription and 
translation dynamics was required. A paper was recently published comparing the 
current mathematical models describing the dynamics of PXR-mediated CYP3A4 
gene regulation (306). Therein, two models were highlighted that specifically 
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described RIF induction, of which only one described RIF-induced DDIs (264, 305). 
The induction equations and optimised parameters reported in the RIF induction DDI 
model were chosen for the induction model implemented in this study and as described 
in results section 6.3.2.1, the CYP3A4 fold change induction profile was well 
replicated in conjunction with the minimal RIF PBPK model (264).   
For the verification of the CYP3A4 induction model, drugs solely metabolised 
by CYP3A4 were required. Unfortunately, there were no clinical data for the DDI 
between single dose RIF coadministered with a CYP3A4 substrate drug at steady state, 
reflecting the required application of this model. Furthermore, there was a limited 
amount of clinical data for DDIs with doses of RIF greater than 600mg. In the absence 
of this data, two clinical studies were identified that would allow for an alternative 
verification of the CYP3A4 induction model and parameters: single dose NIF 10mg 
coadministered with single dose RIF 1200mg (299) and MDZ 2mg QD coadministered 
with RIF 600mg QD and up to 4 weeks after the discontinuation of RIF (300, 301). 
The single dose NIF DDI dataset comprised of data for the first 24 hours of the DDI 
with RIF and so its objective was to verify the delay in the fold change of mRNA after 
the initial administration of RIF. The MDZ DDI dataset provided both data for the RIF 
DDI at steady state, but more importantly for the RIF DDI after its discontinuation, 
thus verifying the duration of the induction effect beyond 24 hours. The whole-body 
PBPK model together with the minimal RIF PBPK model and CYP3A4 induction 
PBPK model with previously optimised parameters were used to predict the 
abovementioned DDI datasets, as described in method section 6.2.5.2. It was 
concluded that, due to the AAFE and ratio values being suboptimal, the induction 
parameters required further optimisation to generate more accurate predictions.  
Optimising induction parameters is challenging. There remains a lack of 
consensus on the parameter values used to described CYP3A4 induction (273). This is 
largely due to the absence of key parameter values as well as discrepancies between 
the values that are available and the clinical datasets used to verify them. For example, 
as previously described and demonstrated in this study, the rate of enzyme degradation 
is a major determinant of the induction profile (273). CYP3A4 degradation rates 
between 0.005 h-1 and 0.07 h-1 have previously been reported using a multitude of in 
vitro methods, of which several differing values have been implemented into PBPK 
models (264, 306, 307). Previous studies have described how values of or similar to 
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0.03 h-1 have improved PBPK model predictions in comparison to smaller values (264, 
307). However, we found that through our optimisation process, the previously 
published value of 0.0096 h-1 provided the most accurate predictions (272). It must be 
noted that the published value was optimised with the same clinical MDZ data used in 
this study. Thus, it cannot necessarily be concluded that one value is more appropriate 
than the other without verifying them against a range of clinical datasets. Furthermore, 
there were limited or no data available for the rate constants for PXR-mediated 
CYP3A4 mRNA synthesis, CYP3A4 synthesis, CYP3A4 mRNA degradation as well 
as the constant for negative feedback inhibition and the inactivation rate constant for 
activated PXR. Thus, these parameters were mostly estimated. Nevertheless, the 
CYP3A4 PBPK induction model was successfully verified largely to the stricter 
criteria if not the widely accepted verification criteria range, albeit with two 
exceptions. The AAFE values for the concentration time profile of MDZ 2mg QD 1 
and 2 weeks after the last RIF dose were outside the 1 – 2 criteria. After visual 
inspection it can be seen that this was due to minimal differences in the tail end of the 
profiles. Considering the accuracy of the rest of the profile alongside the 
pharmacokinetic parameters achieving the strict verification criteria, these AAFE 
values were deemed acceptable.    
6.4.3 UGT1A1 Induction Model 
To our knowledge, this is the first dynamic PBPK model to predict PXR-
mediated induction of UGT1A1 by RIF. Owing to the even more sparsely available 
data surrounding UGT1A1 induction, the verification process was limited in 
comparison to the CYP3A4 induction model. UGT1A1 is induced via the same PXR 
mechanism as CYP3A4 and so the same induction equations were implemented (274). 
Having said that, RIF has previously been described to induce CYP3A4 more 
efficiently than UGT1A1 and so this was taken into consideration whilst optimising 
the induction parameters (99). 
There were several similarities between the optimisation process of UGT1A1 
and CYP3A4. Firstly, drugs solely metabolised by UGT1A1 were required. Again, 
there were no clinical data for the DDI between single dose RIF coadministered with 
a UGT1A1 substrate drug at steady state. Nor were there clinical data available 
reflecting the datasets used in the CYP3A4 induction model. Hence clinical data for 
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the DDI between RAL 400mg QD and RIF 600mg QD (302) at steady state along with 
in vitro data of the fold change of UGT1A1 mRNA (274) were employed for the 
verification of the UGT1A1 induction model. Secondly, the same iterative process for 
optimising parameters was employed, albeit with two exceptions. The value for kinact,pxr 
was assumed to be the same for both CYP3A4 and UGT1A1 because of the paucity of 
information surrounding this process. With the CYP3A4 induction parameters being 
optimised against a larger more coherent clinical dataset, the value for kinact,pxr was 
estimated during the optimisation of the CYP3A4 induction model. The value for p 
was determined by calculating Ki,NF from the estimated CYP3A4 p value and applying 
it to the p equation for UGT1A1. Once more assuming it to be the same for both 
CYP3A4 and UGT1A1 and optimising the value via the CYP3A4 induction model 
with a similar rationale. Nonetheless, the UGT1A1 induction model was successfully 
verified against the RAL data sets. Interestingly, the predicted steady state fold 
induction of UGT1A1 using the abovementioned parameters was approximately 23% 
lower than the reported literature value. That being said, with the UGT1A1 induction 
model being verified against steady state DDI data we must be cautious when 
analysing the predicted data from any future applications.  
6.4.4 Predicting Dolutegravir Drug-Drug Interactions 
Verification of the combined CYP3A4 and UGT1A1 induction PBPK model 
was carried out with clinical data for DTG 50mg QD and DTG 50mg BID 
coadministered with RIF 600mg QD. Although the combined models were 
successfully verified, only 50% were within the strict criteria. It was found that the 
model tended to overpredict the magnitude of induction for RIF 600mg QD with both 
DTG regimens, specifically regarding the Cmin. Three factors should be considered 
regarding this overprediction. Firstly, as described in method section 6.2.2, there were 
no available in vitro data for the metabolic pathways of DTG. In the absence of such 
data the fraction of DTG metabolised by UGT1A1, CYP3A4, UGT1A3 and UGT1A9 
determined from the detection of radioactive metabolites in a human mass balance 
study were implemented (268). However, it was found that by using these fractions 
the clearance of DTG was underpredicted. The abovementioned study advised that due 
to the instability of the UGT metabolite, the fraction metabolised by UGT could be 
underestimated. The fractions relating to UGT1A3, UGT1A9 and the remaining 
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uncategorised fraction were collated with the UGT1A1 fraction and the DTG regimens 
simulated. The pharmacokinetic and concentration time profile predictions proved 
most accurate using this method and due to the lack of available data, was deemed to 
be justified. Although, based on the observed overprediction of DDI between DTG 
and RIF, neither of these enzyme parameters may be accurate. 
Secondly, as described in method section 6.2.5.1, to obtain the most accurate 
predictions a correction factor was estimated and applied to the predicted Vss of DTG. 
During this process it was found that the optimal correction factor for the DTG 
regimens alone and with RIF differed. These findings suggest a potential alteration in 
DTG’s Vss during the DDI with RIF. Information regarding DTG Vss is limited and 
topics divulging such changes in Vss can be controversial. For example, previous 
studies have described the ability of a drug to be displaced in the presence of another 
drug with a higher protein binding affinity (308). For highly protein bound drugs, even 
the smallest of changes in unbound concentration can lead to alterations in the drugs 
Vss (309). However, this phenomenon was not observed for NIF or MDZ which are 
also highly protein bound. This concept also suggests that RIF would be the effected 
drug, not DTG. Taking this into consideration alongside the insufficient clinical data, 
the Vss correction factor estimated for optimal predictions of both DTG with and 
without RIF was selected. However, it should be acknowledged that this factor 
contributed towards the overprediction of Cmin in the DTG 50mg QD and DTG 50mg 
BID regimens.  
Lastly, the DDI magnitude overprediction could also be due in part to the 
limited optimisation and verification of the UGT1A1 induction model as UGT1A1 
contributes towards at least 51% of DTG’s overall metabolism (267). However, as this 
study has identified, future experimentation to expand upon the currently available 
UGT1A1 induction and DTG metabolism data is required to further refine this model. 
Nonetheless, the predictions made by this model for unknown clinical scenarios 
provide a valuable insight and their analysis should take this overprediction into 
careful consideration.  
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6.4.5 High Dose Rifampicin for the Treatment of Leprosy in PLWH 
Taking Dolutegravir 
As previously described, the verified DTG PBPK model together with the 
CYP3A4 and UGT1A1 induction PBPK model were used to predict repeated oral 
administration of DTG 50mg BID with single dose RIF 1200mg for the treatment of 
leprosy in PLWH. There were substantial reductions in the mean Cmax, Cavg and Cmin 
values and interestingly, it took up to 28 days for these pharmacokinetic parameters to 
return to their steady state values. Despite this, the mean values remained above 4 x 
PA-IC90 of DTG. Though when considering the predicted SD, the Cmin ± SD for DTG 
50mg BID fell below 4 x PA-IC90 of DTG for the initial days after single dose RIF 
1200mg administration. As mentioned previously, the models used in this application 
tend to overpredict the magnitude of DDI between RIF 600mg QD and DTG 50mg 
BID and so it is acceptable to describe these DDI predictions as the “worst-case 
scenario”. However, if doses greater than 1200mg were to be implemented for the 
treatment of leprosy, these predictions indicate that the resulting DDI may have the 
potential to produce Cmax, Cavg and Cmin values below 4 x PA-IC90 of DTG. Although 
it must be noted that the pharmacokinetic profiles of differing doses of RIF are not 
linear and so a direct extrapolation cannot be made from these predictions (219). 
Furthermore, higher doses of RIF for the treatment of leprosy have previously been 
avoided partly due to reports of adverse reactions and drug toxicity associated with 
intermittent dosing of RIF at higher doses (60, 61). However, these studies only 
considered once or twice weekly dosing of RIF and so adverse reactions for once 
monthly dosing would require further investigation. Additionally, a previously 
reported static model predicted a 3-fold change in DTG AUC when coadministered 
with clofazimine (310). However, as the effect of RIF induction on CYP3A4 is 
believed to be the dominating DDI mechanism, the impact of clofazimine CYP3A4 
inhibition is thought to be insignificant in the coadministration of DTG and leprosy 
MDT although further confirmatory studies are required.    
6.4.6 Conclusion 
While both the CYP3A4 and UGT1A1 induction models were successfully 
verified, the lack of in vitro and in vivo data for model optimisation and verification 
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remains a limitation of this study and careful consideration must be taken when 
analysing these predictions. Specifically, analysis must acknowledge the tendency to 
overpredict DTG DDIs with RIF. Nevertheless, the model predicted that no further 
dosage adjustments were required to maintain the plasma concentration of DTG above 
the acceptable criteria when coadministered with higher doses of RIF for the treatment 
of leprosy in PLWH. This study provides useful evidence-based guidance towards the 
clinical management of DDI scenarios yet to be investigated in clinical trials. 
Furthermore, this study highlighted the experimental parameter data that is missing to 
create a comprehensive mathematical model for RIF time-based enzyme induction, 
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7.1 DDIs in People Living with HIV 
ART for the treatment of HIV is continuously evolving, with the latest ARVs 
being characterised by more favourable pharmacodynamic and pharmacokinetic 
profiles (311). However, DDIs remain a key issue in the clinical management of 
PLWH. Currently, ART regimens consist of multiple ARVs targeting different stages 
of the HIV replication cycle and PLWH can receive different combinations of ARVs 
due to resistance or specific clinical characteristics, generating an expansive range of 
potential DDIs (103, 312). This is exacerbated by the high rate of comorbidities and 
polypharmacy found in different sub-populations and considering the increased life 
expectancy of PLWH, new and complex clinical scenarios are emerging as a product 
of older age (87). Furthermore, with the introduction of LA ARVs for the treatment of 
HIV and the development of alternative administration strategies for ART, having a 
deep understanding of the role of DDIs and their mechanisms of action is important 
now more than ever (313). In particular, with the cessation of treatment not being as 
simple under some of the abovementioned applications it is imperative that we have a 
detailed knowledge of the potential for an adverse DDI to occur. This also applies to 
innovations in the treatment of other infectious diseases and morbidities, with 
conventional treatment strategies being replaced as research and technology advances.  
It is clear that the landscape of HIV is changing and the underrepresentation of 
sub-populations as well as pharmacokinetic mechanisms in research is hindering our 
ability to make optimised, well-informed clinical decisions for all PLWH. Specifically, 
there continues to be a paucity of knowledge surrounding transporters despite their 
substantial role in drug pharmacokinetics and DDIs (69). This gap is underpinned by 
the inability of current assessment techniques to efficiently extrapolate in vitro data 
and evaluate individual transporters on both an in vitro and clinical level (131, 133). 
Additionally, DDI guidelines for OALWH as well as PLWH with uncommon clinical 
scenarios are lacking due to their limited inclusion in clinical studies (102, 103). The 
overall aim of this thesis was to develop and verify an efficient in vitro-in silico 
framework to delineate the role of transporters in DDIs and assess the robustness of 
the framework in a clinically relevant ARV DDI scenario. Moreover, this thesis aimed 
to apply in vitro and in silico techniques to investigate DDI mechanisms in currently 
underrepresented sub-populations of PLWH.  
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7.2 Integrated Experimental and Computational 
Approaches for the Prediction of DDIs 
Several transporters are located in the liver and mediate multiple DDIs 
involving ARVs (70, 72). Since their recognition as clinically relevant entities in the 
ADME of numerous drugs, their investigation is a prerequisite for the drug approval 
process (132). However, as described above, current in vitro assessment applications 
are unable to accurately quantify the role of transporters in such DDIs. This inability 
largely occurs for three reasons: non-specific transporter substrates, inhibitors and 
inducers, inconsistent IVIVE methods and a limited mechanistic understanding of 
transporters. Furthermore, the interplay between transporters and enzymes in the liver 
adds another layer of complexity during their analysis. In vitro techniques can be used 
together with in silico systems to overcome some of these limitations and provide an 
insight into the mechanisms and magnitudes of transporter-mediated DDIs in the liver 
(131, 153).  
An in vitro-in silico framework was developed and verified in Chapter 2 and 3 
for the investigation of hepatic transporters in a clinically relevant ARV DDI in 
Chapter 4. Whilst the framework was able to adequately predict the CLint,T of the 
OATP1B1 and OATP1B3 probe substrate during verification, there was a tendency to 
slightly underpredict the DDI with the probe inhibitor. However, these predictions 
demonstrated improvements over previous assessment applications. Most notably was 
the ability for the in vitro system to quantify a more accurate IC50 value for the probe 
substrate and inhibitor, which proved efficient at overcoming the large 
underpredictions of transporter DDIs previously reported (190, 191). The in vitro-in 
silico framework was also able to implement an assay specific rather than drug specific 
IVIVE correction factor for the CLint,T across two different drugs. Furthermore, the 
implementation of PBPK modelling to estimate passive hepatic uptake demonstrated 
an effective and sustainable alternative to the quantification of passive uptake in vitro. 
Unfortunately, the in vitro system proved ineffective at quantifying the contribution of 
hepatic transporters in the DDI involving ATV/r and DRV/r. In contrast to the DDI 
between the probe substrate and inhibitor, significant underpredictions were 
determined with ATV/r and DRV/r. Although the cause is unconfirmed, it is likely a 
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false positive result potentially stemming from the physicochemical properties of the 
drugs and incompatibility with the SPHH in vitro system.  
As discussed, current in vitro and clinical transporter-mediated DDI 
assessment strategies are limited by the implementation of non-specific victim and 
perpetrator drugs. This exposes data analysis to the misinterpretation of results as well 
as the partial understanding of the DDI outcomes, especially considering the interplay 
between multiple transporters and enzymes in the ADME of a drug. The identification 
of transporter specific probes is essential for the advancement of transporter 
pharmacology however this task is particularly challenging considering our current 
knowledge gap surrounding transporter biology. Endogenous biomarkers have been of 
increasing interest as prospective transporter substrates in DDI assessment and may 
offer improved specificity. Whilst endogenous biomarker research remains in the early 
stages, studies thus far have highlighted their possible application within the initial 
phases of drug development. With the possibility of quantifying multiple endogenous 
biomarkers from a single study as opposed to conducting multiple in vitro and clinical 
DDI studies, their application could alleviate some of the complexities of DDI 
assessment (314, 315).  
Moreover, the justifications behind current IVIVE methodologies are 
ambiguous. Correction factors for the extrapolation of in vitro transporter data are 
commonplace amongst the literature, however they tend to be drug rather than assay 
specific with one study reporting up to 100-fold variation amongst 7 drugs using 
SCHHs (192). Although the application of IVIVE correction factors have been thought 
to account for differences in the transporter expression and activity between in vitro 
and in vivo systems, these large, drug specific variations seem to represent a relevant 
barrier for a reliable application of predictive systems. Interestingly, the drugs with 
higher active and passive intrinsic clearance values in the abovementioned study had 
higher IVIVE correction factor values. This was also documented in a study analysing 
multiple experiments whereby underpredictions increased with increasing in vitro 
clearance values (316). A further paper investigating the potential causes of IVIVE 
inaccuracies described the incorrect estimation of hepatic blood flow to be a 
contributing factor towards the underprediction of high clearance drugs through IVIVE 
(153). These findings could provide logical reasoning behind the variation in IVIVE 
correction factors and present opportunities for improved extrapolation systems. For 
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example, specific IVIVE correction factors could be generated for low, medium and 
high clearance drugs within each cell system. 
Furthermore, variation resulting from in vitro systems continues to be an issue 
in transporter assessment, concerning both expression and activity (153, 182). The 
application of different cell systems with various protocols, incubation times, drug 
concentrations, donor characteristics and quantification techniques all contribute 
towards the large variation reported in the literature. Although recommendations have 
been published by the FDA and ITC in recent years, a consensus on standardised 
experimental protocols, including IVIVE correction factors, and improved access to 
large donor pools from an array of populations is key to understanding the authenticity 
of the currently observed variations (70, 132). By refining current in vitro 
methodologies, the predictive capabilities of PBPK modelling can be exploited, 
providing sustainable and ethical research strategies for the assessment of transporters.    
7.2.1 Older Adults Living with HIV 
As the population of OALWH increases, clarity is required on the effect of age 
on transporter-mediated DDIs. The current omission of OALWH in clinical studies 
and research compounds their already challenging clinical management. Specifically, 
there are limited in vitro studies investigating transporters in older adults, with the 
available literature assessing transporter expression remaining inconclusive (77, 252). 
PBPK modelling has recently been employed to fill the knowledge gap on 
pharmacokinetics in OALWH, providing a mathematical description of the 
physiological changes occurring with older age. Although initial predictions 
concluded no difference in DDI magnitude with older age irrespective of DDI 
mechanism, the model verification process was limited by minimal transporter DDI 
clinical and in vitro data (123). 
The expression and activity of the clinically relevant OATP1B1 transporter was 
quantified in Chapter 5 presenting preliminary data on the impact of age on 
transporters. The in vitro assay developed and verified in Chapter 2 was implemented 
alongside a commercially available SLCO1B1 sandwich ELISA kit. It was found that 
OATP1B1 expression tended to decrease with increased age although this did not 
correspond to decreased CLint,T. Interestingly, a lesser magnitude of DDI between the 
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OATP1B1 probe substrate and inhibitor was found with increased age, suggesting 
DDIs could be less pronounced in older adults. However, due to the lack of available 
elderly hepatocyte donors the findings cannot be classified as definitive. A much larger 
pool of donors with further substrate and inhibitor combinations are required to 
generate conclusive evidence on the above-mentioned relationship between age and 
transporters. Furthermore, utilising the previously published repository, the PBPK 
model developed as part of the in vitro-in silico framework could be expanded to 
include physiological descriptions of older adults (187). IVIVE of the data produced 
from this study could then be carried out using the PBPK model, allowing us to 
understand the clinical impact of potentially lower magnitudes of DDIs in older adults.  
Future studies correlating age and transporter expression and activity could 
encompass the assessment of biological age vs. chronological age. Biological age 
differs to chronological age in that it considers genetic and epigenetic changes 
resulting from ageing, lifestyle and disease (317). Biological age can be quantified 
through multiple techniques with recent studies recommending a combination of 
assessments involving telomere length, DNA methylation and functional tests such as 
the frailty index (318). Recently, artificial intelligence has been applied to decipher the 
abundance of age-related data, providing exciting opportunities for the identification 
and assessment of age-related biomarkers (319). Of interest, a previously published 
study found that HIV infection caused an increase in the biological age of blood and 
brain tissue (8). Moreover, it is plausible that a multitude of factors are attributable to 
the large variation in transporter data found amongst the literature as well as the 
contradictory findings surrounding the effect of age on transporter expression and 
function. For example, a previous study identified a correlation between HIV infection 
and both enzyme and efflux transporter expression in the intestine (320). However, to 
what extent different diseases impact transporters has yet to be identified. These 
unknowns are problematic in the analysis of transporter studies with the identification 
of causative factors proving difficult to justify. Therefore, research initiatives 
comparing transporter expression and function against a quantifiable measurement of 
the combined effect of age, disease and lifestyle would be invaluable in improving our 
understanding of transporters. 
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7.2.2 Prediction of Novel Induction-Based DDIs 
The induction effect of high, single dose RIF has not been clinically assessed 
and based on current trends towards the application of higher doses of RIF it is 
important for us to understand the clinical impact potential DDIs may have. RIF QMT 
is given as a part of the treatment regimen for leprosy and DDIs involving ARVs are 
possible due to the geographical overlap in the incidence of leprosy and HIV alongside 
reported cases of coinfection from smaller studies. However, owing to the lack of data 
identifying the scale of coinfection, clinical DDI studies have not taken place and there 
is little guidance for such scenarios. PBPK modelling was employed in Chapter 6 to 
investigate the magnitude of DDI in the potential coadministration of high dose RIF 
QMT and the first-line ARV DTG. This involved the mathematical description of 
CYP3A4 and UGT1A1 induction via the interaction between RIF and the PXR nuclear 
receptor. Whilst induction mechanisms were successfully developed and verified, 
providing a first attempt towards the simulation of non-daily induction effects of RIF, 
the PBPK model was limited by the lack of in vitro data for specific induction 
parameters as well as DTG ADME. This resulted in the overprediction of the 
magnitude of DDI between DTG and RIF during the verification process and thus the 
likelihood of overprediction in the application simulations. However, the simulation 
of overpredictions of DDI magnitudes is preferential to underpredictions so that if 
anything the worst-case scenario is known. 
Quantifying the parameters involved in the mechanisms of enzyme induction in 
vitro could improve the reliability and accuracy of the PBPK model’s DDI predictions. 
Although parameter estimations can provide relative accuracy, the estimation of 
multiple parameters facilitates over and under prediction with uncertainty as to which 
parameter could be at fault. Furthermore, having an extensive in vitro assessment of 
DTG metabolism would help improve the current model, allowing for greater 
confidence in the parameter values applied. Similarly, a comprehensive verification of 
the UGT1A1 model with further clinical and in vitro data would help eliminate any 
uncertainty in the prediction of the induction magnitudes. To summarise, the most 
accurate and reliable model simulations are obtained from the implementation of 
legitimised in vitro and in vivo data.  
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As discussed, higher doses of RIF are being investigated for the treatment of 
TB and several clinical studies have been carried out or are currently underway (59, 
262, 321-323). Data from a phase 2b clinical trial in Uganda was recently released at 
the virtual conference on retroviruses and opportunistic infections (vCROI) 2021 
assessing the DDI between DTG 50mg BID and RIF QD dosed at 35mg/kg (324). The 
study found that the magnitude of DDI was like that of RIF 10mg/kg and the reduction 
of DTG’s Cmin did not exceed the minimal therapeutic concentration required for HIV 
treatment. This data suggests that the PXR induction mechanism is potentially 
saturable at these concentrations of RIF. The new data could be used to recalibrate the 
PBPK model and simulate a 35mg/kg dose of RIF. Moreover, further studies would 
be required to define the effectiveness of high doses of RIF for the treatment of leprosy 
although improvements in treatment outcomes are assumed based on previous studies 
investigating doses up to 1500mg (60). 
7.3 Conclusion 
In summary, an in vitro-in silico framework was established for the 
investigation of transporter-mediated DDIs. An accessible platform for the 
quantification of transporter expression was tested and applied in conjunction with the 
developed in vitro techniques to investigate the impact of age on transporters. 
Additionally, in silico methods were utilised to simulate the mechanisms of PXR-
mediated induction to identify potential DDIs. These studies intended to provide 
information towards the advancement of current in vitro and in silico DDI assessment 
strategies and present considerations for the clinical management of PLWH, 
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